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Abstract 
Sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) is an integral 
membrane protein with known involvement in the maintenance of resting membrane 
potentials, nutrient uptake, cellular signal transduction, and cell-cell adhesion. The 
functional enzyme contains a catalytic alpha subunit and a glycosylated beta subunit, of 
which three isoforms of each are known to exist in the central nervous system (CNS). 
Altered expression and/or activity of Na+/K+-ATPase subunit isoforms has been 
previously implicated in the pathophysiology of several neurological disorders. This 
study characterized Na+/K+-ATPase expression and distribution in the myelin membrane, 
identified its specific heterodimeric forms and binding partners, and explored its 
possible involvement in demyelinating disorders, such as multiple sclerosis. For the first 
time, Na+/K+-ATPase α1, α2, and α3, as well as the β1, β2, and β3 subunits, were shown to 
co-express within a tissue of the CNS. These six isoforms, in addition to six isozymes 
(α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3), of Na
+/K+-ATPase were identified in myelin 
isolated from mouse brain; this expression shared both similarities and differences with 
neurons, astrocytes and/or oligodendrocytes. The major isozymes of Na+/K+-ATPase 
identified in myelin were α1β1, α2β3, and α3β1. Co-immunoprecipitation (co-IP) assays 
demonstrated that the three alpha isoforms of Na+/K+-ATPase in the myelin sheath can 
interact with other Na+/K+-ATPase alpha and beta subunit isoforms, in addition to 
associating with certain myelin-specific proteins and other protein types. These protein 
binding partners of Na+/K+-ATPase have known cellular functions, including RNA splicing, 
involvement in cell-cell migration and adhesion, the mediation of cytoskeletal 
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interactions, and the regulation of protein degradation and apoptosis; they also 
suggested localization of Na+/K+-ATPase to the adherens junctions, tight junctions, 
caveolin-1 enriched microdomains, lipid rafts and tetraspanin-enriched microdomains of 
myelin. Western blot analysis indicated that Na+/K+-ATPase expression varies over post-
natal development. Distinct differences in protein expression were observed between 
healthy and diseased myelin. In particular, demyelinating ND4 mice exhibited severe 
impairment of Na+/K+-ATPase β1 subunit maturation. Overall, this study has provided a 
comprehensive look into Na+/K+-ATPase expression and interactions within the myelin 
sheath, emphasizing its importance to both myelin structure and function. 
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Chapter 1 – Introduction 
1.1 The Nervous System 
The nervous system is a complex network of cells which transmit both motor and 
sensory signals between different parts of the body. It allows the body to respond to 
changes in its internal and external environments [1]. The nervous system is divided into 
two distinct, but mutually supporting, branches: the central nervous system (CNS) and 
the peripheral nervous system (PNS). These systems, as well as their subdivisions, are 
described in Figure 1.1. Consisting of the brain and spinal cord, the CNS is responsible 
for higher mental functions and is recognized as the processing center for all of the 
received stimuli. Alternatively, the PNS is fundamental in reacting to stimuli and uses 
nerves to conduct the electrical signals between nerve cell bodies outside of the CNS, 
called ganglia, with the CNS itself [1]. Collaboration between these two divisions is 
critical for the conscious and unconscious processes required to sustain life. 
To facilitate signal transmission throughout the body, specialized cells called 
neurons receive stimuli and conduct electrochemical waves to other parts of the 
system. These waves are traditionally called action potentials. Neurons, or nerve cells, 
receive information via specialized processes called dendrites, which extend from its cell 
body. Receipt of stimuli will trigger an electrical impulse (action potential), originating in 
the cell body and propagating along the axon of the neuron. This process is typically the 
longest extension of the cell, and most neurons generally only have one [1]. 
Neurotransmitters allow the signal to be passed from one neuron to another, via 
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specialized contact points called synapses [1]. A synapse will connect the axon of the 
pre-synaptic neuron with the post-synaptic cell, often the dendrites of another neuron.  
Post-synaptic cells may become excited or inhibited depending on the neurotransmitter 
in effect.  
 
 
Figure 1.1 The divisions of the nervous system 
 
The nervous system is divided into the CNS and PNS. The CNS comprises the brain and spinal cord, and 
processes the neural information that is transmitted. The PNS reacts to stimuli and uses nerves to conduct 
the electrical signals between nerve cell bodies outside of the CNS to the spinal cord and brain. The 
peripheral nervous system accommodates both motor and sensory functions; motor responses may be 
either voluntary or involuntary and therefore are further divided into the somatic and autonomic systems, 
respectively. Involuntary motor responses include those which prime the body to react to stressful stimuli 
or trigger the activities that occur in the resting state. 
 
The non-conductive cells of the nervous system are often designated as 
supporting cells. They can provide protection of the delicate neuronal processes, 
insulation of electrical impulses, and connect the nervous system to the vasculature [1]. 
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In the CNS, these cells are commonly referred to as glia, or glial cells. Astrocytes are the 
most abundant cell type in the nervous system and the largest of all neuroglial cells [1]. 
They are essential in maintenance of the blood-brain barrier, in addition to maintaining 
ionic homeostasis, they provide metabolic support to neurons and respond to injurious 
stimuli [2]. Interestingly, astrocytes have the ability to express voltage-gated sodium 
channels, despite being classically considered inexcitable [2]. Oligodendrocytes are 
another glial cell type; their PNS equivalents are called Schwann cells. Both 
oligodendrocytes and Schwann cells are much smaller in size when compared with 
astrocytes, and are responsible for the formation of and maintenance of the myelin 
sheath. Finally, microglia and ependymal cells are two other types of neuroglia. The 
former possesses phagocytic properties which are often employed in cases of disease or 
tissue damage, whereas the latter forms the lining of the ventricles and canals of the 
CNS [1]. 
1.2 The Myelin Membrane 
1.2.1 Structure, Function and Morphology 
 The propagation of action potentials along a neuronal axon is significantly 
increased when the axon has been electrically insulated [3]. This insulation can be 
provided by oligodendrocytes in the CNS or Schwann cells in the PNS, in the form of 
myelin; however, the formation of the myelin sheath in the CNS is more complicated, as 
a single oligodendrocyte can myelinate several axons [1]. As shown in Figure 1.2, 
myelination of an axon is achieved by the wrapping of cytoplasmic extensions of the 
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supporting cell to form concentric layers of oligodendrocyte or Schwann cell plasma 
membrane [1;4;5]. During this process, cytoplasm within the wrapping processes of the 
myelinating cell becomes extruded such that the lipid bilayers are side by side; the 
intracellular space is compacted to produce the major dense line of myelin, while the 
extracellular space becomes the intraperiod line of myelin [4]. Neighbouring segments 
of myelin, along the same neuronal axon, are generated by different oligodendrocytes 
[6]. The result of myelination is a multi-layered, lipid rich membrane, called the myelin 
sheath, which protects and insulates the axons of vertebrates for rapid neural 
transmission. Action potentials generated in myelinated axons are restricted to the 
nodes of Ranvier; these are segments of the neuron which are not insulated by myelin. 
Consequently, action potentials travel more rapidly via myelinated axons, as they do not 
need to travel the full length of the axon; this phenomenon is referred to as saltatory 
conduction [1].  
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Figure 1.2 The process of myelination by oligodendrocytes 
 
Oligodendrocytes can myelinate multiple axons, and multiple segments of a single axon, by repeatedly 
wrapping extensions of their cytoplasm around the neuronal axons, forming concentric layers of cell 
plasma membrane. The cytoplasm and extracellular space of the myelinating cell become extruded such 
that the lipid bilayers are side by side. The intracellular space is compacted to produce the major dense 
line of myelin. The extracellular space becomes the intraperiod line of myelin. Image adapted from 
references [1;7]. 
 
 The biogenesis of oligodendrocytes begins with their conception from migratory 
and mitotic precursors; these become progenitor cells, specifically oligodendrocyte-
astrocyte glial progenitor cells (OPCs), and mature into post-mitotic myelin-producing 
cells [6;8]. The maturation of the oligodendroglial cell lineage, and differentiation into 
myelin-forming cells, is accompanied by corresponding changes in protein expression; in 
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particular, cell surface antigens which can be recognized by monoclonal antibodies and 
act as markers of the oligodendrocyte cell lineage [6]. The OPCs are generated in waves, 
beginning in early embryonic development and continuing after birth [9]. These 
progenitors migrate throughout the CNS prior to maturation; they are guided by 
extracellular matrix (ECM) molecules. For example, tenascin-C has proposed inhibitory 
effects on oligodendrocyte migration, as increased expression at the rat retina-optic 
nerve junction coincides with an absence of oligodendrocytes [6]. Oligodendrocyte 
maturation into myelinating cells predominately occurs in the early post-natal life of 
mammals. Post-migration, the progenitor cells become established along the neural 
tracts of the CNS that are destined to become white matter; here they differentiate 
further into preoligodendrocytes [6]. These immature oligodendrocytes, or 
preoligodendrocytes, express 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), which 
is the first myelin-specific protein that is known to be produced by oligodendrocytes. 
Finally, the expression of myelin basic protein (MBP), myelin-associated glycoprotein 
(MAG), and proteolipid protein (PLP) indicate fully matured oligodendrocytes [6]. 
1.2.2 Lipid and Protein Composition and Membrane Microdomains 
The myelin sheath has a high lipid to protein ratio, with its protein composition 
classically perceived as low in complexity. An estimated 70-80% of the dry weight of 
myelin is lipid [10;11]. The lipid content is composed of a 2:2:1:1 molar ratio of 
cholesterol to phospholipid to galactolipid to plasmalogen [11]. It is unclear how 
cholesterol and these other lipids are enriched to such an unparalleled degree, in 
myelin. With regards to protein content, oligodendrocytes and Schwann cells express 
7 
 
different myelin-specific proteins [1]. In the PNS, Schwann cells express myelin protein 
zero (P0) and peripheral myelin protein 22 (PMP-22) during myelination; PLP, myelin 
oligodendrocyte glycoprotein (MOG), oligodendrocyte myelin glycoprotein (OMgp), and 
other proteins act as proxies in the CNS [1]. PLP and its isoforms represent 30-45% of 
the total myelin protein in the CNS [11]. It is believed that PLP provides structural 
support for the maintenance of the compact lamellar structure of myelin; though it has 
also been speculated to act as an ionophore [12]. The second most abundant protein 
found in CNS myelin is MBP; 22-35% of total myelin protein consists of a combination of 
MBP isoforms [11]. Finally, CNP makes up 4-15% of the total protein in myelin, while the 
remaining 5-25% is a combination of a variety of different proteins [11]. Transporter 
proteins and ion channels have not been extensively studied in the myelin membrane. 
 The myelin sheath, like any biological membrane, is fluid in nature. Molecules 
within the lipid bilayer are not static; instead, they are dynamic and capable of diffusion 
within the membrane itself. The fluid mosaic model, proposed by Singer and Nicolson in 
1972, describes the ability of proteins and lipids to move via rotational or translational 
diffusion [13]. Consequently, cellular membranes are heterogeneous and exhibit phase 
separation. Two coexisting phases, specifically the liquid-disordered (Ld) and liquid-
ordered (Lo) phases, are identifiable and can be differentiated by their lipid components; 
this compartmentalization is observed in the lipid bilayer of model membranes. The 
liquid-disordered phase is cholesterol-poor and primarily composed of unsaturated 
lipids, or those with short acyl chains, resulting in a more fluid and disordered 
membrane [14;15]. In contrast, cholesterol and other sterols are intrinsic to the liquid-
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ordered phase [14;15]. This phase is often enriched in sphingolipids, while containing 
few transmembrane proteins. Cholesterol and sphingolipids become tightly packed, 
along with saturated lipids, within the Lo phase, creating a thickened, less fluid and more 
ordered membrane. 
Although biological membranes, including the myelin sheath, are fluid, the lipid 
bilayer is maintained by hydrophobic and hydrophilic interactions; hydrogen bonding, 
electrostatic interactions, and van der Waals forces also contribute to the arrangement 
of lipids and proteins in the membrane [13]. These intermolecular forces are involved in 
the maintenance of Lo and Ld phases, as well as the formation of membrane 
microdomains, which are basis for many membrane-associated cellular processes [15]. 
Membrane microdomains, often termed lipid rafts, are enriched in cholesterol and 
other lipids with longer, highly saturated fatty acid chains; these are characteristic of the 
Lo phase. Experimentally, in biological membranes, lipid rafts are isolated as detergent 
resistant membranes (DRMs) using non-ionic detergents at 4oC. Numerous integral and 
peripheral membrane proteins are incorporated amongst these lipids, and they impart 
significant functional roles in biological membranes, including signal transduction, 
cellular transport, secretion and endocytosis [1;14;16]. The close proximity of 
interacting proteins within lipid rafts offers efficient signal transduction and has defined 
these microdomains as “signaling platforms” within biological membranes [1;14]. 
Proteins identified in the microdomains of myelin have demonstrated developmental 
regulation that is essential for maintenance of the myelin sheath; similarly, lipid rafts in 
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oligodendrocyte progenitors have been noted to contain proteins that provide vital 
roles in the signaling cascades necessary for their maturation and differentiation [16]. 
1.3 Demyelinating Diseases 
1.3.1 Multiple Sclerosis 
 Multiple sclerosis (MS) is a chronic disease of the central nervous system. It is 
characterized by the destruction of the myelin sheath; a consequence of myelin 
detachment from the axon of neurons [1]. These two processes are termed 
demyelination and intramyelinic edema, respectively [4]. The loss of myelin is usually 
coupled with damage to the oligodendrocytes which generate and maintain the myelin 
sheath [1]. Consequently, MS is a model example of a myelinopathy, in which the myelin 
sheath is damaged either directly or incidentally as a result of injury to the myelinating 
cells [4]. Grinker myelinopathy and Guillain-Barré syndrome are two other well-known 
myelinopathies. Figure 1.3 illustrates the typical pattern of myelinopathy, in addition to 
depicting other types of neurotoxic injury. The disruption of the myelin sheath, and the 
fundamental changes in its protein and lipid chemistry, contributes to the presentation 
of plaques which are customarily found in the white matter of individuals afflicted with 
MS [1]. In general, the disease manifests in recurring episodes of neurological 
insufficiency; symptoms differ according to the regions of the CNS which are affected 
[1]. Ultimately, the problem remains a consequence of impaired, or non-existent, 
transmission of action potentials. Schwann cells in the PNS are able to remyelinate 
neuronal axons, thereby restoring the transmission of electrical impulses; unfortunately, 
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remyelination in the CNS is more complicated and only occurs to a limited extent [4]. 
Without adequate cell division of the myelinating cells, the axon remains exposed and 
can initiate undesirable cross-talk with adjacent axons [4]. 
 
Figure 1.3 Patterns of injury in the cells of the nervous system 
 
Several different processes can result in injury to the cells of the nervous system; these include 
neuronopathy, axonopathy, myelinopathy and transmission toxicity. Neuron death is termed 
neuronopathy, and often causes the proliferation of astrocytes. Axonopathy occurs when the axon 
degenerates, despite neuron survival; the axon is the primary site of injury. Damage to the myelin sheath 
is termed myelinopathy. Myelinopathies may develop as a consequence of injury to the oligodendrocytes 
in the CNS, or Schwann cells in the PNS. In cases where cells are uninjured, transmission toxicity can still 
occur; excitation may be blocked, or cells may become excessively stimulated. Communication between 
neurons and their post-synaptic cells is disrupted. Image adapted from reference [4]. 
 
MS varies in its presentation of symptoms; as such, it has been clinically divided 
into four different types. Relapsing-remitting MS (RRMS) is diagnosed in individuals who 
experience random episodes of symptom flare-ups, followed by periods of recovery or 
remission [18;19]. These so-called attacks may introduce new symptoms or simply a 
worsening of existing ones.  Both symptomatic episodes and remission periods can last 
anywhere from a few hours to several months. RRMS is most common in MS patients, 
with more than 80% of cases initially presenting as this type [19]. Two subgroups of 
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RRMS exist; benign MS and clinically isolated syndrome. Cases in which remission 
reaches near completion, and in which there is limited progression in physical disability 
15-20 years post-diagnosis, are described as benign MS [18]. Alternatively, patients who 
experience only single episodes of neurological symptoms are often diagnosed with 
clinically isolated syndrome (CIS), sometimes called ‘probable MS’ [18]. The second main 
classification is primary progressive MS (PPMS). It affects roughly 10-15% of MS patients 
and is characterized by the continued advancement of symptoms and escalation of 
physical disability [18;19]. This form of the disease often presents later in life, and is the 
only type of MS which equally affects both men and women [18]. In all other types, 
women  appear to be most vulnerable to the manifestation of MS. Secondary 
progressive MS (SPMS) initially presents as RRMS, with distinct episodes and periods of 
remission; unfortunately, over time the disease evolves such that the disability no 
longer improves but continues to gradually worsen [18;19]. Approximately 50% of 
patients with RRMS will progress to SPMS within 10 years of their initial diagnosis [18]. 
Finally, progressive-relapsing MS (PRMS) is a rare diagnosis, in which the patient 
experiences a persistent worsening of symptoms combined with acute attacks of 
greater severity [18;19]. Although RRMS, PPMS, SPMS and PRMS are clinically discrete, 
the development and symptoms of multiple sclerosis range over a spectrum which can 
ultimately make for a challenging diagnosis. Disease-modifying treatments, in addition 
to those for symptom management, are available; however, the etiology of MS remains 
unclear and there is no known cure. 
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1.3.2 Models for Demyelination 
An animal model utilizes non-human organisms as a representation of the 
pathology, symptoms, and/or prognosis of a human disease.  Animal models have been 
developed not only as tools for investigating human diseases and disorders, but are key 
to the advancement of therapeutics. They provide a means for examining and 
manipulating disease processes, such as the development of MS, without unnecessarily 
harming actual humans. Although it would be ideal to directly study MS in people, tissue 
samples are hard to come by since patients are rarely biopsied [20]. Samples collected 
post-mortem provide limited information, as they are often representative of late-stage 
lesions and the chronic effects of MS; they do not provide much information regarding 
the generation and development of lesions or mechanisms of demyelination [20]. 
Typical models of MS demonstrate (1) immune-mediated demyelination, (2) viral-
induced demyelination, (3) genetic defects leading to demyelination, or (4) toxin-
induced demyelination [21;22]. Well-known examples of each include experimental 
autoimmune encephalomyelitis (EAE), Theiler’s murine encephalomyelitis virus (TMEV), 
DM-20 (deletion mutant of PLP), and the cuprizone model, respectively.  
Pelizaeus Merzbacher Disease (PMD) is an X-linked dysmyelinating disorder of 
the CNS that is characterized by hypomyelination and a reduction in the total number of 
mature oligodendrocytes. This human leukodystrophy has been successfully modelled in 
mice, rats, rabbits, and dogs; each exhibiting spontaneous mutations [21]. More 
specifically, it was discovered that roughly 25% of patients with PMD possess a mutation 
in the DM-20 gene which codes for a myelin PLP. DM-20 has proposed roles in 
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myelinogenesis; its expression has been shown in the normal embryonic development 
of mice, despite being a minor myelin protein in mature adults [23]. Individuals with 
increased protein expression demonstrated a more severe phenotype [21]. This 
discovery guided the development of ND4 transgenic mice, which are now used to 
model MS. The transgenic ND4 mice contain 70 copies of the DM-20 gene [23]. These 
mice are clinically normal up to 3 months of age; however, they develop neurological 
deficits which increase in severity as the animals mature. The transgenic mice die shortly 
after 8-10 months of age, when neurological symptoms are marked and include tremors 
and unsteady gait [23]. It is postulated that as the myelin membrane matures in ND4 
mice, the overexpression of DM-20 impedes the formation of compact myelin and 
triggers spontaneous demyelination. 
1.4 Sodium-Potassium Adenosine Triphosphatase 
1.4.1 Structure, Function, and Localization 
Sodium-potassium adenosine triphosphatase (Na+/K+-ATPase), also known as the 
sodium-potassium pump, is an integral plasma membrane protein responsible for the 
maintenance of the resting potential of cells, including oligodendrocytes, astrocytes, 
and microglia [24;25]. It belongs to the P-type ATPase family [26]. It specifically utilizes 
the energy generated from the hydrolysis of adenosine triphosphate (ATP), in order to 
import two potassium ions into the cell for every three sodium ions the enzyme exports 
out of the cell [24;27]. The resultant sodium ion gradient produced by the enzyme has 
been associated with the cellular uptake of nutrients, such as sugars and amino acids 
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[24]. At rest, the sodium-potassium pump utilizes 20-30% of ATP generated [28]. This 
active transport of sodium and potassium ions, performed by Na+/K+-ATPase, is a Mg2+-
dependent process [29]. Like other P-type ATPases, Na+/K+-ATPase forms an acyl 
phosphate intermediate; ATP binds to an aspartate residue in the enzyme, via the 
terminal phosphate of ATP [27]. All P-type ATPase family members contain a 7 amino 
acid motif that include the necessary aspartate residue; this sequence follows the 
format of D-K-T-G-T-[LIVM]-[TIS] [27]. The most common version of this DKTG motif is 
DKTGTLT [27]. P-type ATPases can be further classified according to their structure and 
function. P1-ATPases transport alkali metal cations, and P2-ATPases transport transition 
metals or metalloid cations [27]. The P3-ATPase subfamily only has a single member; 
KdpB is a protein which specifically transports K+ ions [27;30]. Members of each of these 
subfamilies vary in their arrangement of three key amino acid motifs; the DKTG, TGES, 
and GDGXNDXP sequences. The TGES motif is located in front of phosphorylation site of 
the protein, while the GDGXNDXP motif directly follows the ATP binding domain [27]. 
Generally there are three protein subunits which assemble together via non-
covalent bonds to produce the active form of the sodium-potassium pump [29]. These 
include a catalytic α subunit, a glycosylated β subunit, and a proteolipid γ subunit [29]. 
The subunits are roughly 110 kDa, 45-55 kDa, and 10 kDa, respectively [29]. The α 
subunit is polytopic, whereas the β subunit is a type II membrane protein [26]. 
Alternatively, the γ subunit is a transmembrane protein belonging to the FXYD family 
[25]. It is not required for functional expression of Na+/K+-ATPase; as a result, Na+/K+-
ATPase is commonly identified as a heterodimeric enzyme, composed of a αβ complex. 
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Several isoforms of the α and β Na+/K+-ATPase subunits exist. Each isoform may 
demonstrate variations in ion, ATP or ligand affinities [24]. Likewise, particular isoforms 
can be distinguished according to their location in the plasma membrane, their ability to 
couple with other transporters, or the way in which they are regulated [24]. 
In mammalian cells, studies have successfully identified four isoforms of the α 
subunit [24]. Each of these isoforms is roughly 1000 amino acid residues in length [27]. 
The divergence in amino acid sequences between the isoforms is minor, and it is unclear 
how these changes influence the functional roles of the subunits [27]. The amino acid 
sequences of Na+/K+-ATPase α1, α2, and α3 are available in Appendix B. The α1 subunit is 
the most prominent isoform, with ubiquitous expression in mammalian cells, and it is 
typically the dominant or exclusive isoform found in epithelia and kidney cells [24;27]. 
Alternatively, the α2 subunit is found in specific tissues including brain, muscle, adipose, 
osteoblasts, retina, choroid plexus, lung, and the optic nerve [24]. It regulates muscle 
contractility, and is involved in responding to stress by adjusting blood pressure [31]. 
The α3 and α4 subunits demonstrate significant tissue specificity. The α3 subunit is 
expressed in the neural tissue of most animals, though it has also been identified in 
human cardiac tissue [24]. With restriction to the testis, the α4 subunit has only been 
identified in spermatogonia and sperm [24;27]. It was demonstrated that inhibition of 
the α4 subunit results in immotile sperm, and mutations can ultimately impair fertility 
[27;31]. Diversity in Na+, K+, ATP and cardiac glycoside affinity has been noted among 
the α subunit isoforms [24]. For example, the rat α3 isoform has demonstrated a 
reduced affinity for Na+ in comparison to α1 and α2, whereas α1 exhibits a greater K
+ 
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affinity than its α2 and α3 counterparts [24]. The isoforms of the α subunit have 
displayed a minimum of 85% conserved sequences, across species [32]. Neurological 
diseases such as familial hemiplegic migraine type 2 and rapid-onset dystonia-
parkinsonism have been associated with human mutations of the α1- and α2-subunits 
[31]. 
The C- and N-termini of the α subunit are both intracellular, and the subunit also 
possesses five extracellular and four intracellular loops [27]. Consequently, the α 
subunit of Na+/K+-ATPase has 10 transmembrane domains, as shown in Figure 1.4. This 
observation is consistent with other P-type ATPases, as all family members have at least 
six transmembrane helices (M1-M6); also, the P2-type ATPase subclass, of which Na
+/K+-
ATPase belongs, have 10 transmembrane helices (M1-M10) [33]. These transmembrane 
regions accommodate the ion binding sites for Na+ and K+ [32]. Three major cytoplasmic 
domains have also been identified in the α subunits; these include the actuator (A-), 
nucleotide binding (N-), and phosphorylation (P-) domains [32]. The actuator domain is 
composed of the N-terminal and second cytoplasmic domain (CD2) connecting helices 
M2 and M3; it contains the TGES motif [27]. Alternatively, the third cytoplasmic domain 
(CD3) connecting M4 and M5 accommodates the nucleotide binding and 
phosphorylation domains, with the N-domain being inserted in the P-domain [32]. The 
conserved aspartate residue, and its associated DKTG sequence, is located within the P-
domain [27]. 
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Figure 1.4 The typical structure of the α subunit of Na+/K+-ATPase 
 
The α subunit of Na
+
/K
+
-ATPase has 10 transmembrane domains, with both N and C-termini located on 
the cytoplasmic side of the plasma membrane. Image modified from reference [27]. 
 
To date, four isoforms of the 370 amino acid long β subunit have been 
discovered [27]. Only three of the isoforms (β1, β2, β3) have been shown to occur in 
mammalian cells [24]. Limited information is available regarding the β4 subunit, at this 
time. Similar to the α1 subunit, the β1 subunit is found in most tissues [24]. It is 
intimately involved in the intracellular adhesion of epithelial cells [31]. Alternatively, the 
β2 subunit is limited primarily to neural tissue, whereas the β3 subunit can be found in a 
broader range of tissues [27;34]. The β2 subunit, sometimes referred to as the adhesion 
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molecule on glia (AMOG), plays an important role in the adhesion and subsequent 
migration of neurons on glial cells [31]. The N-terminus of the β subunit and roughly 30 
amino acid residues reside in the cytoplasm [27]. All isoforms of the β subunit are 
heavily glycosylated, with the extracellular portion of the β subunit containing N-linked 
glycosylation sites, either NXS or NXT [3;27]. Each isoform varies in its number of 
potential N-glycosylation sequences; this value also depends on the species of origin. 
For example, the mammalian β1 subunit has three possible extracellular N-glycosylation 
sites; alternatively, the β2 subunit may have eight or nine potential N-glycosylation sites 
if derived from a human or mouse, respectively [3]. The β1 subunit extracellular domain 
is also the site of several disulfide bridges; enzyme activity is lost if these disulfide 
bridges are disrupted [3;27]. The structure of the mammalian β1 subunit is illustrated in 
Figure 1.5. Conservation of amino acid sequences is much lower for the isoforms of the 
β subunit when compared to the α subunit, with β3 subunits being as low as 50% 
identical across species [32]. The amino acid sequences of Na+/K+-ATPase β1, β2, and β3 
are available in Appendix B. A decrease in β1 subunit expression has been linked to 
certain forms of cancer, whereas disturbances in β2 subunit expression and distribution 
within cells and/or tissues have been associated with gliomas and epilepsy [31]. 
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Figure 1.5 The structure of the mammalian β1 subunit of Na
+/K+-ATPase 
 
The β1 subunit of Na
+
/K
+
-ATPase has a single transmembrane segment, with a large extracellular region. 
The N-terminal is located with the cytoplasm, while the C-terminal, 3 N-glycosylation sequences and 3 
disulfide bridges are found on the extracellular portion of the protein. Image modified from reference 
[27]. 
1.4.2 Altered and Proposed Functions 
Both α and β subunits are vital for cardiac glycoside-sensitive Na+/K+-ATPase 
activity; separation of these components results in a loss of enzymatic activity [27]. It 
has been unmistakably shown that the β subunit is responsible for the transport and 
placement of the α subunit into the plasma membrane; nonetheless, the β subunit can 
be expressed in the membrane without α expression [27]. These components are 
combined in the endoplasmic reticulum, where independent production of the subunits 
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also occurs [27]. Despite the obvious tissue-specific distribution of both the α and β 
isoforms of Na+/K+-ATPase, little is known regarding specific αβ heterodimers [31].  
Members of the FXYD family have been closely associated with Na+/K+-ATPase; 
these proteins modulate the kinetic activity of the enzyme [25]. Currently, all 
crystallized structures of the αβ complex of Na+/K+-ATPase have been shown to 
associate with an FXYD protein; nonetheless this γ subunit is not essential for the 
functional expression of the αβ complex [32]. It is for this reason that the sodium 
potassium pump is commonly classified as a heterodimeric protein. Regardless, it is 
important to recognize the influence these proteins have on the enzymatic activity of 
Na+/K+-ATPase. The various isoforms of the γ subunit, FXYD1-7, are summarized in Table 
1.1. These variants differ in their localization and have distinct structural divergence in 
their N-terminal sequences [25]. The γ subunit has been shown to influence the catalytic 
function of Na+/K+-ATPase in two distinct ways; it increases the affinity between ATP 
and the enzyme, in addition to increasing antagonism between sodium and potassium 
ions [35]. The sodium and potassium ions will compete for Na+ activation sites on the 
cytoplasmic side of the plasma membrane [25].  
Table 1.1 FYXD Proteins 
This table provides the distribution of FXYD proteins which associate with Na
+
/K
+
-ATPase, in addition to 
providing the known effects that these proteins have on its enzymatic activity. Table modified from 
reference [36]. 
Isoform Distribution Function 
FXYD1 
 Known to combine with 
Na+/K+-ATPase α1,α2, and α3 
in the cerebellum 
 Most abundant in Purkinje 
cells, choroid plexus and 
ependymal cells 
 Present in neurons and glia 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
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 Limited expression identified 
in Allan Atlas rat brain 
FXYD2 
 Moderate expression 
identified in Allan Atlas rat 
brain 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
FXYD3 
 No expression in Allan Atlas 
rat brain 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
FXYD4 
 No expression in Allan Atlas 
rat brain 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
FXYD5 
 Limited expression identified 
in Allan Atlas rat brain 
 Increased Na+/K+-ATPase 
maximum enzyme inhibition 
(Imax) 
FXYD6 
 Abundant expression 
identified in Allan Atlas rat 
brain 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
FXYD7 
 Almost exclusive to brain 
 Abundant expression 
identified in Allan Atlas rat 
brain 
 Decreased affinity of Na+/K+-
ATPase for Na+ and K+ 
 
 The general reaction mechanism for Na+/K+-ATPase is depicted in Figure 1.6. 
Na+/K+-ATPase exists largely in two enzymatic states. These states, E1 and E2, are due to 
extreme conformational changes which occur during the catalytic process [33]. E1 is the 
high affinity state for the primary transported ion (Na+ in this case), whereas E2 is the 
low affinity state for sodium ions [33]. It has been suggested that a minimum of four of 
these steps are voltage-dependent. In particular, the cytoplasmic Na+ binding, the E1 to 
E2 conformational change, the extracellular release of Na
+, and the extracellular binding 
of K+, are all thought to be voltage dependent [37].  
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Figure 1.6 The Na+/K+-ATPase reaction cycle 
 
Sodium and potassium ions are represented by purple and green dots, respectively. The E1 state has a 
high affinity for sodium ions, while the E2 state has a low affinity for sodium ions. Sodium and potassium 
ions are exchanged across the plasma membrane by Na+/K+-ATPase, using the energy captured from the 
hydrolysis of ATP. Image adapted from reference [27]. 
 
 There are two main categories within which Na+/K+-ATPase inhibitors can be 
classified; these include glycoside inhibitors and non-glycoside inhibitors. Glycoside 
inhibitors, otherwise known as cardiac glycosides, are characterized by the union of an 
aglycone, or genin, and one to four sugars [38]. The aglycone is pharmacologically 
active, with a chemical structure similar to steroids or bile acids; conversely, the sugars 
determine the potency and duration of action of the inhibitor by managing its solubility 
[38]. Examples of cardiac glycosides include digoxin and ouabain. Like all cardiac 
glycosides, these compounds can be further divided into two classes of glycoside 
inhibitors: the cardenolides and the bufadienolides. In contrast, non-glycoside inhibitors 
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have distinctive chemical structures from the glycosides, or have a modified aglycone 
component. For example, cassaine is a non-glycoside inhibitor, in which the steroid ring 
is broken [38].   
 Though ion transport is the primary function of Na+/K+-ATPase, several unrelated 
functions have been proposed. It has demonstrated a role in cellular signalling 
pathways. Exposure to low levels of the glycoside inhibitor ouabain, at concentrations 
which do not affect ion gradients, has been associated with increased cellular growth 
[24]. Na+/K+-ATPase appears to be involved in two Ras-dependent signalling cascades, 
which are activated by ouabain inhibition of the enzyme. In the first pathway, Ras 
promotes the formation of reactive oxygen species which in turn activate nuclear factor 
kappa light-chain-enhancer of activated B cells (NF-κB); while in the second pathway, 
the induced Ras protein initiates a Raf/MEK/MAPK cascade [24]. MAPK refers to the 
mitogen-activated protein kinase, and MEK is the MAPK kinase. It is unclear if the 
induction of these signalling cascades is due to the inhibition of a specific α subunit, or if 
several isoforms are affected. The effect has been demonstrated in kidney and HeLa 
cells which only express the α1 subunit; however, ouabain-induced signalling and cell 
growth has also been witnessed in cardiac myocytes and smooth muscle cells which 
express both α1 and α2 subunits [24]. 
1.5 Purpose of the Study 
Disrupted Na+/K+-ATPase activity has already been implicated in a variety of 
disorders, such as male infertility, rapid onset dystonia Parkinsonism, essential 
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hypertension, migraine headaches, and epilepsy [24;27;39;40]. Decreased Na+/K+-
ATPase expression has also been previously recognized in bladder, kidney, colon, breast 
and pancreatic cancers [41]. Changes in the activity or expression of Na+/K+-ATPase 
within the central nervous system may designate this protein as a biomarker of certain 
neurological conditions, including MS. The three CNS neural cell types, specifically 
neurons, astrocytes and oligodendrocytes, do not demonstrate equivalent expression of 
either the α or β isoforms of Na+/K+-ATPase [36]. In addition, neither the α4 or β4 
isoforms are known to exist in the central nervous system of humans. The role of 
Na+/K+-ATPase in the myelin membrane, and its potential as a biomarker of MS, has not 
been previously investigated. MS affects people of all age demographics, emphasizing 
the value in successfully treating this condition. Likewise, it is one of the main causes of 
permanent disability in not only paediatric and elderly populations, but also young 
adults [17]. 
The main purpose of this study was to characterize sodium-potassium adenosine 
triphosphatase in the myelin membrane, using a mouse model. In order to achieve this 
feat, three primary objectives were defined: 
 The first objective of this study was to identify which Na+/K+-ATPase 
subunit isoforms exist in mouse myelin, determine how they are 
distributed among the various microdomains, and to characterize their 
expression. 
 The second objective was to determine: 
o The heterodimeric forms of Na+/K+-ATPase in mouse myelin. 
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o The specific binding partners of Na+/K+-ATPase in mouse myelin. 
 The third objective was to evaluate any differences in the expression of 
Na+/K+-ATPase, and its individual subunit isoforms, in healthy mouse 
myelin and in diseased mouse myelin, specifically using ND4 mice to 
model MS. 
The realization of these objectives will provide insight into the structural and 
functional roles of Na+/K+-ATPase within the myelin sheath. Establishing the normal 
protein interactions of Na+/K+-ATPase and its expression in healthy, intact myelin will 
provide the basis for its comparison in models of myelinopathies such as MS. Although 
Na+/K+-ATPase is an integral membrane protein, making its use as a biomarker more 
challenging, understanding its role in demyelination will also provide crucial information 
for the development of therapies for neurological diseases. Determining the 
contribution of Na+/K+-ATPase to either demyelination or remyelination processes, and 
identifying its binding partners, will indicate possible ways that the protein can be 
manipulated for preventative or therapeutic purposes. 
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Chapter 2 – Materials, Experimental Techniques, and 
Methodology 
2.1 Materials 
Mouse brains, collected from CD1 strain mice, were purchased from Rockland 
Inc. (Gilbertsville, PA, USA) and Bioreclamation LLC (Liverpool, NY, USA). The transgenic 
ND4 mouse brains were provided by Dr. George Harauz, from the University of Guelph 
(Guelph, ON, Canada). All animal tissues were stored at -80oC. The Pierce Micro 
Bicinchoninic acid (BCA) Protein Assay Kit used in this study was from ThermoScientific 
(Rockford, IL, USA). Protease Inhibitor Cocktail (PIC) and Phosphatase Inhibitor Cocktail 
(PhosSTOP) tablets were from Roche (Mannheim, Germany). Grade 703 blotting paper 
was from VWR International (Mississauga, ON, Canada), while 0.45 μm nitrocellulose 
membrane was purchased from both Bio-Rad Laboratories Ltd. (Mississauga, ON, 
Canada) and Santa Cruz Biotechnology (Dallas, TX, USA). 
Ethyl ether and ammonium bicarbonate were purchased from EMD Chemicals 
(Gibbstown, NJ, USA). Anhydrous alcohol and acetonitrile were from Mallinckrodt Baker, 
Inc. (Philipsburg, NJ, USA). Methanol was from Fischer Scientific (Fair Lawn, NJ, USA) and 
acetone was purchased from Caledon Laboratories Ltd. (Georgetown, ON, Canada). 
Sodium thiosulfate, silver nitrate, 37% formaldehyde, sodium carbonate, triton X-100 
(TX-100), and 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) 
detergent were purchased from Sigma-Aldrich (St. Louis, MO, USA). TX-100 10% (w/v) 
solution was also purchased from ThermoScientific (Rockford, IL, USA) as Surfact-Amps 
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X-100. Sodium dodecyl sulfate (SDS) was purchased from Bio Basic Inc. (USA) and Fluka 
Chemie (Switzerland). Additionally, AccuGENE 10% (w/v) SDS was obtained from Lonza 
(Rockland, ME, USA). Tetramethylethylenediamine (TEMED) was from both Fisher 
Scientific (Fair Lawn, NJ, USA) and Bio-Rad Laboratories, Inc. (Hercules, CA, USA). 
Acrylamide/bis 30% solution (37.5:1) was purchased from Bio-Rad Laboratories, Inc. 
(Japan). Tween-20 10% solution, Precision Plus Protein Dual Color Standards, and 
Coomassie G-250 BioSafe stain were from Bio-Rad Laboratories, Inc. (Hercules, CA, 
USA). Hydrochloric acid (HCl) was purchased from VWR Scientific Products (West 
Chester, PA, USA) and from EM Science (Darmstadt, Germany). Glacial acetic acid was 
also purchased from EM Science (Darmstadt, Germany). Ammonium persulfate (APS), 
glycerol and trypsin gold, mass spectrometry grade, were from MD Biochemicals, LLC 
(Solon, OH, USA), Sigma-Aldrich (St. Louis, MO, USA) and Promega Corporation 
(Madison, WI, USA), respectively. 
Tris base was obtained from both BioBasic Inc. (USA) and Sigma-Aldrich (St. 
Louis, MO, USA). Sucrose was purchased from Fischer Scientific (Fair Lawn, NJ, USA) and 
Sigma-Aldrich (St. Louis, MO, USA). Potassium chloride (KCl), magnesium chloride 
(MgCl2), sodium chloride (NaCl), ethylene diamine tetraacetic acid (EDTA), ethylene 
glycol tetraacetic acid (EGTA), dithiothreitol (DTT), iodoacetamide, 2-mercaptoethanol, 
sodium orthovanadate (Na3VO4), phenylmethanesulfonylfluoride (PMSF), and 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) were also from Sigma-Aldrich. 
Bromophenol blue sodium salt was obtained from Fisher Scientific (Fair Lawn, NJ, USA). 
Percoll was from GE Healthcare (Uppsala, Sweden). Skim milk powder was from Metro 
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Selection (Toronto, ON, Canada). Glycine was purchased from Fischer Scientific (Fair 
Lawn, NJ, USA). Formic acid was purchased under the Fluka brand of Sigma-Aldrich 
(Steinheim, Germany). D-mannitol was from Acros Organics (Geel, Belgium). Cholera-
toxin B subunit peroxidase conjugate was from Sigma-Aldrich (St. Louis, MO, USA). 
Table 2.1 Primary antibodies used in this study 
Primary antibodies were obtained from EM Millipore (Temecula, CA, USA), Santa Cruz Biotechnology 
(Dallas, TX, USA), Sigma-Aldrich (St. Louis, MO, USA) and ThermoScientific (Rockford, IL, USA). 
Antibody Type Specificity/Epitope Host Supplier 
Product 
Identifier 
β-Actin Monoclonal N-terminal Mouse Sigma-Aldrich A-1978 
Na+/K+-
ATPase α 
Monoclonal 
aa 551-850 of 
Na+/K+-ATPase α 
Mouse Santa Cruz SC-48345 
Na+/K+-
ATPase α1 
Monoclonal 
Purified renal 
outer medulla of 
rabbit origin 
Mouse Santa Cruz SC-21712 
Na+/K+-
ATPase α2 
Polyclonal 
Peptide mapping 
within a 
cytoplasmic 
domain of Na+/K+-
ATPase α2 of 
human origin 
Goat Santa Cruz SC-31391 
Na+/K+-
ATPase α3 
Monoclonal Na+/K+-ATPase α3 Mouse ThermoScientific 
XVIF9-G10, 
MA3-951 
Na+/K+-
ATPase β1 
Monoclonal 
External domain of 
Na+/K+-ATPase β1 
Mouse Santa Cruz SC-58626 
Na+/K+-
ATPase β2 
Polyclonal 
aa 15-141 from the 
central region of 
human Na+/K+-
ATPase β2 
Rabbit ThermoScientific PA5-26279 
Na+/K+-
ATPase β3 
Polyclonal 
Internal region of 
Na+/K+-ATPase β3 
of mouse origin 
Goat Santa Cruz SC-66343 
MBP Monoclonal aa 82-87 Rat Millipore MAB386 
MCT1 Polyclonal aa 430-460 Rabbit ThermoScientific PA5-12335 
NQO1 Polyclonal 
aa 200 to C-
terminus of human 
NQO1 
Rabbit ThermoScientific PA5-19624 
VDAC Polyclonal Human VDAC Rabbit Millipore AB10527 
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EZview Red Protein A and G Affinity Gels were from Sigma-Aldrich (St. Louis, MO, 
USA), while the Na+/K+-ATPase α1 antibody conjugated agarose (SC-21712) was acquired 
from Santa Cruz Biotechnology (Dallas, TX, USA). The antibodies, their suppliers, and 
product information, used in this study, are provided in Tables 2.1 and 2.2. The two 
enhanced chemiluminescent reagents, SuperSignal West Femto Substrate and VisiGlo 
Select HRP Chemiluminescent Substrate, were from ThermoScientific and AMRESCO 
(Solon, OH, USA), respectively. The water used throughout this study was filtered using 
a Milli-Q water purification system (Millipore).  
Table 2.2 Secondary antibodies used in this study 
Secondary antibodies were obtained from Rockland Inc. (Gilbertsville, PA, USA), Sigma-Aldrich (St. Louis, 
MO, USA) and ThermoScientific (Rockford, IL, USA). 
Antibody Type Specificity/Epitope Host Supplier 
Product 
Identifier 
Anti-Goat 
IgG-HRP 
Polyclonal IgG Rabbit Sigma-Aldrich A-5420 
Anti-Mouse 
IgG-HRP 
Polyclonal IgG, Fc fragment Goat Sigma-Aldrich A-2554 
Anti-Rabbit 
IgG-HRP 
Polyclonal IgG Goat Sigma-Aldrich A-0545 
DyLight 488 
Anti-Rat IgG 
Polyclonal IgG Goat Rockland 612-141-120 
DyLight 549 
Anti-Rabbit 
IgG 
Polyclonal IgG Goat ThermoScientific 35557 
DyLight 649 
Anti-Mouse 
IgG 
Polyclonal IgG Goat ThermoScientific 35515 
 
 Refer to Appendix A for information regarding the structure and physical and 
chemical properties of the detergents used in this study. 
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2.2 Experimental Techniques 
2.2.1 Electrophoretic Separation of Proteins 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
commonly used biochemical technique, also known as Laemmli gel electrophoresis, 
which separates proteins according to their molecular mass. In this technique, the 
proteins are exposed to a detergent, specifically SDS, and a reducing agent, such as 2-
mercaptoethanol. These compounds are responsible for the disruption of tertiary and 
quaternary protein structures. They denature the proteins by interacting with 
hydrophobic domains and breaking disulfide bonds, respectively. SDS also imparts a 
negative charge to proteins by coating their surfaces, which allows for separation using 
an electrical current. When these protein samples are applied to a discontinuous 
polyacrylamide gel, the now negatively charged proteins migrate towards the positive 
electrode; since all the proteins are linearized, they migrate according to their overall 
size and the smaller, lower molecular mass proteins will migrate the fastest.  
A typical Laemmli SDS-PAGE gel system consists of a stacking gel of pH 6.8, a 
resolving gel of pH 8.8, and an electrophoresis buffer containing glycine [42]. Both the 
stacking and resolving gels consist of polymerized acrylamide which is formed by the 
addition of APS and TEMED; these ingredients initiate the polymerization of acrylamide 
by both introducing and stabilizing free radicals. The presence of bisacrylamide allows 
cross-linking between polyacrylamide chains, thereby producing the gel structure. 
Stacking gels generally contain a lower percentage of acrylamide; thus, they have larger 
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pores for the proteins to migrate through during electrophoresis. Alternatively, the 
resolving gels have a higher acrylamide concentration, though it can vary as needed; 
higher acrylamide content is necessary for the resolution of smaller molecular mass 
proteins, as it produces a gel with smaller pores. During electrophoretic separation, 
glycine from the running buffer migrates towards the cathode and becomes fully 
deprotonated while transitioning between the stacking and resolving gels. Chloride ions 
in the gel also migrate towards the cathode. In the stacking gel, glycine migrates slower, 
and chloride ions migrate faster, than the negatively charged sample proteins; however, 
once in the resolving gel, the newly deprotonated glycine ions become increasingly 
mobile and pass the sample proteins, thereby encouraging their separation according to 
molecular mass [42].  
SDS-PAGE can separate proteins ranging from 20-250 kDa in size, though the 
scope can be altered by increasing or decreasing the acrylamide content of the resolving 
gel. Although it offers high resolution of protein separation, the Laemmli gel system can 
be inconvenient due to the time consuming gel casting procedure. Preparation and 
polymerization of both stacking and resolving gels can take a total of 60-90 minutes, 
while the running time takes roughly an additional 80 minutes [42]. Once proteins are 
separated, SDS-PAGE gels can be stained with Coomassie or silver; they can also be 
transferred to a solid support for Western blot analysis. 
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2.2.2 Western Blotting with Chemiluminescence and Fluorescence 
Detection 
Western blotting was used throughout this study to qualitatively and 
quantitatively evaluate protein product expression. It allows for the identification of 
specific proteins within complex biological samples; it is a useful tool for monitoring 
protein expression in various tissues and under different conditions. Gel electrophoresis 
is used to separate proteins according to molecular mass, and these proteins can then 
be transferred to a solid support such that they can be probed with antibodies. 
Nitrocellulose or polyvinylidene difluoride (PVDF) are two types of membranes which 
are commonly used as the solid support in Western blotting. In this study, a wet 
electrotransfer procedure was used to transfer myelin proteins to nitrocellulose 
membranes; similar to electrophoresis, the proteins migrate from the gel towards the 
membrane using an electrical current.  
Once the solid support membrane is prepared, it is probed with a primary 
antibody. Primary antibodies are designed for the unambiguous identification of a single 
protein; they contain paratopes which recognize and bind unique epitopes, or antigenic 
regions, of their respective protein targets. Epitopes which are not unique between two 
or more different proteins may result in non-specific binding and cross-reactivity of the 
antibody with other proteins in the sample or in the blocking buffer. 
Antibodies can also be developed in two different ways; consequently, there are 
two main types of antibodies. Monoclonal antibodies are produced using identical 
immortalized B lymphocytes; they target a specific antigen or region of the molecule of 
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interest. Polyclonal antibodies, on the other hand, are developed through the 
immunization of animals; therefore, they are a collective of antibodies which can target 
different components of the same molecule [1]. Polyclonal antibodies are produced by 
many different B lymphocytes and since they recognize multiple epitopes of a single 
antigen, they are far less specific than monoclonal antibodies. 
After a primary antibody has been applied, Western blots are subsequently 
exposed to a secondary antibody that is designed to bind the primary antibodies which 
are securely adhered to the proteins of interest on the solid support. Secondary 
antibodies may be fluorescently tagged or conjugated to an enzyme, thereby allowing 
the antibody bound regions of the membrane to be visualized. Alternatively, 
chemiluminescent blots take advantage of secondary antibodies which are conjugated 
to an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase [43]. These 
blots are incubated in a detection reagent prior to imaging; this reagent contains the 
substrate for these enzymes and light is emitted as a by-product of the reaction. Both 
fluorescent and chemiluminescent detection methods produce a signal which can be 
measured by densitometric analysis and used to quantify protein expression. The 
intensity of the measured signal is proportional to the amount of protein bound by 
antibody. The two methods provide extremely sensitive protein detection; for example, 
2-4 pg of transferrin protein can be detected using fluorescence, whereas little as 1 pg is 
detectable with chemiluminescence [44].  
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2.2.3 Individual Protein and Protein Complex Immunoprecipitation 
Individual protein, or immunoprecipitation (IP), assays are used for the 
purification of a specific protein from a complex mixture. Alternatively, protein complex, 
or co-immunoprecipitation (co-IP), studies are used for the purification of a group of 
interacting proteins; it is also an effective way to examine indirect protein-protein 
interactions [45]. Co-IP procedures use an antibody to specifically isolate a bait protein 
and its respective targets. The bait is the protein of interest, while its binding partners or 
associated proteins are the targets [45]. In contrast, IP studies directly capture only the 
target protein. In either scenario, a solid support, such as agarose or other polymeric 
beads which are covalently bonded to Protein A or G, are used to bind an antibody 
specific for the protein of interest; Protein A and G bind antibodies at either the Fc 
portion or Fab fragments of Immunoglobulin G (IgG) [46]. Protein A and G are able to 
interact with antibodies of various species and subclasses; however, not every antibody 
is capable of immunoprecipitation and therefore may require use of a polyclonal 
antibody or the addition of a bridging antibody which is reactive with the primary 
antibody but also has a higher affinity for Protein A or G.  
When the biological sample (i.e., complex mixture) is introduced to the beads, 
the target or bait/target protein complexes will bind to the antibody and become 
immobilized. Unbound proteins can then be washed away, and the bait and/or targets 
can be eluted using detergents or by boiling. Non-specific binding by undesirable 
proteins can be prevented by altering the wash buffer; salt or detergent content will 
affect the stringency of IP/co-IP studies. The antibody may also co-elute, resulting in 
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immunoglobulin light and heavy chains appearing in the final product. Softer elution 
methods, which avoid boiling, can be developed; these may reduce the likelihood of 
antibody contamination. In situations where IP/co-IP experiments are paired with 
Western blotting, antibody contamination poses a problem since many secondary 
antibodies are raised against immunoglobulins. The signal may become overwhelmingly 
high if the IP/co-IP capture antibody and the Western primary antibodies were 
produced in the same species; thus, it is important to use antibodies from different 
species or minimize contamination [45]. Similarly, the light and heavy immunoglobulin 
chains of the antibody may mask unique protein bands in the eluted product, if 
examined using Coomassie or silver staining. 
2.2.4 Protein Identification by Mass Spectrometry 
Mass spectrometry is a popular analytical technique for the identification of 
biological molecules. It is highly sensitive and allows for the identification of compounds 
based on their mass spectrum. A mass spectrum is a graph of ion intensity versus mass-
to-charge ratio (m/z); in essence, it illustrates the distribution of ions, generated from a 
sample, according to their mass. All mass spectrometers are made up of three distinct 
part components: the source in which ions are produced from the input sample, an 
analyzer which separates the ions according to their m/z, and a detector which turns the 
ions into a signal. 
 Ion sources vary depending on the chemical properties of the analytes under 
investigation; for protein identification, electrospray ionization (ESI) is typically used. It 
is a soft ionization method, which minimizes fragmentation of the molecular or parent 
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ions generated. Furthermore, it permits the detection of high mass compounds and is 
easily coupled to liquid chromatography. Matrix-assisted laser desorption ionization 
(MALDI) is another ionization technique that is effective for the analysis of peptides, 
proteins, and other biological molecules. The analyzed sample is co-crystallized with an 
excess of a solid matrix, which absorbs light from a pulsed laser; unfortunately, the 
matrix-related ions generate an increased background signal which impairs the analysis 
of smaller molecules. In addition, it cannot be readily coupled with liquid 
chromatography for chemical separation. 
Mass analyzers have three major features: a mass limit which represents the 
highest m/z that is measurable, its ability to successfully transmit ions from the source 
to the detector, and the resolving power to distinguish between ions of minimal mass 
difference. Quadrupole mass analyzers are commonly paired with ESI, while time-of-
flight (TOF) mass spectrometers are matched with MALDI.  The quadrupole mass 
spectrometer can operate in a scanning mode which allows a range of m/z ratios to be 
monitored; alternatively, it can monitor for selected ions, thereby targeting only a few 
m/z ratios. Selected ion monitoring is possible when analyte masses are known in 
advance, and this allows for more rapid detection. TOF systems provide higher 
resolution, superior ion transmission and can analyze a greater range of masses; 
however, TOF is limited when compared with quadrupole mass analyzers, as it does not 
have tandem mass spectrometry capabilities. 
Protein identification is often achieved by following a bottom-up approach; 
proteins are digested with proteolytic enzymes and then the resultant peptides are 
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separated and analyzed by liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) [47]. The identified peptides can then be compared with 
protein databases and/or peptide libraries; alternatively, programs are available that 
perform de novo sequencing on LC-MS/MS data, and search the results against specific 
databases. Collision-induced dissociation of digested peptides is commonly used to 
generate fragment ions for the database searches; the primary fragments are b-ions 
which represent the N-terminus of the peptide, and y-ions that are generated from the 
C-terminus [47]. The fragment b- and y-ions can be used to obtain the actual amino acid 
sequence of the peptides being analyzed (refer to Appendix F). Unfortunately, the 
bottom-up approach can result in the loss of post-translational modifications during 
fragmentation, and sequence coverage is often between 5-70% [47]. 
When using a top-down approach for proteomic analysis, intact proteins are 
directly examined using mass spectrometry. The direct measurement of the intact 
molecular protein species allows its molecular form to be established. Use of alternative 
dissociation techniques, such as electron-capture dissociation, allows for the generation 
of c- and z-ions from cleavage of the N-C(R) bond; this type of fragmentation preserves 
post-translational modifications [47]. Post-translational modifications of particular 
importance include glycosylation and phosphorylation; however, ubiquitylation, 
deamidation, acetylation and methylation also occur in proteins. These modifications 
are critically important to the structural and functional features of proteins, and can 
control biological processes. The top-down approach can provide 100% sequence 
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coverage, including these modifications, but it is not readily coupled to liquid 
chromatography; all protein purification must be performed offline [47]. 
2.3 Methodology 
2.3.1 Myelin Isolation 
Myelin was isolated from mouse brains using a modified version of the method 
developed by Norton [48]. Whole brains were homogenized with a Dounce 
homogenizer, on ice, in 10.5% sucrose in TNE (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 
mM EDTA) containing 1 mM Na3VO4, 1X PIC, 1X PhosSTOP and 1 mM PMSF. The 
homogenate was overlaid on top of an equal volume of 30% sucrose in TNE, in 5 mL 
centrifuge tubes. In order to separate the myelin from the remaining brain tissue, the 
homogenate was subjected to a series of centrifugation steps using the Optima Max 
Ultracentrifuge (Beckman Coulter). The MLS-50 rotor for this ultracentrifuge was used. 
First, the sucrose gradient was centrifuged for 60 minutes at 35,000 rpm. The middle 
myelin layer, at the 10.5%-30% sucrose interface, was removed. This fraction was 
diluted with an equal volume of ice cold water and gently vortexed. Centrifugation for 
30 minutes at 35,000 rpm was subsequently used to pellet the myelin membranes. 
Pellets were osmotically shocked by the addition of 10 volumes of ice cold water, gentle 
vortexing and incubation for 10 minutes on ice. The myelin was pelleted at 23,000 rpm 
for 20 minutes, and then resuspended in 10.5% sucrose in TNE containing Na3VO4, PIC, 
PhosSTOP and PMSF. This mixture was overlaid onto an equal volume of 30% sucrose in 
TNE, and all of the centrifugation steps were repeated. The final myelin pellet was 
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resuspended in myelin storage buffer (25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2 mM 
EDTA) containing 2 mM Na3VO4, 1X PIC, 1X PhosSTOP and 2 mM PMSF. The isolated 
myelin was aliquoted and stored at -80oC until needed. The protein concentration of the 
isolated myelin was determined, after each preparation, using the Micro BCA Protein 
Assay Kit from ThermoScientific. The manufacturer’s instructions were followed, using 
bovine albumin standard (BSA) as the standard, and the microplate spectrophotometer 
was set to measure absorbance at a wavelength of 562 nm. 
 A second method for isolating myelin was also used in this study. This method, 
based on the protocol developed by Kristian, isolates mitochondria from the central 
nervous system; myelin and synaptosomes are isolated by-products of this protocol 
[49]. Rather than using a sucrose gradient, this method applies the brain homogenate to 
a Percoll gradient. The two types of gradients are depicted in Figure 2.1. Percoll is made 
of colloidal silica particles which have been coated with polyvinylpyrrolidone, and it has 
a low viscosity. As a result, the use of Percoll, rather than sucrose, allows for the use of 
lower centrifugal forces, and accelerates sedimentation rates [50]. Whole mouse brains 
were homogenized with a Dounce homogenizer, on ice, in isolation medium (225 mM 
sucrose, 75 mM mannitol, 1 mM EGTA, 5 mM HEPES, pH 7.4); more specifically, two 
brains were homogenized in 1 mL of isolation medium, and then brought to a total 
volume of 10 mL using the isolation medium. This protocol used a total of four mouse 
brains, in contrast to the eight used by the sucrose gradient method. The homogenate 
was centrifuged for three minutes at 1,300xg at 4oC using a F1010 fixed-angle rotor in 
the Allegra 64R centrifuge (Beckman Coulter). The supernatant was set aside, and the 
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pellet was resuspended in 5 mL of isolation medium and centrifuged again. The pooled 
supernatant was then centrifuged at 21,000xg for 10 minutes, and the resultant pellet 
was resuspended in 3.5 mL of 15% Percoll  containing 225 mM sucrose, 75 mM 
mannitol, 1 mM EGTA, and 5 mM HEPES, pH 7.4. A Percoll gradient was prepared by 
overlaying the 15% Percoll on 24% and 40% Percoll. The discontinuous gradient was 
subsequently centrifuged for eight minutes at 30,700xg, using slow acceleration and 
deceleration. The very top layer, above the gradient, contained the myelin. It was 
collected, resuspended in 15% Percoll, and the discontinuous gradient was prepared a 
second time and centrifuged as before. This time the myelin layer was removed, diluted 
with 3-4 mL of ice cold water, vortexed, and centrifuged for 10 minutes at 30,700xg. The 
pellet was resuspended in myelin storage buffer, aliquoted and stored at -80oC. The BCA 
protein assay was performed, exactly as done for the myelin prepared using the sucrose 
gradient method. 
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Figure 2.1 Schematic of sucrose and Percoll gradient myelin isolation methods 
 
A) The sucrose gradient method; myelin membranes accumulate at the 10.5%-30% sucrose interface after 
60 minutes of centrifugation at 100,000xg using the Beckman Coulter Optima Max Ultracentrifuge. B) The 
Percoll gradient method; myelin membranes accumulate in the very top layer, above the gradient, while 
synaptosomes and mitochondria accumulate at the 15%-24% and 24%-40% Percoll interfaces, 
respectively, after 8 minutes of centrifugation at 30,700xg with the Beckman Coulter Allegra 64R 
centrifuge. 
2.3.2 Partial Delipidation of Whole Myelin 
 Myelin prepared using each isolation protocol, was compared by Western blot 
analysis. Both preparations of whole myelin were partially delipidated prior to 
electrophoretic separation, for enhanced detection. For each, 500 μg of myelin protein 
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was brought to a total volume of 200 μL with water. The samples were then extracted 
using a 2:1 mixture of ether to ethanol. They were incubated on ice for 10 minutes, then 
centrifuged at 13,000 rpm for another 10 minutes, at 4oC, using an Eppendorf centrifuge 
5415 D. The supernatant was discarded, and the remaining pellets were air-dried at 
room temperature and resuspended in pellet resuspension buffer (10 mM Tris-HCl, 1% 
SDS, pH 8.0). 
2.3.3 Detergent Extraction of Myelin 
Mouse myelin, isolated from CD1 mice, was subjected to two different detergent 
extraction protocols. First, a differential detergent extraction with CHAPS and TX-100 
was performed. For each extraction, 500 µg of myelin protein was brought to a total of 1 
mL in Tris-buffered saline (TBS; 25 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2 mM EDTA), 
with a final concentration of 1.5% CHAPS. This mixture, which represents the initial 1.5% 
CHAPS homogenate (I), was incubated on ice for 30 minutes with occasional mixing. This 
incubation was followed by centrifugation at 5,000xg for 10 minutes, at 4oC, using the 
Eppendorf centrifuge 5415 D. The supernatant (S1) was set aside while the pellet (P1) 
was resuspended in 1 mL of 2% TX-100 in TBS. Once again, the mixture was incubated 
on ice for 30 minutes, with occasional mixing, and then centrifuged at 14,000xg for 15 
minutes at room temperature using the Microfuge 18 Centrifuge (Beckman Coulter). 
The supernatant (S2) was carefully removed, and the pellet (P2) was resuspended in 1 
mL of 3% TX-100 in TBS. In some instances, the initial pellet (P1) was resuspended in 1 
mL of 3% TX-100 in TBS, at which point the S1 and P1 fractions were directly examined; 
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the second extraction was completely eliminated in this case. All myelin extracts were 
stored at -20oC until required. 
 A different detergent extraction followed by isopycnic centrifugation was 
performed to isolate the DRMs, or lipid rafts, from myelin isolated from CD1 mice; this 
protocol was previously described by DeBruin et al. [16;51;52]. Initially, 500 µg of myelin 
protein was brought to a total of 1 mL in 1.5% CHAPS in TBS with 10 mM Na3VO4, 10 
mM PMSF, and 1X PIC solution; the myelin was added last, after 10 minutes of 
incubation on ice. Once added, the myelin mixture was vortexed and incubated on ice 
for 30 minutes, with occasional mixing, followed by centrifugation at 5,000xg for 10 
minutes, at 4oC, using the Eppendorf centrifuge 5415 D. The pellet was resuspended in 
pellet resuspension buffer, while the supernatant was combined with an equal volume 
of 80% sucrose in 25 mM Tris-HCl, pH 7.5, 140 mM NaCl (Tris-buffered saline). The 
resultant sample in 40% sucrose was overlaid with 30% sucrose and 5% sucrose. The 
discontinuous gradients were centrifuged at 35,000 rpm for 16-18 hours, at 4oC, using 
the MLS-50 rotor in the Optima Max Ultracentrifuge (Beckman Coulter). Afterwards, 
samples were fractionated into approximately ten 340-µL fractions from the top of the 
tube. The lipid rafts fractions were identified by GM1 dot blot. Cholera-toxin B subunit 
peroxidase conjugate was used in conjunction with SuperSignal West Femto Substrate 
for visualization by enhanced chemiluminescence, and imaging with the VersaDoc 4000 
(Bio-Rad). Lipid raft fractions destined for analysis by Western blotting were precipitated 
with acetone. A 4:1 ratio of ice-cold acetone to sample was combined, vortexed and 
incubated overnight at -80oC. Later on, the acetone precipitated samples were 
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centrifuged at 16,100xg for 20 minutes, at 4oC, using the Eppendorf centrifuge 5415 D. 
Pellets were air-dried and resuspended in 10 µL of pellet resuspension buffer. These 
samples were prepared for SDS-PAGE by the addition of 5 µL of 5X sample loading 
buffer (0.5 M Tris-HCl, pH 6.8, glycerol, 10% w/v SDS, 0.5% w/v bromophenol blue). 
2.3.4 SDS-PAGE 
In this study, protein samples were electrophoretically separated using SDS-
PAGE mini-gels, with the Mini-Protean 3 cell (Bio-Rad). Either 12% or 14% freshly cast, 1-
mm thick, resolving gels were used for protein separation. Each protein sample was 
prepared for separation by combining the sample with 5X sample loading buffer in a 1:4 
ratio, and heating the mixture to 65oC, unless otherwise specified. They were then run 
at 90V as they passed through the stacking gel, and the voltage was increased to 120V 
until separation was completed and the tracking dye had run off the gel. The gels were 
often transferred to nitrocellulose for Western blot analysis, or stained with Coomassie. 
For each gel, Precision Plus Protein Dual Color Standard (Bio-Rad) was used as a 
molecular mass marker.  
2.3.5 Coomassie and Silver Staining 
In this study, protein visualization in SDS-PAGE gels was achieved with 
Coomassie G-250 BioSafe Stain (Bio-Rad), as per the manufacturer’s directions, or by 
silver staining. The silver staining protocol was based on the original method developed 
by Switzer et al. [53]. First, the polyacrylamide gels were fixed in 50% methanol, 10% 
acetic acid for 30 minutes, with occasional shaking, and then incubated in 5% methanol, 
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1% acetic acid for 15 minutes. The gels were subsequently rinsed in 50% methanol and 
washed with ultrapure water three times, five minutes each time. After removing the 
water, the gels were incubated in 0.02 g/100 mL sodium thiosulfate for 90 seconds; this 
step was followed by three 30 second rinses with water. Next, the gels were incubated 
for 45 minutes in 0.2 g/100 mL ice cold silver nitrate. The gels were rinsed again in 
water, three times, for 60 seconds each time. Lastly, each gel was developed in 100 mL 
of a developing solution which contained 6.0 g of sodium carbonate, 50 µL of 37% 
formaldehyde, and 0.4 mg of sodium thiosulfate. Development was ceased when 
protein bands became stained light brown; often requiring 5 to 20 minutes of 
incubation. The development solution was decanted and gels were covered in 6% acetic 
acid, for 10 minutes, to stop development. Gels were rinsed several times with water 
prior to imaging. 
2.3.6 Western Blotting 
In this study SDS-PAGE gels were electrotransferred to nitrocellulose for 90 
minutes, at 200 mA, in cold transfer buffer (25 mM Tris-HCl, pH 8.3, 192 mM glycine, 
20% methanol). The membranes were subsequently blocked with 5% skim milk solution 
in Tris-buffered saline with Tween-20 (247 mM Tris-HCl, pH 7.6, 27 mM KCl, 1.37 mM 
NaCl, 0.5% Tween-20; TTBS), for at least 2 hours. After blocking, the membranes were 
washed for 1 minute, and again for 5 minutes, in TTBS. The specific primary antibody 
was then applied to the membranes, for the specified incubation period, as listed in 
Table 2.3. To reduce non-specific binding, membranes were washed for 1 minute, 
followed by three 5 minute washes, in TTBS. The corresponding secondary antibody was 
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subsequently applied to the membranes, as per Table 2.3. Once again, membranes were 
washed for 1 minute, followed by three 5 minute washes, in TTBS, post-antibody 
incubation. Detection of HRP-tagged, chemiluminescent proteins was performed by 
incubating the membranes in either SuperSignal West Femto Substrate or VisiGlo Select 
HRP Chemiluminescent Substrate for 5 minutes, followed by immediate imaging with 
the VersaDoc 4000 (Bio-Rad). Alternatively, proteins bound to fluorescently tagged 
antibodies could be imaged directly after the final wash step using specific filters on the 
VersaDoc 4000; a blue LED excitation source and 530BP emission filter, or a red LED 
excitation source and a 695BP emission filter, was used for the detection of the various 
DyLight conjugated secondary antibodies. For all Western blots, Precision Plus Protein 
Dual Color Standard was used as a molecular mass marker. 
Table 2.3 Antibody dilutions used for Western blotting 
This table summarizes the dilutions and incubation periods of primary antibodies used in this study, in 
addition to the dilutions and incubation periods of their corresponding secondary antibodies. 
Primary 
Antibody 
Dilution 
Incubation 
Time 
Secondary 
Antibody 
Dilution 
Incubation 
Time 
β-Actin 1:2,000 2-3 hours 
DyLight 649 
Anti-Mouse IgG 
1:12,000 1 hour 
Na+/K+-ATPase 
α 
1:2,000 4-5 hours 
Anti-Mouse 
IgG-HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
α1 
1:500 4-5 hours 
Anti-Mouse 
IgG-HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
α2 
1:500 4-5 hours 
Anti-Goat IgG-
HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
α3 
1:3,000 4-5 hours 
Anti-Mouse 
IgG-HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
β1 
1:500 4-5 hours 
Anti-Mouse 
IgG-HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
β2 
1:500 4-5 hours 
Anti-Rabbit IgG-
HRP 
1:80,000 30 minutes 
Na+/K+-ATPase 
β3 
1:500 4-5 hours 
Anti-Goat IgG-
HRP 
1:80,000 30 minutes 
MBP 1:500 4-5 hours DyLight 488 1:12,000 1 hour 
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Anti-Rat IgG 
MCT1 1:100 4-5 hours 
Anti-Rabbit IgG-
HRP 
1:80,000 30 minutes 
NQO1 1:100 4-5 hours 
Anti-Rabbit IgG-
HRP 
1:80,000 30 minutes 
VDAC 1:1,000 4-5 hours 
Anti-Rabbit IgG-
HRP 
1:80,000 30 minutes 
 
 When β-actin was used as a protein loading control for Western blots, the 
membranes were stripped after imaging of the target protein. Each membrane was 
stripped twice, 5 minutes each time, in stripping buffer (25 mM glycine-HCl, pH 2.2, 1% 
SDS). The membranes were rinsed several times with water, and then washed in TTBS 
for 5 minutes. The nitrocellulose membranes were then reblocked with 5% skim milk 
solution, for 2 hours. The primary and secondary antibodies used for the detection of β-
actin are specified in Table 2.3. The same antibody incubation procedure, as described 
earlier, was followed. 
2.3.7 Quantification of Protein Expression by Densitometric Analysis 
Protein expression levels in myelin samples were quantified by densitometric 
analysis of prepared Western blots, using Image Lab Version 5.0 (Bio-Rad). Volumes for 
each fluorescent or chemiluminescent signal were measured and compared with 
corresponding samples of equivalent area (mm2). Volume was adjusted using local 
background subtraction. 
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2.3.8 Immunoprecipitation Assays 
 An individual protein immunoprecipitation assay was used to identify the 
heterodimeric forms, or isozymes, of Na+/K+-ATPase. This IP method used the antibodies 
for each β isoform, to capture the αβ complexes present in mouse myelin. EZview Red 
Protein A and/or G affinity gels were used as the antibody binding matrix for these IPs; 
the affinity gel and amount of each antibody used are summarized in Table 2.4. For each 
IP, 25 µL of the corresponding 50% slurry suspension of the affinity gel was washed and 
equilibrated in 50 mM Tris-HCl, pH 7.6, on ice. Isolated CD1 mouse myelin was extracted 
with 1.5% CHAPS, as per first step of the differential detergent extraction protocol. A 
sample of the initial 1.5% CHAPS homogenate (I) was set aside for comparison, while 2 
µg of the β1, β2 and β3 antibodies were each added to separate 100 µL aliquots of the 
1.5% CHAPS supernatant (S1). These antibody-sample mixtures were rotated for 2-4 
hours, at 4oC, after which they were introduced to their respective affinity gels and 
rotated, at 4oC, overnight. Each sample was subsequently centrifuged for 30 seconds at 
1,500xg using the Microfuge 18 Centrifuge (Beckman Coulter). The unretained material 
was removed and the affinity gels were washed with 50 mM Tris-HCl, pH 7.6. The αβ 
complexes were eluted from the affinity gel by the addition of 10 µL of pellet 
resuspension buffer and 10 µL of 5X sample loading buffer. The eluted material was 
heated to 50oC for 5 minutes, and then cooled, pulse centrifuged, and examined using 
Western blotting. Specifically, 20 µL of each β subunit IP elution were 
electrophoretically separated on 12% SDS-PAGE gels, along with 20 µL of the initial 1.5% 
CHAPS homogenate in sample loading buffer. Eluted material was otherwise stored at  
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-20oC until required. 
Table 2.4 Affinity gel and antibodies for individual protein immunoprecipitations. 
Target Sample 
Antibody 
Introduced 
Amount of 
Antibody 
Used 
Affinity Gel Used 
β1 
1.5% CHAPS 
supernatant (S1) 
Mouse 
monoclonal 
Na+/K+-ATPase β1 
2 µg 
50/50 mixture of 
EZview Red Protein 
A and Protein G 
β2 
1.5% CHAPS 
supernatant (S1) 
Rabbit polyclonal 
Na+/K+-ATPase β2 
2 µg 
EZview Red Protein 
A 
β3 
1.5% CHAPS 
supernatant (S1) 
Goat polyclonal 
Na+/K+-ATPase β3 
2 µg 
EZview Red Protein 
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 Protein complex immunoprecipitations were used to identify the specific binding 
partners of Na+/K+-ATPase in the myelin membrane. Similar to the beta subunit IP, this 
co-IP used the antibodies for each α isoform to capture the protein complexes which 
include the catalytic component of Na+/K+-ATPase. A non-specific binding control was 
also used to identify which proteins interact with the affinity gel, without the presence 
of an antibody. For these co-IPs, EZview Red Protein G Affinity Gel was used as the 
antibody binding matrix, in addition to use of an α1 antibody-conjugated agarose for the 
α1 subunit co-IP; the affinity gel and amount of each antibody used are summarized in 
Table 2.5. The EZview Red Protein G Affinity Gel was prepared as above with the beta 
subunit IPs. The antibodies mentioned in Table 2.5 were each combined with 150 µL of 
the 1.5% CHAPS supernatant and rotated for 2-4 hours, at 4oC; no antibody was added 
to the control sample. For the α1 subunit co-IP, this step was omitted as the antibody 
was conjugated to the agarose beads prior to use. Afterwards, the antibody-sample 
mixtures were added to their respective affinity gels, and 150 µL of the 1.5% CHAPS 
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supernatant was combined with the α1 antibody-conjugated agarose; these samples 
were then rotated, at 4oC, overnight. Samples were spun down at 1,500xg for 30 
seconds, the unretained material removed, and the matrix washed with 50 mM Tris-HCl, 
pH 7.6, three times. After the removal of the final wash, protein complexes were eluted 
from the affinity gel or agarose beads by the addition of 10 µL of pellet resuspension 
buffer and 10 µL of 5X sample loading buffer. The eluted material was heated to 50oC 
for 5 minutes, and then cooled and pulse centrifuged. The initial CHAPS homogenate (I) 
was combined with sample loading buffer and 5 µL of it, and 20 µL of the non-specific 
binding control and sample elutions, was run on a 12% SDS-PAGE gel and stained with 
Coomassie G-250 BioSafe Stain, as per the manufacturer’s directions. 
Table 2.5 Affinity gel and antibodies for complex protein immunoprecipitations. 
Target Sample 
Antibody 
Introduced 
Amount of 
Antibody Used 
Affinity 
Gel/Agarose 
Beads Used 
Control 
1.5% CHAPS 
supernatant (S1) 
None N/A 
EZview Red 
Protein G 
α1 
1.5% CHAPS 
supernatant (S1) 
Mouse 
monoclonal 
Na+/K+-ATPase 
α1 
N/A 
Na+/K+-ATPase α1 
antibody-
conjugated 
agarose 
α2 
1.5% CHAPS 
supernatant (S1) 
Goat polyclonal 
Na+/K+-ATPase 
α2 
2 µg 
EZview Red 
Protein G 
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α3 
1.5% CHAPS 
supernatant (S1 
Mouse 
monoclonal 
Na+/K+-ATPase 
α3 
2 µg 
EZview Red 
Protein G 
 
2.3.9 Trypsin Digestion and Proteomic Analysis 
 Unique protein bands from the α subunit co-IPs, identified on the Coomassie 
stained SDS-PAGE, were cut from the gels and digested with trypsin for protein 
identification by mass spectrometry. A negative control band was also cut and trypsin 
digested. The in-gel trypsin digestion was performed as outlined by the SPARC BioCentre 
at the Hospital for Sick Children (Toronto, ON, Canada). The predicted trypsin cleavage 
sites of Na+/K+-ATPase α1, α2, and α3, and β1, β2, and β3, are available in Appendix B. 
Excised protein bands were washed with 50 µL of 50 mM ammonium bicarbonate, for 5 
minutes. The gel was shrunk with 50 µL of 50% acetonitrile/25 mM ammonium 
bicarbonate for 10 minutes, and dried to completeness at ambient temperature in a 
Labconco CentriVap Benchtop Concentrator. Each band was then reduced with 30 µL of 
10 mM DTT for 30 minutes, at 56oC, alkylated with 30 µL of 100 mM iodoacetamide for 
15 minutes, at room temperature, in the dark, shrunk with 50 µL of 50% acetonitrile/25 
mM ammonium bicarbonate for 15 minutes, and then completely dried again in the 
vacuum centrifuge at ambient temperature. Gel pieces were covered in 13 ng/µL trypsin 
in 50 mM ammonium bicarbonate, and incubated on ice for 30-45 minutes. After that, 
any remaining solution was removed and 50 mM ammonium bicarbonate was added to 
cover the gel pieces while they were incubated, at 37oC, for 16-18 hours. The peptide 
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extraction was performed after incubation; first, by sonicating the samples for 5 minutes 
in cool water. The supernatant of each gel piece was collected and combined with the 
supernatants from the following incubation steps. Each gel piece was incubated in 20 µL 
of 25 mM ammonium bicarbonate for 10 minutes, then 20 µL of 5% formic acid for 10 
minutes, 20 µL of 100% acetonitrile for 10 minutes, 20 µL of 5% formic acid for 10 
minutes, and finally 20 µL of 100% acetonitrile for 10 minutes. The final solution was 
evaporated to dryness in the vacuum centrifuge, at 44-48oC. The samples were stored at 
-20oC until sent for analysis by LC-MS/MS. 
The LC-MS/MS samples were analyzed using both Sequest version 1.4.0.288 
(ThermoFisher Scientific, San Jose, CA, USA) and X!Tandem version CYCLONE (The GPM, 
thegpm.org). Sequest was set up to search Mouse-UniProt-Jan-09-2013.fasta (unknown 
version, 50272 entries) assuming the digestion enzyme trypsin. X!Tandem was set up to 
search the Uniprot_Mus_musculus_May222014.fasta database (unknown version, 
43362 entries) also assuming trypsin digestion. Sequest and X!Tandem were searched 
with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 2.0 Da. 
Deamidation of asparagine and glutamine, oxidation of methionine and 
carbamidomethyl of cysteine were specified in Sequest as variable modifications. Glu-
>pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, Gln->pyro-Glu of the N-
terminus, deamidation of asparagine and glutamine, oxidation of methionine and 
carbamidomethylation of cysteine were specified in X!Tandem as variable modifications. 
Mass spectrometry peptide and protein identifications were validated using 
Scaffold, version 4.3.2, proteome software (Proteome Software Inc., Portland, OR, USA). 
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Peptide identifications were accepted if they could be established at greater than 20.0% 
probability to achieve a false detection rate (FDR) less than 1.0%. Peptide Probabilities 
from Sequest were assigned by the Scaffold Local FDR algorithm. Peptide probabilities 
from X!Tandem were assigned by the Peptide Prophet algorithm with Scaffold delta-
mass correction [54]. Protein identifications were accepted if they could be established 
at greater than 95.0% probability to achieve an FDR less than 1.0% and contained at 
least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet 
algorithm [55]. Proteins that contained similar peptides and could not be differentiated 
based on LC-MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
Proteins sharing significant peptide evidence were grouped into clusters. 
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Chapter 3 – Results 
3.1 Identification of Na+/K+-ATPase in the Myelin Membrane 
3.1.1 Expression of Na+/K+-ATPase Subunit Isoforms 
 Understanding the distribution of proteins within tissues, as well as identifying 
changes in their expression over a lifespan, is central to comprehending their 
involvement in both developmental and disease processes [56]. Many methods exist for 
the identification of temporal and spatial gene or protein expression; in this study, 
protein expression of each Na+/K+-ATPase subunit isoform, present in the myelin 
membrane, was evaluated by the Western blot analysis of myelin from mouse brain. 
Myelin was isolated from brains of euthanized mice from different age groups, thereby 
allowing examination of changes in protein expression during post-natal development. 
The myelin produced in mature CD1 mice was also investigated; this initial survey of 
protein expression was informative and outlined which Na+/K+-ATPase subunit isoforms 
exist in mouse myelin, and should therefore be further examined. 
 The products of both sucrose-gradient and Percoll-gradient isolated CD1 mouse 
myelin were partially delipidated, and subsequently examined by Western blot analysis. 
Ultimately, it was shown that Na+/K+-ATPase is expressed in the myelin membrane, and 
can be successfully detected using this analysis technique. As illustrated in Figure 3.1, 
Na+/K+-ATPase α1, α2, and α3, as well as the complementary β1, β2, and β3 subunits, were 
readily detected in both myelin preparations. These three alpha and three beta subunits 
represent all known isoforms of Na+/K+-ATPase in the CNS. 
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 All subsequent analyses of Na+/K+-ATPase were performed using myelin isolated 
by the sucrose-gradient method. Both the sucrose-gradient and Percoll-gradient 
isolation protocols generated myelin with detectable levels of each subunit isoform, in 
addition to MBP, voltage-dependent anion channel (VDAC), monocarboxylate 
transporter 1 (MCT1) and NAD(P)H quinone oxidoreductase 1 (NQO1) (refer to Appendix 
G). Nevertheless, when these myelin preparations were compared with a brain 
homogenate sample, of equal protein content, the myelin produced using the Percoll-
gradient method appeared less purified although it had a greater yield. 
 
 
Figure 3.1 Detection of Na+/K+-ATPase subunit 
isoforms in partially delipidated sucrose-gradient 
and Percoll-gradient isolated CD1 mouse myelin 
 
Enhanced chemiluminescent Western blot detection of each 
alpha and beta isoform of Na
+
/K
+
-ATPase in partially 
delipidated myelin samples, of equivalent protein content, 
from sucrose-gradient and Percoll-gradient isolation 
methods. Equal volumes (15 µL), and therefore equal 
protein (approximately 60 µg of total myelin protein), of 
each sample were separated on 12% SDS-PAGE and 
transferred to nitrocellulose membrane. The corresponding 
primary and secondary antibodies used are described in 
Table 2.3. Each Western blot was imaged using the 
VersaDoc 4000 (Bio-Rad) with an exposure time of 30-400 
seconds, ensuring non-saturation. 
 
 
 
3.1.2 Detergent Solubility of Na+/K+-ATPase 
Non-ionic detergents, such at TX-100, have formerly proven incapable of 
solubilizing certain regions, or microdomains, of plasma membranes. These DRMs are 
enriched in cholesterol, sphingomyelin, and lipid-anchored proteins. They show 
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similarities to the Lo phase (refer to section 1.2.2) of model membranes, and may 
represent membrane microdomains such as lipid rafts, caveolae and/or cellular 
junctions [14;16]. Consequently, the detergent-insolubility of these coalesced lipid rafts 
became the basis for the isolation and characterization of both raft proteins and lipids 
[57]. As earlier studies of Na+/K+-ATPase have demonstrated its localization within 
various membrane microdomains, such as the caveolae of kidney cells, detergent 
extraction has proven essential in the successful characterization of this protein in other 
tissue and cell types [58]. 
The initial extraction of Na+/K+-ATPase from the myelin membrane using the 
differential detergent extraction procedure with 1.5% CHAPS, followed by 2% TX-100, 
indicated that limited protein was detectable in the TX-100 supernatant (S2) and pellet 
(P2) fractions. Each of the Na+/K+-ATPase subunit isoforms was observed in the initial 
pellet (P1), but preferentially partitioned into the 1.5% CHAPS supernatant (S1) fraction; 
refer to Figure 3.2. Densitometric data indicated that Na+/K+-ATPase α1, β1, β2, and β3 
were highly enriched in the CHAPS supernatant; more than 90% of all Na+/K+-ATPase α1, 
β1, β2, and β3 was detected in this S1 fraction. Alternatively, the P1 fraction contained 
approximately 20-30% of all Na+/K+-ATPase α2 and α3. 
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Figure 3.2 Detection of Na+/K+-ATPase subunit isoforms in detergent extracted CD1 
mouse myelin 
 
A) Enhanced chemiluminescent Western blot detection of each alpha and beta isoform of Na
+
/K
+
-ATPase 
in the 1.5% CHAPS supernatant (S1), pellet (P1) and the initial CHAPS homogenate (I). Equal volumes (20 
µL) of each sample were separated on 12% SDS-PAGE and transferred to nitrocellulose membrane. The 
corresponding primary and secondary antibodies used are described in Table 2.3. Each Western blot was 
imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds, ensuring non-
saturation. B) Relative intensity of each Na
+
/K
+
-ATPase subunit isoform in the 1.5% CHAPS supernatant 
and pellet, ensuring non-saturation and subtracting background. Each value was corrected by 
normalization with the initial CHAPS homogenate. 
 
 The propensity of Na+/K+-ATPase to become solubilized in 1.5% CHAPS detergent 
suggested that its subunit isoforms may be present in the myelin lipid rafts. DRMs, 
coalesced lipid rafts, were isolated from CD1 mouse myelin by treatment with 1.5% 
CHAPS detergent, followed by separation with a discontinuous sucrose density gradient. 
Larger fragments of the myelin membrane, as well as subcellular organelles, were 
compacted by low speed centrifugation of the 1.5% CHAPS mixture; whereas the 
resultant CHAPS supernatant contained the DRMs, as well as solubilized proteins and 
lipids [52]. When this supernatant subsequently underwent ultracentrifugation on a 
discontinuous sucrose density gradient, the DRMs and solubilized proteins and lipids 
were separated according to buoyancy. As the DRMs are rich in cholesterol and 
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glycosphingolipids, and represent the Lo phase, they are typically more buoyant and 
found in the lower density fractions; in contrast, solubilized proteins and lipids are 
detectable in the high density fractions of the density gradient. Ganglioside GM1 dot 
blot immunodetection was used to identify specifically which fractions contained the 
DRMs. All fractions were examined by Western blot analysis for each Na+/K+-ATPase 
subunit isoform, and then compared to the GM1 dot blot. All three alpha and three beta 
subunits of Na+/K+-ATPase were detected in the non-raft, high density fractions. Na+/K+-
ATPase α1, α3, β2, and β3 were also successfully identified in the low density, raft 
fractions; for that reason, it is expected that these isoforms are part of the lipid rafts of 
the myelin membrane. Two of these Western blots are shown in Figure 3.3 below. It is 
unclear whether the α2 and β1 isoforms are also part of the DRMs, as the enhanced 
chemiluminescent signal was near the limit of detection (refer to Appendix G). All the 
same, Na+/K+-ATPase α2 and β1 are not highly enriched in the lipid rafts of myelin. 
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Figure 3.3 Detection of Na+/K+-ATPase subunit isoforms in myelin DRMs 
 
Enhanced chemiluminescent Western blot detection of: A) Na
+
/K
+
-ATPase α1 and β2; B) Na
+
/K
+
-ATPase α3. 
Equal volumes (20 µL) of each acetone-precipitated lipid raft fraction (A1-A10 and B1-B10), isolated as 
CHAPS DRMs, were separated on 12% SDS-PAGE and transferred to nitrocellulose membrane. Fractions 
A3, A4, B3 and B4 represent the low density, raft fractions; alternatively, fractions A9, A10, B9 and B10 
represent the non-raft, high density fractions. The red arrows indicate the low density, raft fractions. The 
corresponding primary and secondary antibodies used are described in Table 2.3. Each Western blot was 
imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds, ensuring non-
saturation. 
 
3.2 Heterodimeric Forms of Na+/K+-ATPase in the Myelin Membrane 
 Determination of each heterodimeric form, or isozyme, of Na+/K+-ATPase in CD1 
mouse myelin was performed using an IP with each beta subunit isoform. This method 
captures the αβ complexes formed by each individual beta subunit isoform. Equal 
volumes of each eluted fraction were then examined for all alpha subunits by Western 
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blotting, using primary antibodies specific for each isoform (Figure 3.4). Six 
heterodimeric forms of Na+/K+-ATPase were discovered; α1 was shown to pair with β1, 
α2 dimerized with β1 and β3, and α3 was found to couple with all three beta isoforms. 
These six isozymes, α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3, were six of nine possible 
functional Na+/K+-ATPase heterodimers; α1β2, α1β3 and α2β2 were not observed in these 
myelin samples. Three major isozymes, α1β1, α2β3, and α3β1, were established; they 
appeared to be the most abundant of each αβ complex according to signal intensity. 
 
 
Figure 3.4 Identification of heterodimeric forms of the Na+/K+-ATPase in CD1 mouse 
myelin 
 
Enhanced chemiluminescent Western blot detection of each alpha isoform of Na
+
/K
+
-ATPase in the initial 
CHAPS homogenate and final eluted fractions from each beta isoform immunoprecipitation. Equal 
volumes (20 µL) of each sample were separated on 12% SDS-PAGE and transferred to nitrocellulose 
membrane. The corresponding primary and secondary antibodies used are described in Table 2.3. Each 
Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-200 seconds, 
ensuring non-saturation. 
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3.3 Specific Binding Partners of Na+/K+-ATPase in the Myelin 
Membrane 
Initial inspection of the proteins eluted from each Na+/K+-ATPase alpha subunit 
isoform co-IP revealed several unique protein bands, when compared to a non-specific 
binding control. Protein bands were identified using both silver and Coomassie G-250 
BioSafe staining. These bands, in addition to those which became concentrated by the 
co-IP, are indicated in Figure 3.5 and Figure 3.7; they suggest that Na+/K+-ATPase 
interacts with several different proteins within the myelin membrane. Likewise, unique 
protein bands differed between the co-IPs of each individual alpha isoform; hence each 
isoform may have independent binding partners and form distinct protein complexes. 
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Figure 3.5 Silver stained SDS-PAGE of eluted proteins from co-immunoprecipitations of 
each Na+/K+-ATPase alpha isoform using CD1 mouse myelin 
 
Silver stained 1-mm thick 12% SDS-PAGE, loaded with 3 µL of initial CHAPS homogenate (I) and equal 
volumes (20 µL) of a non-specific binding control (C) and the final eluted fraction of each alpha isoform 
co-immunoprecipitation. Precision Plus Protein Dual Color Standards (M) was used as a molecular mass 
standard. The stained gel was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 0.1-5 
seconds, ensuring non-saturation. The indicated bands are unique when compared to the non-specific 
binding control, or became concentrated by the co-IP. 
 
 Each lane of the silver stain, shown in Figure 3.5, was scanned for a comparison 
of protein band intensities and their corresponding rate relative to front (Rf) values. The 
intensity and separation of these protein bands are illustrated in Figure 3.6. Many 
proteins are shown in the initial CHAPS homogenate; however, the intensity of these 
proteins is lesser, as only 3 µL of this sample was loaded onto the SDS-PAGE gel. Several 
proteins can also be identified in the non-specific binding control, according to signal 
intensity. By examining the separated proteins according to signal intensity, it is clear 
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that there are indeed both unique and shared protein bands in each Na+/K+-ATPase 
alpha subunit isoform co-IP elution. There are also non-unique protein bands which are 
of greater intensity in the Na+/K+-ATPase alpha subunit isoform co-IP elutions. It is also 
likely that there are a greater number of eluted proteins than identified protein bands, 
as the signal intensity of one protein may be masked by the signal intensity of a protein 
of similar molecular mass.  
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Figure 3.6 Separation of proteins eluted from Na+/K+-ATPase co-immunoprecipitations 
 
Separation of proteins from: A) initial CHAPS homogenate; B) non-specific binding control; C) Na
+
/K
+
-
ATPase α1 co-IP elution; D) Na
+
/K
+
-ATPase α2 co-IP elution; E) Na
+
/K
+
-ATPase α3 co-IP elution. The signal 
intensity corresponds to the amount of protein, while the Rf value indicates the distance travelled by the 
protein from the origin. Larger Rf values correspond with proteins of smaller molecular mass. Analysis was 
completed with Image Lab Version 5.0 (Bio-Rad). The symbols (*,◊,ᵻ,‡) indicate a few of the common 
protein peaks observed between samples. 
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 The unique protein bands identified in the Na+/K+-ATPase alpha subunit isoform 
co-IP elutions, by staining with Coomassie G-250 BioSafe, were examined by mass 
spectrometry. Ultimately, 21 bands (Figure 3.7) were excised and digested with trypsin; 
of these, 15 were analyzed by LC-MS/MS. Bands 10, 13, 14, 15, 17 and 19 were not sent 
for analysis due to the similarity of their molecular masses when compared with Bands 
21, 5 and 6, 9, 1 and 11, 4, and 7, respectively. It was anticipated that the three alpha 
isoforms of Na+/K+-ATPase would share several binding partners; therefore, protein 
bands identified in different co-IP elutions but of similar molecular mass, were digested 
and stored but not sent for analysis unless necessary. 
 
 
Figure 3.7 Coomassie stained SDS-PAGE of eluted proteins from co-
immunoprecipitations of each Na+/K+-ATPase alpha isoform using CD1 mouse myelin 
 
Coomassie G-250 BioSafe stained 1-mm thick 12% SDS-PAGE, loaded with 5 µL of initial CHAPS 
homogenate (I) and equal volumes (20 µL) of a non-specific binding control (C) and the final eluted 
66 
 
fraction of each alpha isoform co-immunoprecipitation. Precision Plus Protein Dual Color Standards (M) 
was used as a molecular mass standard. The stained gel was imaged using the VersaDoc 4000 (Bio-Rad) 
with an exposure time of 0.1-5 seconds, ensuring non-saturation. The indicated bands were excised and 
digested with trypsin for identification by mass spectrometry. 
 
A total of 33 proteins were identified in the 15 digested bands; however, 
absolutely no proteins were detected  by mass spectrometry in Band 4. Of the 33 
documented proteins, positive identification was assigned to those recognized with 
100% certainty using the Scaffold 4.3.2 proteome software. These proteins also required 
a minimum of two unique peptides to be recognized, for confirmation of identity. After 
applying these criteria, there were 13 major proteins identified; these are listed in Table 
3.1. Several immunoglobulin chains from the antibodies used in the co-IPs were also 
detected by mass spectrometry; these proteins are not listed. 
Table 3.1 Major proteins identified in Coomassie G-250 BioSafe stained bands from 
SDS-PAGE separation of Na+/K+-ATPase alpha co-immunoprecipitation elutions 
Each band number corresponds to the indicated protein bands in Figure 3.7. Gel bands were trypsin 
digested and analyzed by LC-MS/MS. Each major protein was identified with 100% probability using the 
Scaffold 4.3.2 proteome software, in addition to having a minimum of two unique peptides identified. The 
ID indicated the UniProtKB/Swiss-Prot accession number, whereas Gene represents the gene name 
provided by NCBI. The number of unique peptides, the percent coverage, and molecular mass of each 
protein, as identified by LC-MS/MS, is also provided. 
Band No. Protein Identified ID Gene 
Unique 
Peptides 
% Coverage 
MW 
(kDa) 
1 
Sodium/potassium-
transporting ATPase 
subunit alpha-1 
Q8VDN2 Atp1a1 7 19 113 
Sodium/potassium-
transporting ATPase 
subunit alpha-3 
Q6PIC6 Atp1a3 6 19 112 
Serine/arginine 
repetitive matrix 
protein 2 
Q8BTI8 Srrm2 3 2 295 
3 
Peripheral myelin 
protein 22 
18858 Pmp22 3 9 57 
Sodium/potassium-
transporting ATPase 
subunit alpha-3 
Q6PIC6 Atp1a3 2 3 112 
5 
Peripheral myelin 
protein 22 
18858 Pmp22 2 4 57 
Spermatogenesis-
associated protein 7 
Q80VP2 Spat7 2 1 66 
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6 
Sodium/potassium-
transporting ATPase 
subunit beta-1 
P14094 Atp1b1 3 12 35 
7 
2’,3’-cyclic nucleotide 
3’-phosphodiesterase 
P16330 Cnp 7 16 47 
9 
Myelin proteolipid 
protein 
P60202 Plp1 2 9 30 
11 
Sodium/potassium-
transporting ATPase 
subunit alpha-2 
Q6PIE5 Atp1a2 2 6 112 
Sodium/potassium-
transporting ATPase 
subunit alpha-3 
Q6PIC6 Atp1a3 3 7 112 
12 
Cullin-associated 
NEDD8-dissociated 
protein 1 
Q6ZQ38 Cand1 2 2 136 
18 
Sodium/potassium-
transporting ATPase 
subunit beta-1 
P14094 Atp1b1 4 16 35 
Brain acid soluble 
protein 1 
Q91XV3 Basp1 2 16 22 
Protein MRVI1 Q9WUX5 Mrvi1 2 2 100 
20 
Peripheral myelin 
protein 22 
18858 Pmp22 3 5 57 
21 
Serine/arginine 
repetitive matrix 
protein 2 
Q8BTI8 Srrm2 2 1 295 
Myelin proteolipid 
protein 
P60202 Plp1 5 17 30 
Krueppel-like factor 6 O08584 Klf6 2 5 32 
 
According to the mass spectrometry results, the α1 and α2 isoforms were 
confirmed to be present in their respective co-IP elutions. Similarly, Band 15 should 
represent the α3 isoform, as it shares an equivalent molecular mass to Bands 1 and 11; 
both of which were found to contain the Na+/K+-ATPase α3 subunit isoform. The α1 
subunit isoform was shown to interact with 7 other proteins in myelin; Na+/K+-ATPase 
α3, Na
+/K+-ATPase β1, serine/arginine repetitive matrix protein 2 (SRRM2), PMP-22, 
spermatogenesis-associated protein 7 (SPAT7), CNP, and PLP1. Each of these proteins 
co-eluted with the α1 subunit. In comparison, the α2 subunit isoform was also found to 
interact with Na+/K+-ATPase α3, in addition to cullin-associated NEDD8-dissociated 
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protein 1 (CAND1). Lastly, the α3 subunit isoform co-eluted with 7 other identified 
proteins; Na+/K+-ATPase β1, brain acid soluble protein 1 (BASP1), protein MRVI1 
(MRVI1), PMP-22, SRRM2, PLP1, and krueppel-like factor 6 (KLF6). The identification of 
the Na+/K+-ATPase β1 subunit isoform, within both the α1 and α3 subunit co-IP elutions, 
supports the previous Western blot analysis which identified α1β1 and α3β1 as two of the 
three major Na+/K+-ATPase isozymes present in the myelin membrane. 
Potential protein binding partners of Na+/K+-ATPase were also identified using 
the STRING database. STRING version 9.1 (http://string-db.org/) was used to integrate 
the information from collections of experimental data and other resources, in order to 
provide evidence-based predictions of protein-protein interactions for each of the 
subunit isoforms [59]. Each alpha and beta subunit isoform was predicted to interact 
with all other alpha and beta subunit isoforms of Na+/K+-ATPase. FXYD2 was also a 
predicted functional partner of all Na+/K+-ATPase subunit isoforms. For a complete list of 
the predicted functional partners of Na+/K+-ATPase, and illustrations of the 
corresponding protein-protein interactions, refer to Appendix C. 
3.4 Na+/K+-ATPase Expression in Myelin from CD1 and ND4 Mice 
 As previously mentioned, establishing changes in protein expression over various 
life stages is imperative to understanding their role in development. This knowledge also 
provides a basis for determining how protein expression may become altered in a 
diseased state, thereby offering insight regarding which biological and chemical 
processes could be manipulated for therapeutic benefit. In particular, ND4 transgenic 
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mice provide a suitable model of multiple sclerosis. In this study, myelin isolated from 
these mice was compared with the myelin of age- and sex-matched control CD1 mice. 
The animals were euthanized at 3.10, 7.65, 9.00 or 13.02 months of age; and each line 
was raised and sacrificed under the same conditions. Western blot analysis of equal 
amounts of protein from both myelin preparations, and from each age group, was 
performed for all three alpha and three beta subunit isoforms of Na+/K+-ATPase (Figure 
3.8). Densitometric analysis was then carried out to evaluate changes in the expression 
of each isoform, from each myelin preparation, over post-natal development. All of the 
densitometric data, for both CD1 and ND4 myelin, can be found in Appendix D. 
 Western blots were performed in duplicate; samples from both myelin 
preparations, at each age group, were examined once without a β-actin protein loading 
control (refer to Appendix H) and once with a β-actin protein loading control. Without 
normalization to β-actin, each data set showed distinct similarities; however, the 
normalized densitometric data was the primary focus in this study. By using β-actin as 
an internal control, technical artifacts, such as pipetting errors during gel loading and 
inconsistent protein transfer to blotting membranes, were minimized [60]. It also 
permits the comparison of two different blots, when they are otherwise not directly 
comparable [61].  
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Figure 3.8 Detection of Na+/K+-ATPase subunit isoforms in partially delipidated CD1 
and ND4 mouse myelin of varying ages 
 
Enhanced chemiluminescent Western blot detection of each alpha and beta isoform of Na
+
/K
+
-ATPase in 
partially delipidated CD1 and ND4 mouse myelin. Equal volumes (15 µL), and therefore equal protein 
(approximately 60 µg of total myelin protein), of each sample were separated on 12% SDS-PAGE and 
transferred to nitrocellulose membrane. The corresponding primary and secondary antibodies used are 
described in Table 2.3. Each Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an 
exposure time of 30-200 seconds, ensuring non-saturation. 
 
71 
 
The normalized densitometric data in this study is represented as the relative 
intensities of each Na+/K+-ATPase subunit isoform. Expression levels were described in 
terms of the ratios of individual Na+/K+-ATPase subunit isoform levels, to the levels of β-
actin in each sample; this is considered a robust normalization method for Western 
blotting [62]. First, the signal intensity of each β-actin control was divided by the highest 
measured intensity value of all β-actin controls; this process generated a relative 
intensity factor, between 0 and 1.00. The signal intensities of each Na+/K+-ATPase 
subunit isoform were subsequently divided by their respective relative intensity factor; 
the result is the relative intensity for each Na+/K+-ATPase subunit isoform. 
3.4.1 Age-Related Protein Expression in Healthy CD1 Mouse Myelin 
 All three alpha and three beta subunit isoforms of Na+/K+-ATPase were detected 
at 3.10, 7.65, 9.00 and 13.02 months of age in the CD1 control mouse myelin. These 
samples represent typical, healthy myelin, and are indicative of the normal age-related 
changes in protein expression. Upon the measurement of protein band intensity for 
each subunit isoform, in each age group, it was noted that intensities fluctuated over 
the course of normal development. These changes persisted even after each 
densitometric measurement was normalized to a β-actin, as a protein loading control, in 
the same sample. The adjusted values, and corresponding fluxes in the expression of 
each subunit isoform, are displayed in Figure 3.9. Upon inspection, each alpha isoform 
consistently exhibits an increase in expression when approaching the final 13.02 month 
age group. In contrast, the beta isoforms are relatively divergent. Na+/K+-ATPase β1 
expression increases between 9.00 and 13.02 months but remains lesser than the initial 
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measurement at 3.10 months. Alternatively, Na+/K+-ATPase β2 and β3 expression 
steadily increases or decreases, respectively, over time. 
 
 
Figure 3.9 Relative Na+/K+-ATPase subunit isoform expression in CD1 mouse myelin 
with aging 
 
Intensity of each Na
+
/K
+
-ATPase subunit isoform, ensuring non-saturation and subtracting background. 
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by 
normalization with a β-actin protein loading control. 
 
 Beyond the observed fluctuations in the protein expression of each subunit 
isoform, it was also discovered that the protein bands for each glycosylation state of 
Na+/K+-ATPase β1 could be detected by Western blotting (Figure 3.8). The mammalian 
Na+/K+-ATPase β1, such as that found in mice, can have three N-glycans or N-linked 
glycosylation sites occupied; in addition to these three forms, Na+/K+-ATPase  β1 can also 
exist as a core, unglycosylated subunit [3]. This core protein is often considered its 
immature form. Three β1 protein bands, that were approximately 60 kDa, 52 kDa and 48 
kDa in size, represented the β1 subunit with all three N-glycans, two N-glycans, and only 
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one N-glycan, respectively. The largest form of Na+/K+-ATPase β1, with the highest 
molecular mass, was designated Band 1 of the Na+/K+-ATPase β1 subunit; similarly, Band 
2 and Band 3 were assigned to the other glycosylated forms, from highest to lowest 
molecular mass. And lastly, another small molecular mass protein band was identified 
by the Na+/K+-ATPase β1 antibody; it was approximately 40 kDa in size. It was designated 
as Band 4 of the Na+/K+-ATPase β1 subunit, and represents the β1 core protein. 
 
Figure 3.10 Relative Na+/K+-ATPase β1 glycosylation state expression in CD1 mouse 
myelin with aging 
 
Intensity of each Na
+
/K
+
-ATPase β1 glycosylation state, ensuring non-saturation and subtracting 
background. Bands 1 to 4 represent the highest molecular mass form of Na
+
/K
+
-ATPase β1 to the lowest 
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00 
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading 
control. 
 
 Resembling the other subunit isoforms of Na+/K+-ATPase the protein expression 
of the individual glycosylation states of Na+/K+-ATPase β1 varied over the course of 
development. The normalized intensities of each glycosylation state, at each age, are 
illustrated in Figure 3.10. It was observed that expression levels generally increased 
74 
 
between 3.00 to 7.65 months, decreased after 7.65 months, and bounced back at 13.02 
months of age. Band 1, the highest molecular mass form of Na+/K+-ATPase β1, was 
unique in the fact that its expression continually decreased from 3.00 months onward, 
until rebounding at 13.02 months of age. Bands 2 and 3 were typically found in the 
greatest abundance, when compared with the fully glycosylated and core forms of 
Na+/K+-ATPase β1. Additionally, the core, unglycosylated form of Na
+/K+-ATPase β1, at 
both 9.00 and 13.02 months of age, was extremely difficult to perceive upon visual 
inspection of the blot. These Western blots indicated that expression of the immature 
form of Na+/K+-ATPase β1 was extremely limited in the later months of development; it 
was also the least abundant of all forms, across all four age groups. 
3.4.2 Age-Related Protein Expression in Diseased ND4 Mouse Myelin 
 As a follow-up to studying each Na+/K+-ATPase subunit isoform in healthy CD1 
control mouse myelin, the myelin isolated from ND4 mice, which represent a 
demyelinating model of MS, was subsequently assessed. These mice were sacrificed at 
the same time as the CD1 mice; either at 3.10, 7.65, 9.00 or 13.02 months of age. 
Analogous to the examination of Na+/K+-ATPase subunit isoform expression in CD1 
control mice, Western blotting in conjunction with densitometric analysis was 
performed. These images are shown alongside their control counterparts in Figure 3.8. 
Once again, all three alpha and three beta subunit isoforms of Na+/K+-ATPase were 
successfully detected in the ND4 myelin from each age group. When normalized to a β-
actin protein loading control, the fluctuations in protein band intensity for each subunit 
isoform closely resembled the changes which occurred in the CD1 control myelin, across 
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all four age groups; refer to Figure 3.11, and compare with Figure 3.9. Na+/K+-ATPase β3 
appeared to be an exception, as its expression within the ND4 myelin increased after 
9.00 months; whereas the CD1 myelin showed a decrease in expression during this time 
period.  
 
Figure 3.11 Relative Na+/K+-ATPase subunit isoform expression in ND4 mouse myelin 
with aging 
 
Intensity of each Na
+
/K
+
-ATPase subunit isoform, ensuring non-saturation and subtracting background. 
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by 
normalization with a β-actin protein loading control. 
 
As with the CD1 control myelin, the three glycosylation states as well as the core, 
unglycosylated form of Na+/K+-ATPase β1 were evident in the ND4 myelin. In this case, 
the trends of protein expression over the course of development were once again 
similar to that of the CD1 myelin, with several slight differences. As shown in Figure 
3.12, the fully glycosylated form of Na+/K+-ATPase β1 (Band 1), rather than its core (Band 
4), was the least abundant of all other Na+/K+-ATPase β1 proteins. The two intermediate 
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molecular mass protein forms, Bands 2 and 3, remained the most abundant, as also 
seen in the CD1 control myelin (Figure 3.10). 
 
Figure 3.12 Relative Na+/K+-ATPase β1 glycosylation state expression in ND4 mouse 
myelin with aging 
 
Intensity of each Na
+
/K
+
-ATPase β1 glycosylation state, ensuring non-saturation and subtracting 
background. Bands 1 to 4 represent the highest molecular mass form of Na
+
/K
+
-ATPase β1 to the lowest 
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00 
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading 
control.  
3.4.3 The Effect of Demyelination on Na+/K+-ATPase Protein Expression 
 A direct comparison of the corrected intensities for each Na+/K+-ATPase subunit 
isoform as well as the various glycosylation states of Na+/K+-ATPase β1, within each 
individual age group, can be found in Figure 3.13 and Figure 3.14. Certain differences 
between the protein expressions of the two myelin preparations were immediately 
recognized. Firstly, Na+/K+-ATPase α1 initially demonstrates increased expression within 
the ND4 myelin, until 13.02 months when it is lesser than, but close to, the levels of 
expression detected in the CD1 myelin. Secondly, the expression of the fully 
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glycosylated form of Na+/K+-ATPase β1 (Band 1) in the ND4 myelin was strikingly lesser 
than that of the CD1 myelin, across all age groups. Na+/K+-ATPase β2 also exhibited 
reduced expression within the ND4 myelin at 3.00 and 7.65 months of age, but 
surpassed the measured expression of the CD1 myelin at 9.00 and 13.02 months of age. 
Lastly, Na+/K+-ATPase β3 was consistently elevated in the ND4 myelin, across all age 
groups. 
 
Figure 3.13 Compared relative intensities of each Na+/K+-ATPase subunit isoform, 
between CD1 and ND4 myelin, in each age group 
 
Relative intensity of each Na
+
/K
+
-ATPase subunit isoform, ensuring non-saturation and subtracting 
background. Each value was corrected by normalization with a β-actin protein loading control. 
Comparisons were for CD1 (blue) and ND4 (red) myelin at: A) 3.00 months of age; B) 7.65 months of age; 
C) 9.00 months of age; D) 13.02 months of age.  
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Figure 3.14 Compared relative intensities of each Na+/K+-ATPase β1 glycosylation state, 
between CD1 and ND4 myelin, in each age group 
 
Relative intensity of each Na
+
/K
+
-ATPase β1 glycosylation state, ensuring non-saturation and subtracting 
background. Bands 1 to 4 represent the highest molecular mass form of Na
+
/K
+
-ATPase β1 to the lowest 
molecular mass form (core, non-glycosylated), respectively. Each value was corrected by normalization 
with a β-actin protein loading control. Comparisons were for CD1 (blue) and ND4 (red) myelin at: A) 3.00 
months of age; B) 7.65 months of age; C) 9.00 months of age; D) 13.02 months of age. 
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Chapter 4 – Discussion 
4.1 Comparison of Sucrose and Percoll Gradient Isolation Methods 
 The biochemical analysis of specific cell types, a particular membrane, or the 
subcellular organelles of certain tissues, requires the successful isolation of pure cellular 
populations or subcellular fractions. The complex nature of the CNS, and its highly 
interconnected cellular processes and cell types, has prompted the development of 
several different isolation strategies which aid in the study of cellular neurochemistry 
[63]. Firstly, the successful isolation of subcellular organelles and biological membranes, 
such as myelin, requires a method of cell lysis or tissue homogenization which 
maximizes yield while minimizing cellular debris and contaminants [64]. It is also 
important that the procedure maintains the functional integrity of the target, as well as 
preserving its structure as much as possible. In this study, whole mouse brains were 
homogenized, using a Dounce homogenizer, in an isotonic sucrose solution of low ionic 
strength. Under these conditions, the myelin membrane becomes detached from 
neuronal axons and forms small vesicles; these myelin vesicles are similar in size to 
mitochondria and nuclei [65]. The high lipid to protein ratio in myelin also confers the 
lowest intrinsic density of any membrane fraction derived from the CNS, including 
mitochondria and nuclei [65]. 
Essentially all myelin isolation protocols exploit the size and density of the myelin 
vesicles generated during the homogenization of CNS tissue. Often, an isolation protocol 
will use differential centrifugation at low speeds to remove bulky debris from the initial 
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homogenate [49]. This process is then followed by the separation of the remaining cell 
membranes and organelles using a discontinuous density gradient. Mitochondria, 
synaptosomes, nuclei and other large cellular components will sediment through the 
denser layer of the isolation medium, while small membrane fragments and certain 
organelles will remain in the upper, less dense fraction; the myelin vesicles, however, 
will gather at the density interface due to their size and buoyancy [11;65]. After 
collecting the crude myelin from the interface, the sucrose is diluted out and the 
vesicles are osmotically shocked. By treating the isolated myelin with ice cold purified 
water, any residual microsomes, axoplasm or major impurities are released [65]. Myelin 
vesicles of higher purity can be obtained by adding supplementary centrifugation and 
osmotic shock steps to the methodology. A second round of density gradient 
centrifugation can be introduced; by doing so, further removal of large particles, which 
may become trapped in the crude myelin layer that forms at the density interface, is 
achieved [66]. Continuous density gradients can also be introduced as a way of 
preventing contaminating materials from becoming trapped in the crude myelin layer; 
this addition may be either supplementary to, or in place of, the discontinuous gradient 
centrifugation steps [66]. A range of myelin vesicles, of different sizes, densities, and 
lipid to protein ratios, can be separated by the use of continuous gradients; thereby 
permitting a more detailed examination of the myelin membrane to be conducted. 
 In this study, the myelin vesicles were separated from the remaining neural 
tissue using either a discontinuous sucrose or Percoll gradient; each method offered its 
own advantages and disadvantages. The method by Kristian used a discontinuous 
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Percoll gradient [49]. Percoll, like sucrose, can be prepared in an isotonic solution which 
allows osmolarity to be maintained throughout the isolation [67]. It has a low viscosity, 
as it is made of colloidal silica particles which have been coated with 
polyvinylpyrrolidone [67]. Consequently, the use of Percoll, rather than sucrose, allows 
for the use of lower centrifugal forces, and accelerates sedimentation rates [50]. More 
specifically, the maximum centrifugal force applied by this method was 30,700xg, and 
gradient separation took merely eight minutes. In fact, the entire procedure for isolating 
myelin, mitochondria and synaptosomes is estimated to take 90 minutes [49]. 
 The sucrose gradient isolation method developed by Norton takes slightly over 
two hours to complete [48]; however, modifications used in this study increased the 
isolation time to 4-5 hours total. A discontinuous density gradient was applied twice; 
first to isolate the crude myelin, and a second time to obtain purified myelin. Unlike the 
Percoll gradient isolation, this method excluded an initial low speed centrifugation step 
to remove major debris, prior to applying the homogenized CNS tissue to a 
discontinuous density gradient [48]. It also required significantly greater centrifugal 
forces and separation times; the density gradient centrifugation steps depended upon 
the use of an ultracentrifuge, as forces up to 100,000xg were reached. Due to the longer 
isolation time, protease and phosphatase inhibitor cocktails were included in the 
isolation medium of the sucrose gradient method, during homogenization; they were 
not present in the isolation medium of the Percoll gradient method, though were 
incorporated into the myelin storage buffer used in each procedure. These inhibitors 
prevent protein denaturation which is often triggered by disturbance of the highly 
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regulated cellular environments; in so doing, total protein recovery is boosted and 
enzyme activity is preserved [68]. The sucrose gradient method also took advantage of 
two osmotic shock steps, which ensured removal of impurities from within the myelin 
vesicles. Unfortunately, this procedure required a greater number of mouse brains to 
produce an equivalent myelin yield to that generated using the Percoll method. The 
additional purification steps included in the sucrose gradient isolation led to the loss of 
some myelin vesicles; consequently, 8 mouse brains were needed to attain comparable 
amounts of myelin protein when judged against the product of the alternate Percoll 
procedure, which used only 4 mouse brains. The sucrose method was variable and 
yielded 2.5-14 mg of total protein, whereas the Percoll method generated 
approximately 5 mg of protein. 
Preliminary tests indicated that both sucrose and Percoll gradient isolation 
protocols generated myelin with measurable levels of Na+/K+-ATPase α1, α2, and α3, as 
well as their complementary β1, β2, and β3 subunits. Similarly, MBP, VDAC, NQO1 and 
MCT1 were successfully detected by Western blotting in the products of each myelin 
preparation (refer to Appendix G). MBP is a known myelin-specific protein, while VDAC 
and NQO1 are currently being investigated in the DeBruin lab as possible myelin-
associated proteins. Alternatively, MCT1, MCT2 and MCT4 have all been previously 
shown to localize within the CNS; MCT1 is predominately expressed in oligodendrocytes, 
while MCT2 and MCT4 are expressed in neurons and astrocytes, respectively [69]. 
Differences in the isolated myelin samples were only observed when examined side by 
side, along with a brain homogenate sample of equal protein content. VDAC and MCT1 
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were more enriched in the myelin vesicles of the Percoll gradient protocol, despite 
containing equivalent levels of MBP when compared with myelin isolated using a 
sucrose-gradient; therefore, the myelin produced using the sucrose-gradient method 
was selected for all further analyses despite being a more timely and expensive 
procedure. 
4.2 Role of Na+/K+-ATPase Isoforms and Heterodimers in the Myelin 
Membrane 
 To date, four alpha and three beta isoforms of Na+/K+-ATPase have been 
identified in mammalian tissues; of these, only Na+/K+-ATPase α1, α2, and α3, and β1, β2, 
and β3 have been identified in CNS tissue. Each of these isoforms are encoded by 
separate genes and they show a high degree of conservation, even across species 
[3;70;71]. Despite any differences in sequence and/or post-translational modifications, 
past studies have demonstrated that each of the four alpha subunit isoforms are 
capable of forming a functional ion pump with any of the three beta subunit isoforms 
[31]. 
4.2.1 Co-expression of Na+/K+-ATPase Isoforms and Isozymes 
The isoforms of each subunit demonstrates spatial and temporal patterns of 
expression; specifically, tissue-specific and developmental variations in protein 
expression [70]. The α1 and β1 subunits have been classically perceived as the 
“housekeeping” isoforms, as they are typically abundant and ubiquitously expressed 
[24;27;31;72]. Conversely, the α2, α3, α4, β2, and β3 subunit isoforms demonstrate 
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varying levels of tissue-specificity or variations in expression throughout the stages of 
development; these differences suggest that each provides unique functional roles. So 
far, the α2 subunit has been primarily identified in the brain, muscle, adipose, 
osteoblasts, retina, choroid plexus, lung, and the optic nerve; the α3 and β2 subunits are 
found in neural tissue, with Na+/K+-ATPase α3 also having been identified in human 
cardiac muscle; and the α4 and β3 subunits are expressed in spermatogonia and sperm, 
although Na+/K+-ATPase β3 has also been noted in the brain, kidneys, lung, spleen, 
intestines, and liver [24;27;31;34]. With regards to the specific cell types of the CNS, the 
α1 isoform distributes between neurons and glia, while the α2 and α3 isoforms are 
primarily expressed in glia or neurons, respectively; also, the β1, β2, and β3 isoforms 
predominantly exist within neurons, both astrocytes and oligodendrocytes, or 
oligodendrocytes, respectively [36]. Refer to Table 4.1 and section 4.2.2 for further 
discussion. In this study, it was identified that all three alpha and three beta subunit 
isoforms of the mammalian CNS were expressed in the myelin membrane of both CD1 
and ND4 mice; these represented healthy and diseased myelin, respectively. 
 Apart from the tissue- and organ-specific distribution of each subunit isoform, 
the alpha and beta subunits of Na+/K+-ATPase can also exhibit subplasmalemmal 
organization. Na+/K+-ATPase has the potential to reside within certain microdomains 
and membrane regions; therefore, it often demonstrates targeted distribution within 
the plasma membrane [32]. This phenomenon has been observed in cultured astrocytes 
and neurons, both of which have a unique and complex cellular architecture (Figure 
4.1). In particular, the α1, α2, and α3 subunit isoforms have demonstrated unique 
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patterns of expression in these cell types. Na+/K+-ATPase α1 is expressed throughout 
astrocytes, but appears limited to the cell bodies of neurons [72]. Alternatively, Na+/K+-
ATPase α2 localizes in regions of the plasma membrane that overlap with the cellular 
distribution of the endoplasmic reticulum [72]; this pattern of expression could be an 
unintentional consequence of integral membrane protein synthesis and transport from 
the endoplasmic reticulum to the plasma membrane, via the Golgi complex. And lastly, 
Na+/K+-ATPase α3 non-uniformly distributes throughout the processes (dendrites, axons, 
and terminal fibers) and cell bodies of neurons; Na+/K+-ATPase α3 stands apart from its 
α1 counterpart, as it is expressed in clusters or focused regions within neurons [72].  
 
Figure 4.1 The basic structure of neurons and astrocytes 
 
A typical neuron has a cell body, which contains the nucleus and other cellular organelles, as well as 
dendrites to receive impulses, and axons and fibers to transmit impulses. Astrocytes are characteristically 
star-shaped, and extend processes which commonly terminate on blood vessels or the axons of neurons. 
Image adapted from references [1;4]. 
 
Known protein-protein interactions indicated that Na+/K+-ATPase stabilizes 
components of adherens junctions and regulates the expression of proteins found in the 
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tight junctions of epithelial cells [58;73;74]. These two microdomains form the apical 
junctional complex, which is responsible for critical cell-cell adhesion. Na+/K+-ATPase has 
been shown also to localize within the caveolar microdomain of renal epithelial cells; 
this result was anticipated as both Na+/K+-ATPase and caveolae exist at the basolateral 
plasma membrane of these polarized cells [32;58]. In these caveolae, oligomers of 
caveolin-1, tetramers of annexin-2, and oligomers Na+/K+-ATPase formed large 
multiprotein complexes [58]. Furthermore, when activity was investigated in both 
caveolar and non-caveolar Na+/K+-ATPase pools, it was determined that ion transport 
capabilities were retained in the caveolae; this has also been demonstrated in Na+/K+-
ATPase within caveolae derived from cardiac myocytes [58]. Caveolin-1 enriched 
microdomains, adherens junctions and tight junctions are all found in the myelin 
membrane as well; the caveolin-1 enriched microdomain and adherens junctions are 
both components of the outer loops of myelin, the adherens junctions and tight 
junctions are part of the paranodal loops of myelin, and the adherens junctions and 
tight junctions are also found in the incisures and radial components of the myelin 
membrane, respectively [16]. 
Ultimately, the unique subplasmalemmal distribution of each Na+/K+-ATPase 
subunit isoform may confer unique physiological properties to specific cell types. On top 
of these distinct localization patterns, the subunit isoforms also vary in their 
comparative levels of expression. For example, neurons typically express Na+/K+-ATPase 
α1, α2, and α3; however the α1 and α3 isoforms are most abundant [72]. In the same 
way, all three alpha isoforms of the CNS are expressed in the myelin membrane, as 
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identified in this study; however, as shown by Western blot analysis, myelin is rich in the 
α3 isoform, while the α1 and α2 isoforms are less abundant. As in neurons, the α2 
isoform in myelin is the least abundant. With regards to the beta subunit in myelin, 
Na+/K+-ATPase β2 and β3 are more abundant than the β1 isoform. Each individual Na
+/K+-
ATPase alpha or beta isoform, within a specific tissue or cell type, also experiences 
fluctuations in their expression over the course of development. 
 As discussed earlier, multiple subunit isoforms are often co-expressed within a 
tissue or specific cell type.  The coexistence of different Na+/K+-ATPase subunit isoforms, 
and in turn various isozymes, may be essential due to differences in their sensitivity to 
inhibitors, substrate affinities, and varying cellular roles. Firstly, Na+/K+-ATPase is often 
targeted by cardiac glycosides, such as ouabain, in the treatment of congestive heart 
failure and other cardiomyopathies. These compounds can inhibit enzymatic activity by 
disrupting the catalytic site of the alpha subunit. They are also naturally occurring in 
biological systems. Interestingly, the α1 isoform is ouabain-resistant; Na
+/K+-ATPase α2 
and α3, however, are ouabain-sensitive and can be inhibited by such compounds [75]. 
With regards to their substrate affinities, disparity in both Na+ and K+ ion affinities 
between isoforms have been experimentally proven. In a rat model, the α1 isoform 
exhibited a greater K+ affinity than its α2 and α3 counterparts; while the α3 isoform has 
demonstrated a reduced affinity for Na+ in comparison to α1 and α2 [24]. The enzymatic 
activity of each of the heterodimeric forms of Na+/K+-ATPase can also be modulated by 
associations with the FXYD1 protein, which is often co-expressed [76]. Thirdly, 
adaptations or isoform specific interactions are reflected in the distinct distribution of 
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the Na+/K+-ATPase beta subunit isoforms within oxidative and glycolytic tissues; in 
particular, the β1 isoform is found in oxidative muscle fibers whereas the β2 isoform 
resides primarily in the glycolytic fibers [77]. The slight differences in these enzymatic 
properties, between individual isoforms and isozymes, may support different 
physiological requirements and provide adaptability to inconsistent ionic and osmotic 
cellular environments [72]. Likewise, the chromosomal dispersion of the genes for each 
alpha subunit isoform, as well as their individual expression patterns, suggests selection 
in response to various physiological demands [72]. Negative and positive elements have 
been identified for the genes of each alpha isoform; they bind transcription factors and 
regulate both spatial and temporal expression. The existence of these elements also 
indicates that Na+/K+-ATPase expression is strongly associated with physiological 
requirements [72]. Alternative splicing has also been shown to generate truncated alpha 
and beta isoforms; both have been identified in several tissue types and retain their ATP 
binding and phosphorylation sites, suggesting that they maintain their ATPase activity 
[3]. The expression of these truncated proteins could have significant structural or 
functional importance. Finally, it is possible that co-expression may primarily offer 
functional redundancy, as Na+/K+-ATPase is responsible for several critical cellular 
functions and is a key regulator of homeostasis. 
4.2.2 Comparison with Cell Types of the Brain 
 Na+/K+-ATPase α1, α2, and α3, as well as the complementary β1, β2, and β3 
subunits, represent all known isoforms of Na+/K+-ATPase in the CNS. Table 4.1 
summarizes the findings of this study, in addition to the known subunit isoform 
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expression of the major cell types of the CNS. Myelin, unlike these cell types, is the only 
component of the CNS known to express all six subunit isoforms. Although Na+/K+-
ATPase α3 expression has not been detected in oligodendrocytes [34;75;79;81], it is 
found in the myelin sheath; thus, expression must occur post-myelination. The use of 
antibodies with unique epitope binding sites, for each alpha and beta isoform, ensured 
no cross-reactivity and provided confidence in the identification of each subunit 
isoform. The specific epitopes for each antibody used in the study were described 
previously in Table 2.1. 
Table 4.1 The distribution of alpha and beta isoforms within the various cell types of 
the brain 
The known expression of Na
+
/K
+
-ATPase subunit isoforms is represented by  a positive (+) sign; 
alternatively, Na
+
/K
+
-ATPase subunit isoforms not known to exist in the specified tissue or cell type is 
represented by a negative (-) sign. 
Cell Type 
Isoform 
References 
α1 α2 α3 β1 β2 β3 
Neurons + + + + + 
Only in retinal 
photoreceptors 
[34;75;78-
81] 
Astrocytes + + - + + - [75;78-81] 
Oligodendrocytes + + - + + + [34;75;79;81] 
Myelin + + + + + + This study 
 
 Although any of the three alpha isoforms could potentially associate with any of 
the three beta isoforms to produce a functional ion pump, it is atypical to observe all 
possible isozymes co-expressed within a single tissue or cell type [31]. In fact, all nine 
heterodimeric forms of Na+/K+-ATPase have only been noted within cartilage tissue [72]. 
Only six of these isozymes were revealed, by this study, to exist in the myelin membrane 
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of healthy CD1 mice; these included α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3. Of these, 
α1β1, α2β3, and α3β1 were the most abundant heterodimeric forms of Na
+/K+-ATPase in 
the myelin membrane, and α2β3 and α3β3 were unique when compared with neurons 
and glial cells. The isozymes found in neurons, oligodendrocytes, astrocytes and other 
mammalian tissues or cell types, are specified in Table 4.2. Neurons, oligodendrocytes 
and astrocytes also express Na+/K+-ATPase heterodimers which can distinguish these 
cells from the myelin membrane; both α1β2 and α1β3 exist in neurons, while α1β2, α1β3, 
and α2β2 have been identified in oligodendrocytes and/or astrocytes [72]. 
Table 4.2 The distribution of Na+/K+-ATPase isozymes within mammalian tissues 
The known expression of Na
+
/K
+
-ATPase isozymes within various mammalian tissues and/or cell types. 
This table was adapted from reference [72]. The results of this study are included; the six heterodimeric 
forms of Na
+
/K
+
-ATPase, which were identified in the myelin membrane of CD1 mice, are listed. 
Type of Tissue/Cell Known Na+/K+-ATPase Isozymes 
Renal tubule cells α1β1 
Cardiac myocytes α1β1, α1β2, α1β3, α2β1, α2β2, α2β3, α3β2, α3β3 
Gut α1β1 
Alveolar epithelial cells α1β1, α1β3, α2β1, α2β3 
Liver α1β1, α1β3 
Neurons α1β1, α1β2, α1β3, α3β1, α3β2 
Oligodendrocytes and/or astrocytes α1β1, α1β2, α1β3, α2β1, α2β2 
Ciliary epithelium α1β1, α1β2, α2β1, α2β2, α3β1 α3β2 
Chondrocytes α1β1, α1β2, α1β3, α2β1, α2β2, α2β3, α3β1, α3β2, α3β3 
Osteoblasts α1β1, α1β2 
Osteoclasts α1β1 
Vascular endothelial cells α1β1, α1β2, α3β1, α3β2 
Skeletal muscle α1β1, α1β2, α1β3, α2β1, α2β2, α2β3 
Smooth muscle α1β1, α2β1 
Testis α1β1, α1β2, α1β3, α4β3 
Prostatic epithelial cells α1β1, α1β2 
Myelin α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3 
 
 The assortment of Na+/K+-ATPase isozymes are generated by the expression of 
different genes, variations in transcriptional modifications and processing, and the 
successful formation of different heterodimeric combinations [3]. As noticed in Table 
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4.2, α1β1 is present in all examined mammalian tissues and cell types to date; this 
observation supports the role of both α1 and β1 isoforms as the “housekeeping” Na
+/K+-
ATPase subunit isoforms [24;27;31;72]. Other isozymes have proposed functional roles 
according to the known ion affinities of their corresponding subunit isoforms, as well as 
known functions and physiological needs of the tissues or cell types in which they are 
expressed. In particular, heterodimeric forms which incorporate the α3 isoform may 
provide additional ion transport capabilities in situations or locales of major fluctuations 
in ion concentration. As mentioned earlier, Na+/K+-ATPase α3 demonstrates the lowest 
affinity for Na+ ions, out of all the alpha isoforms [24]. Likewise, the α3β1 isozyme  has 
reduced affinity for both Na+ and K+ ions, and is found primarily in excitable tissues [72]. 
These qualities may be interpreted as the evolutionary adaptability of Na+/K+-ATPase to 
meet the requirements of excitable tissues, which experience extreme variations in their 
ionic environments; for example, the extreme fluctuations observed throughout the 
firing of action potentials [72]. Similarly, α3β1, α3β2, and α3β3 are expressed in cartilage 
tissue or chondrocytes, where recovery from major variations in the concentration of 
Na+ ions is necessary following mechanical joint loading [72]. It is therefore not 
surprising that the myelin membrane expresses all α3-containing isozymes, as it is tightly 
associated with neuronal axons and may be needed to support the changes in ionic 
environments as action potentials are transmitted.  Between the unique kinetic 
properties and sensitivity in inhibitors, each expressed isozyme appears to provide the 
necessary adaptations for their resident tissue requirements. 
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4.3 Protein-Protein Interactions in the Myelin Membrane 
 Proteins are responsible for carrying out cellular processes, and although they 
can have independent functions they often collaborate to maintain activity and control 
their environment. Considering there is a significant number of proteins, and 
exponentially more cellular functions, protein-protein interactions exhibit both 
structural and functional diversity. Firstly, proteins may interact with proteins of either 
identical or non-identical chains; these interactions generate either homo- or hetero-
oligomers, respectively [82]. In turn, oligomers formed by homologous proteins can join 
in either an isologous or heterologous fashion. Isologous associations are formed on the 
equivalent surfaces of each protein unit, whereas heterologous connections occur at 
alternative interfaces [82]. Secondly, protein complexes may be functionally obligate; 
the individual protein components cannot exist alone, as they may not be stable without 
their specific binding partners. In contrast, non-obligate interactions are those produced 
from the assembly of proteins which can exist independently from one another [82;83]. 
A prime example of a non-obligate interactions are cellular signalling cascades; the 
individual proteins are generally not co-localized until the moment of interaction, and 
therefore must be stable on their own. Nonetheless, co-localized proteins, particularly 
homo-oligomers, can participate in non-obligate interactions [82]. Lastly, protein-
protein interactions may be either permanent and form very stable complexes, or they 
can be transient and provide dynamic associations and disassociations in response to 
the environment or external factors [82;83]. These interactions may also be regulated 
by post-translational modifications, such as glutathionylation and carbonylation [84-86]. 
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Despite the discrete types of protein complexes which can form, it is unusual for a 
particular interaction to be neatly categorized, as these complexes can vary in stability 
according to their surrounding environment. 
Na+/K+-ATPase has several known binding partners and participates in various 
protein-protein interactions. The individual alpha and beta subunit isoforms of Na+/K+-
ATPase, themselves, also interact and assemble to produce the functional enzyme. Thus, 
this enzyme is an example of a hetero-oligomer, or in this particular instance a 
heterodimer; it is also an example of a non-obligate and usually permanent interaction. 
Both alpha and beta subunits are produced independently, but the beta subunit is 
required for the successful insertion of the alpha subunit into the plasma membrane. It 
interacts with the alpha subunit via a heptad repeat motif, in order to form the αβ 
hetero-oligomer [87]. The beta subunit can exist within the plasma membrane 
regardless of alpha expression, although independent roles of this subunit are unknown 
[27]. It is, however, fundamentally important in cell-cell adhesion, as Na+/K+-ATPase β1 
also contains a glycine zipper motif which allows homo-oligomerization between beta 
subunits [87]. As a transmembrane protein of the plasma membrane, Na+/K+-ATPase has 
the potential to associate with cytosolic, extracellular, and other transmembrane 
proteins. Isozymes may also have unique or shared binding partners. Each of these types 
of associations is depicted in Figure 4.2. 
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Figure 4.2 Potential protein-protein interactions involving Na+/K+-ATPase 
 
Many unknown proteins may form complexes with Na
+
/K
+
-ATPase, or act as protein binding partners. The 
six heterodimeric forms of Na
+
/K
+
-ATPase, known to exist in the myelin membrane, are illustrated above. 
The dashed lines indicate the potential connections between the various subunit isoforms and other 
unknown proteins. Protein-protein interactions of the Na
+
/K
+
-ATPase alpha and beta subunit isoforms 
may include cytosolic, extracellular and/or other transmembrane proteins. The indicated associations are 
provided as examples and do not necessarily represent actual associations of these Na
+
/K
+
-ATPase 
isozymes. 
4.3.1 Structural and Functional Properties 
 Co-immunoprecipitation of the three Na+/K+-ATPase alpha subunit isoforms 
revealed their involvement in several protein-protein interactions, within the myelin 
membrane. When analyzed by LC-MS/MS, a total of 13 major proteins were identified, 
with 100% probability and a minimum of two unique peptides recognized using the 
Scaffold 4 proteome software. The α1 and α2 isoforms were successfully detected within 
their respective isolated protein complexes; the remaining protein binding partners 
included additional Na+/K+-ATPase subunit isoforms, myelin specific proteins, and other 
protein types. The identified binding partners of each alpha isoform are listed in Table 
4.3, along with their proposed structural and/or functional roles. Due to the transient 
nature of certain protein-protein interactions, it is likely that the number of identified 
95 
 
binding partners in myelin has been underestimated. Similarly, the conditions of the co-
immunoprecipitation could have potentially disrupted various protein associations. For 
example, TX-100, although not used in this co-IP, has been reported to disrupt the 
Na+/K+-ATPase α1β2 isozyme but not α1β1 or α2β2 [31]. 
Table 4.3 Known physiological functions of binding partners identified by co-
immunoprecipitation and mass spectrometry in this study 
Protein-protein interactions within the myelin membrane, which involved Na
+
/K
+
-ATPase, were identified 
by mass spectrometry. Each alpha isoform of Na
+
/K
+
-ATPase had both unique and shared binding 
partners. These binding partners are listed, along with their proposed structural and/or functional 
properties from the literature. 
Na+/K+-
ATPase α 
Isoform 
Identified 
Binding Partner 
Abbreviation 
Structural and Functional 
Properties 
References 
α1 
Sodium/potassium-
transporting 
ATPase subunit 
alpha-3 
Na
+
/K
+
-ATPase 
α3 
Ion transport of Na
+
 and K
+
; 
lower affinity for Na
+
 
[24;72] 
Sodium/potassium-
transporting 
ATPase subunit 
beta-1 
Na
+
/K
+
-ATPase 
β1 
Transport and insertion of the α 
subunit into the plasma 
membrane; lower affinity for K
+
 
[27;72] 
Serine/arginine 
repetitive matrix 
protein 2 
SRRM2 
RNA splicing factor; binds 
components of pre-mRNA and 
the splicesome; plays a role in 
cell migration 
[88] 
Peripheral myelin 
protein 22 
PMP-22 
Minor tetraspan membrane 
protein of PNS myelin; provides 
structural support and 
maintains compact myelin; 
component of membrane 
junctions with involvement in 
cell-cell interactions and cell 
proliferation 
[1;89;90] 
Spermatogenesis-
associated protein 
7 
SPAT7 
Involved in normal retinal 
function; possible interactions 
with chromatin and the 
initiation of meiotic 
recombination in testis 
[91;92] 
2’,3’-cyclic 
nucleotide 3’-
phosphodiesterase 
CNP 
Forms stable associations with 
tubulin and anchors 
microtubules to membranes; 
regulates tubulin polymerization 
[11;93] 
Proteolipid protein 
1 
PLP1 
Major tetraspan membrane 
protein of CNS myelin; provides 
structural support and 
maintains compact myelin; 
[12;94] 
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possible ionophore 
α2 
Sodium/potassium-
transporting 
ATPase subunit 
alpha-3 
Na
+
/K
+
-ATPase 
α3 
Ion transport of Na
+
 and K
+
; 
lower affinity for Na
+
 
[24;72] 
Cullin-associated 
NEDD8-dissociated 
protein 1 
CAND1 
Regulates the assembly and 
activity of Cullin-RING E3 
ubiquitin-ligases; role in protein 
degradation pathways 
[95-97] 
α3 
Sodium/potassium-
transporting 
ATPase subunit 
beta-1 
Na
+
/K
+
-ATPase 
β1 
Transport and insertion of the α 
subunit into the plasma 
membrane; lower affinity for K
+
 
[27;72] 
Brain acid soluble 
protein 1 
BASP1 
Co-localizes with raft proteins; 
possible involvement in cell-cell-
interactions; transcription 
regulator 
[98;99] 
Protein MRVI1 MRVI1 
Component of cGMP kinase 
signalling complexes; interacts 
with inositol 1,4,5-triphosphate 
receptor 1; mediates nitric oxide 
dependent inhibition of calcium 
signalling 
[100-103] 
Peripheral myelin 
protein 22 
PMP-22 
Minor tetraspan membrane 
protein of PNS myelin; provides 
structural support and 
maintains compact myelin; 
component of membrane 
junctions with involvement in 
cell-cell interactions and cell 
proliferation 
[1;89;90] 
Serine/arginine 
repetitive matrix 
protein 2 
SRRM2 
RNA splicing factor; binds 
components of pre-mRNA and 
the splicesome; plays a role in 
cell migration 
[88] 
Proteolipid protein 
1 
PLP1 
Major tetraspan membrane 
protein of CNS myelin; provides 
structural support and 
maintains compact myelin; 
possible ionophore 
[12;94] 
Krueppel-like factor 
6 
KLF6 
Contain zinc finger motifs that 
bind promoter and enhancer 
regions; regulate proliferation, 
differentiation and apoptosis 
[104] 
 
Na+/K+-ATPase interacts with an array of proteins within the myelin membrane. 
Its association with several myelin specific proteins alludes to the possibility of its direct 
or indirect involvement in the maintenance of myelin. Other binding partners may 
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provide significant structural and functional roles when associated with Na+/K+-ATPase, 
or vice versa. For example, SRRM2 is a RNA splicing factor which can bind sequence 
elements on pre-mRNA, as well as components of the splicesome, to form the 
complexes needed in excision-splicing [88]. The interaction of Na+/K+-ATPase with 
proteins involved in transcriptional processing is logical as the alternative splicing of the 
alpha and beta isoforms has been implicated in the generation of various Na+/K+-ATPase 
isozymes [3]. KLF6, one of the proteins associated with Na+/K+-ATPase α3, is a 
transcription factor with proposed roles in promoting apoptosis in Schwann cells, 
following nerve injury; it appears to increase the susceptibility of a cell to apoptotic 
stressors [104]. Overexpression of KLF6 has also been linked to increased neurite growth 
[104]. Another binding partner, CAND1, is known to interact with diverse families of 
proteins, and consequently participate in a wide range of cellular processes. More 
specifically, CAND1 regulates Cullin3-mediated E3 ligase activity and suppresses Cullin-
RING ubiquitin ligases by sequestering unneddylated Cullin1 [96]. Cullin-RING ubiquitin 
ligases are critical for targeting cellular proteins for ubiquitin-mediated degradation; 
hence, CAND1 delays or prevents the destruction of cellular proteins which are targeted 
for ubiquitination [97]. And lastly, MRVI1, also known as inositol 1,4,5-trisphosphate 
receptor-associated cGMP kinase substrate, not only interacts with Na+/K+-ATPase α3 
but has known associations with inositol 1,4,5-triphosphate receptor 1 [101]. 
Interestingly, inositol 1,4,5-triphosphate receptor 1 was a predicted functional partner 
of the α1 and α2 isoforms, but not α3; these protein-protein interactions were revealed 
using STRING 9.1 (http://string-db.org/) [59]. Refer to Appendix C for more information. 
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Many of the proteins identified as Na+/K+-ATPase binding partners are 
responsible for cell to cell interactions, signal transduction, and the mediation of cellular 
responses. These proteins were also indicative of the distribution of Na+/K+-ATPase 
between the various microdomains of the myelin membrane. Specifically, PLP1 is a 
protein marker of the tetraspanin-enriched microdomain of compact myelin [16]; its 
association with both the α1 and α3 isoforms suggests that Na
+/K+-ATPase also exists 
within this microdomain. Likewise, the partnership between the Na+/K+-ATPase α3 and 
BASP1 indicates that this isoform is likely present in the lipid raft microdomains of the 
myelin membrane, as lipid rafts are found in all cell types and seem to sequester BASP1 
in endothelial cells [99]. This result corresponds with the detection of Na+/K+-ATPase α3 
in the DRMs of mouse myelin, as demonstrated by Western blot analysis. Na+/K+-ATPase 
has also been identified in kidney caveolae; it forms complexes with caveolin-1 and 
associates with annexin-2 [58]. Caveolin-1 is also enriched in microdomains of the outer 
loop of myelin, in the PNS [16]. It is therefore possible that Na+/K+-ATPase could interact 
with caveolin-1 in the myelin membrane, and become localized to these caveolin-1 
enriched microdomains.  
The co-expression of the Na+/K+-ATPase beta subunit and E-cadherin is essential 
for the formation of tight junctions and desmosomes [105]. Similarly, in renal epithelia, 
Na+/K+-ATPase demonstrates co-localization with E-cadherin but not occludin; as a 
result, Na+/K+-ATPase has been proposed to regulate cellular junctions, including 
adherens junctions, via ion transport and signal transduction [58]. In particular, Na+/K+-
ATPase has known involvement in EGFR/Src-Ras-Raf-ERK and PI3K-PDK-Akt cell 
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signalling pathways [24;58]. Ouabain can initiate the carbonylation of two amino acid 
residues in the A-domain of Na+/K+-ATPase α1, which results in stimulation of Src 
signalling; however, this process appears to be regulated by reactive oxygen species, as 
signalling is prevented by pre-treatment with N-acetyl-L-cysteine [86]. Finally, the 
association of CNP with tubulin in brain tissue, and its roles in microtubule assembly and 
organization, corresponds with the known interactions of Na+/K+-ATPase with 
components of the cytoskeleton [93]. The non-random distribution of Na+/K+-ATPase 
within biological membranes has been attributed to interactions with ankyrin, fodrin, 
actin, and uvomorulin; these are cytoskeletal proteins which provoke the assembly of 
the cytoskeleton together with Na+/K+-ATPase, in addition to mediating the specific 
distribution of Na+/K+-ATPase within the plasma membrane [70;72]. 
The ability of Na+/K+-ATPase to respond to changes in physiological requirements 
largely relies on its interaction with other cellular proteins. As previously mentioned, 
reactive oxygen species can initiate signal transduction by Src, via Na+/K+-ATPase [86]. 
The induction of these signalling cascades can trigger a variety of cellular processes, 
likely in response to oxidative stress. Similarly, cysteine residues in Na+/K+-ATPase 
become S-glutathionylated when exposed to oxidized glutathione. S-glutathionylation 
results in enzyme inhibition, as glutathione disrupts the ability of Na+/K+-ATPase to bind 
adenine nucleotides [84]. This inhibition is not observed at high ATP levels, suggesting 
that S-glutathionylation regulates Na+/K+-ATPase activity in situations of oxidative stress 
and ATP depletion, such as in cases of hypoxia [84]. S-glutathionylation of Na+/K+-
ATPase can also be reversed by enzymes such as glutaredoxin 1; this deglutathionylation 
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has been demonstrated in the β1 subunit following superoxide scavenging by superoxide 
dismutase [85]. The reversible glutathionylation of Na+/K+-ATPase by glutaredoxin 1 
indicates that it is an oxidative regulator of Na+/K+-ATPase activity.  
The major isozymes of Na+/K+-ATPase which were identified in this study, by 
Western blot analysis, included α1β1, α2β3, and α3β1. Of these, both the α1β1 and α3β1 
associations were confirmed by mass spectrometry, as the Na+/K+-ATPase β1 subunit 
isoform was detectable in both the α1 and α3 isoform isolated protein complexes. 
Interestingly, the α1 and α2 isoforms demonstrated the ability to interact with other 
alpha subunits, specifically the α3 isoform. This finding was anticipated, as the 
promiscuous nature of Na+/K+-ATPase alpha and beta subunits permits the assembly of 
oligomeric complexes. Different alpha isoforms have demonstrated the ability to form 
stable oligomers, proving the complexity of Na+/K+-ATPase and its molecular 
heterogeneity; however, the influence of Na+/K+-ATPase supracomplexes on enzymatic 
function remains unclear [3]. 
4.4 Na+/K+-ATPase Involvement in Demyelination 
4.4.1 Temporal Na+/K+-ATPase Expression 
 The subunit isoforms of Na+/K+-ATPase not only demonstrate tissue specificity, 
but also display changes in expression over the stages of development. Of course, 
Na+/K+-ATPase provides important cellular functions that are required for normal 
development; therefore, patterns of expression are expected as a consequence of 
responding to changing physiological requirements. This enzyme has proven critical 
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during morphogenesis; in embryonic development the sodium-potassium pump 
collaborates with other sodium exchangers of trophoblasts, to produce the 
transepithelial flow of water and Na+ ions necessary for the formation of the fluid or 
yolk-filled component of what eventually becomes the blastula [72]. In experiments 
which disrupted Na+/K+-ATPase activity during blastocyst formation, pre-natal 
development ceased.  
Hormones, specifically thyroid hormones and glucocorticoids, appear to 
influence alpha isoform expression at various stages of development [106]. Thyroid 
hormone stimulates an increase in α2 and α3 isoform mRNA levels, whereas 
glucocorticoids have shown to suppress α3 isoform gene transcription [70]. Combined, 
these two types of hormones adjust isoform expression in cardiac tissue; the α3 isoform 
is transcribed to the greatest extent during fetal and neonatal development, while the 
α2 isoform appears to take over during post-natal development [70]. Regardless, Na
+/K+-
ATPase α1 remains the predominant alpha isoform at all stages of development. Similar 
changes in the gene transcription of the alpha isoforms have been observed in other 
tissues; for example, neuronal Na+/K+-ATPase α3 mRNA and protein levels are 
significantly reduced with normal aging [36].  
Both β1 and β2 isoforms are expressed in the CNS of rats at varying stages of 
post-natal development. The β1 isoform is expressed equally with the β2 isoform, in 
neurons, during the neonatal stage of development; its expression significantly 
increases after birth, and reaches mature levels as quickly as 6 days later [107]. In 
contrast, β2 expression decreases continuously over post-natal development and 
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eventually becomes undetectable in the fully mature adult rat neurons [107]. Thyroid 
hormones appear to have limited or no effect on the transcription of these beta subunit 
isoforms [70]. Transcriptional regulation of the beta isoforms is possible; however, it 
seems to be primarily driven by immediate physiological needs, rather than major 
developmental changes. For example, myoblasts induce beta subunit biosynthesis in 
response to increased intracellular Na+ ion concentrations; as a result, Na+/K+-ATPase 
alpha subunits can be promptly transported to the plasma membrane to restore ionic 
balance [70]. Conversely, in situations where Na+ entry becomes impaired, the Na+/K+-
ATPase isozymes are internalized in order to maintain ionic homeostasis [70]. 
Regardless of the transcriptional regulation of the Na+/K+-ATPase beta subunit, 
these isoforms demonstrate developmental changes in their glycosylation. Bear in mind 
that all isoforms of the beta subunit are heavily glycosylated, and that each isoform 
varies in its number of potential N-glycosylation sequences according to its species of 
origin [3;27]. In mammals, the β1 subunit has three possible extracellular N-glycosylation 
sites; on the other hand, the β2 subunit of chicken, human, and mouse origin have four, 
eight, and nine potential N-glycosylation sites, respectively [3;108]. The β3 subunit is 
much more variable between species, and little information is known regarding its 
glycosylation. The fully glycosylated forms of each beta subunit are classically identified 
as the mature beta subunits, whereas the unglycosylated core protein is, by definition, 
the immature form. In this study, variations in expression of each glycosylation state of 
the β1 subunit were noted over post-natal development in mice. Unsurprisingly, the 
unglycosylated core of Na+/K+-ATPase β1 demonstrated limited expression in the later 
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months of development and was the least abundant of all forms. Conversely, the 
Na+/K+-ATPase β1 subunits containing either one or two N-glycans were found in the 
greatest abundance. It is possible that these glycosylated, yet immature, β1 subunits are 
held in reserve and become glycosylated when the mature form is needed. 
4.4.2 Modifications to Na+/K+-ATPase Expression in a Demyelinating 
Model 
 Demyelination, as modelled by ND4 transgenic mice, is characterized by the 
destruction of the myelin sheath [1]. It is one of the fundamental causes of multiple 
sclerosis, and contributes significantly to the development of symptoms. This study 
identified several important dissimilarities in Na+/K+-ATPase expression between healthy 
CD1 control mouse myelin and transgenic ND4 mouse myelin. Although the patterns of 
expression for each subunit isoform evaluated using the ND4 model were relatively akin 
to those observed in the CD1 mouse myelin, when compared side-by-side the individual 
protein levels at each stage of development were strikingly different; these variations 
are illustrated in Figure 4.3. Na+/K+-ATPase α1, α2, and α3 levels were 1.5 to 3.2 times 
higher at 3.00 months of age in the demyelinating model; however, this elevation was 
followed by a rapid decrease, with levels dropping below those observed in the healthy 
myelin over varying stages of post-natal development. The β1 isoform had reduced 
expression in the ND4 myelin, with the exception of a spike at 9.00 months of age; here, 
the expression of β1 was more than 2.5 times that measured in the CD1 myelin. 
Alternatively, β2 isoform expression fluctuated throughout development but remained 
relatively close to levels demonstrated in healthy myelin. And lastly, expression of the β3 
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isoform was extremely similar in both CD1 and ND4 myelin until 13.02 months of age, 
when levels in ND4 myelin slightly increased. 
 
Figure 4.3 Ratio of corrected intensities for each Na+/K+-ATPase subunit isoform in 
ND4 myelin, relative to CD1 myelin, with aging 
 
Intensity of each Na
+
/K
+
-ATPase subunit isoform in ND4 myelin relative to CD1 myelin, ensuring non-
saturation and subtracting background. Data corresponds with the Western blots shown in Figure 3.8. 
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. Each value was corrected by 
normalization with a β-actin protein loading control, and the CD1 myelin Na
+
/K
+
-ATPase subunit isoforms 
have relative intensities equal to 1.0.  
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Figure 4.4 Ratio of corrected intensities for each Na+/K+-ATPase β1 glycosylation state 
in ND4 myelin, relative to CD1 myelin, with aging 
 
Intensity of each Na
+
/K
+
-ATPase β1 glycosylation state in ND4 myelin relative to CD1 myelin, ensuring non-
saturation and subtracting background. Data corresponds with the Western blots shown in Figure 3.8. 
Bands 1 to 4 represent the highest molecular mass form of Na
+
/K
+
-ATPase β1 (3 N-glycans) to the lowest 
molecular mass form (core, non-glycosylated), respectively. Intensity was measured at 3.10, 7.65, 9.00 
and 13.02 months of age. Each value was corrected by normalization with a β-actin protein loading 
control, and the CD1 myelin Na
+
/K
+
-ATPase β1 glycosylation states have relative intensities equal to 1.0. 
 
In the mouse model of demyelination, Na+/K+-ATPase β1 demonstrated 
noteworthy differences in the expression of its various glycosylation states. These 
changes in expression are displayed in Figure 4.4. Aside from the mature, fully 
glycosylated form of Na+/K+-ATPase β1, expression appears increased in the ND4 myelin 
at 9.00 months. Very little of the mature β1 isoform exists in the ND4 myelin; at 9.00 
months it reaches maximum expression, yet it remains to be only half as much as the 
protein levels observed in CD1 myelin. Ultimately, Na+/K+-ATPase β1 does not reach full 
maturation in the demyelinating mouse model.  
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Mutated Na+/K+-ATPase beta subunits, with altered N-glycosylation sites, are 
able to maintain enzyme activity as well as their affinity for K+ ions and their sensitivity 
to ouabain; however, these non-glycosylated subunits demonstrate an impaired ability 
to assemble into αβ complexes, and also increase the susceptibility of Na+/K+-ATPase to 
proteolysis [3]. This experimental observation suggests that glycosylation of the beta 
subunit may contribute to protein folding events necessary for maintaining proper 
Na+/K+-ATPase structures. An absence of the normal N-glycans of the β1 isoform has also 
proven to disrupt its role in adherens junctions, by destroying its ability to bind ankyrin 
and increasing its susceptibility to endocytosis [109]. Respectively, a lack of Na+/K+-
ATPase β1 N-glycans has been held responsible for the impairment of mature cell-cell 
associations [110]. There is substantial evidence supporting the role of β-β interactions 
between the caveolar Na+/K+-ATPase αβ complexes of adjacent cells [58]; thus, 
glycosylation is not only vital for proper assembly of the alpha and beta Na+/K+-ATPase 
subunits, but is also important for the maintenance of cell-cell communication and 
adhesion. As interactions between unglycosylated beta subunits and components of 
adherens junctions and cytoskeletal elements can be more easily disrupted, the limited 
expression of mature Na+/K+-ATPase β1 could potentially contribute to the formation of 
demyelinating lesions in ND4 mice. Glycosylation has also been proposed as a 
therapeutic target for the treatment of viral infections, cancer, and an array of human 
disorders [111;112]. By understanding the glycosylation changes of the Na+/K+-ATPase 
beta subunits in instances of demyelination, it may be possible to eventually establish 
methods for the therapeutic manipulation of N-glycans, as a treatment of MS. 
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Aside from demyelinating disorders, Na+/K+-ATPase has also been implicated in 
other neurological disorders, as it is ubiquitously expressed in the CNS. It has proposed 
involvement in the pathophysiology of bipolar mood disorder as well as potentially 
acting as a molecular target of prion infections, such as Creutzfeld-Jakob disease. Firstly, 
individuals with bipolar mood disorder are known to experience both generalized 
decreases in CNS glucose metabolism and ATP synthesis; these two processes could 
easily correspond to decreased, or impaired, Na+/K+-ATPase activity [72]. In fact, 
patients who have experienced digoxin or digitalis neurotoxicity, and animals 
administered ouabain, exhibit mania-like hyperactivity and symptoms of depression 
[72;113]. With regards to prion infections, animals injected with ouabain experience 
similar neurological changes to those observed in various spongiform encephalopathies 
[72]. 
4.4.3 Considerations for Evaluating Protein Expression 
 Evaluating and comparing Na+/K+-ATPase protein expression between myelin 
samples of different genetic backgrounds can present several challenges. To begin with, 
Na+/K+-ATPase expression is highly influenced by circadian rhythms, dehydration or 
over-hydration, diet, and hormonal changes [36]. Na+/K+-ATPase demonstrates diurnal 
patterns of expression; the neurons of the ventral suprachiasmatic nucleus experience 
increased enzymatic activity during the day and decreased activity at night [114]. 
Alternatively, extreme changes in ionic environments, such as those accompanying 
dehydration or over-hydration, can directly control Na+/K+-ATPase activity. It has also 
been claimed that a diet with increased saturated fatty acid composition, or decreased 
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polyunsaturated fatty acids, is able to inhibit Na+/K+-ATPase activity by becoming 
incorporated into biological membranes [36]. The influence of thyroid hormones and 
glucocorticoids on Na+/K+-ATPase expression was discussed previously; they appear to 
influence alpha isoform expression at various stages of development [106]. Similarly, 
estrogens have been implicated in increased Na+/K+-ATPase activity; it has been 
suggested that Na+/K+-ATPase becomes activated by estrogen-mediated signal cascades 
or by estrogen-dependent changes in membrane fluidity [36]. With particular regards to 
this study, Na+/K+-ATPase expression may also vary in ND4 myelin as efforts to 
remyelinate transpire. Injury to the myelin membrane may trigger changes in Na+/K+-
ATPase subunit isoform expression. A similar effect has been documented in neurons; 
Na+/K+-ATPase α3 expression increases post-axonal damage, and remains elevated 
during the period of regeneration [115]. Unfortunately, in this particular strain of ND4 
mice, any remyelination or compensation mechanisms eventually become overwhelmed 
and lead to death. 
 Undoubtedly there are many factors, both environmental and endogenous, 
which can alter Na+/K+-ATPase activity and expression in a living animal model. Thus, 
standardized housing conditions for laboratory animals are imperative for 
reproducibility and minimizing bias [116]. Housing conditions such as animal feed and 
water, caging, bedding material, lighting, ventilation, temperature, noise, and sanitation 
must all be considered in animal research. Likewise, animals need to be euthanized 
under equivalent conditions, following a standard operating procedure. For the 
comparison of Na+/K+-ATPase expression in myelin isolated from both CD1 and ND4 
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mice, it was particularly important for all of the animals to be housed and sacrificed 
identically; samples from each mouse line needed to be euthanized at an equivalent 
age. Nonetheless, all efforts to maintain comparable standards of living can still not 
account for the fact that two genetically distinct lines (control and transgenic) of mice 
were compared; therefore, it is possible that innate differences may exist which could 
alter Na+/K+-ATPase activity and expression. 
 Finally, all densitometric data obtained in this study, by chemiluminescent or 
fluorescent detection, was normalized using β-actin. This housekeeping protein is one of 
many commonly used protein loading controls; others include β-tubulin, glyceraldehyde 
3-phosphate dehydrogenase, cyclophillin, etc. [60;62]. As these proteins perform 
housekeeping roles, they are typically constitutively expressed. The use of an internal 
control takes technical artifacts, like pipetting errors during gel loading and inconsistent 
protein transfer to blotting membranes, into account [60]. Normalization using these 
controls can be easily applied to data, pending that all replicates destined for 
comparison contain the control protein band [61]. For all densitometric measurements 
of both samples and controls, non-saturation was ensured when measuring signal 
intensities, in addition to performing background subtraction. Unfortunately, variability 
in the expression of housekeeping proteins in certain tissues and disease states could 
undermine the validity of β-actin as an internal control. Specifically regarding the ND4 
transgenic mice used in this study, by 10 months of age total myelin protein content can 
be reduced to as little as 17% of that found in normal healthy mice [23]. It is therefore 
difficult to imagine that when the total myelin protein content is disrupted to such an 
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extent, that β-actin levels remain normal. As a result, innovative approaches for the 
accurate quantification of protein expression using densitometric analysis may need to 
be developed. 
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Chapter 5 – Conclusions and Future Studies 
In 1981, the question of whether or not Na+/K+-ATPase is a myelin-associated 
enzyme was put forth by Reiss et al. [117]. They found that Na+/K+-ATPase activity in 
purified myelin was significantly more than expected as a result of microsomal 
contamination. Other studies using electron microscopic cytochemistry, in addition to 
other subcellular fractionation techniques, were also suggestive of an association 
between Na+/K+-ATPase and myelin [118]. Now, over 30 years later, this study aimed to 
answer that original question by comprehensively examining the expression of myelin-
associated Na+/K+-ATPase, and its individual subunit isoforms, using a mouse model. 
Mouse myelin closely resembles human myelin; in fact, they share 308 common 
proteins [119]. As a result, the study of myelin proteins using a mouse model can 
provide relevant information pertaining to human demyelinating diseases. 
It was discovered that Na+/K+-ATPase α1, α2, and α3, as well as the 
complementary β1, β2, and β3 subunits, are expressed in mouse myelin prepared by 
both sucrose and Percoll gradient isolation methods. These six subunit isoforms 
represent all known forms of Na+/K+-ATPase in the CNS; they are uniquely co-expressed 
within the myelin sheath, when compared with neurons, astrocytes and 
oligodendrocytes [34;75;78-81]. Similarly, six different isozymes of Na+/K+-ATPase were 
identified in myelin; these included α1β1, α2β1, α2β3, α3β1, α3β2, and α3β3. The most 
abundant isozymes were α1β1, α2β3, and α3β1. All six αβ complexes were also distinct 
when compared with neurons and glia; more specifically, α2β3 and α3β3 are unique to 
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myelin, whereas α1β2, α1β3, and α2β2 are known to exist in neurons and/or glia but were 
not identified in the myelin membrane [72].  
Several protein-protein interactions involving Na+/K+-ATPase were revealed using 
mouse myelin. In particular, the various alpha isoforms demonstrated interactions with 
other Na+/K+-ATPase alpha and beta subunit isoforms, in addition to associating with 
certain myelin-specific proteins and other protein types. These protein binding partners 
of Na+/K+-ATPase have known cellular functions, including RNA splicing, involvement in 
cell-cell migration and adhesion, the mediation of cytoskeletal interactions, and the 
regulation of protein degradation and apoptosis. Furthermore, several of these binding 
partners are known to localize in adherens junctions, tight junctions and caveolae. 
Na+/K+-ATPase also demonstrated associations with protein markers of lipid raft and 
tetraspanin-enriched microdomains [32;58;73;74]. The results of this study suggest that 
Na+/K+-ATPase likely localizes in the corresponding microdomains of the myelin 
membrane. 
 When the temporal expression of each subunit isoform of Na+/K+-ATPase was 
examined by Western blot analysis, this protein displayed noticeable changes over the 
course of normal development. This result corresponds with the known variations in 
Na+/K+-ATPase expression and activity observed in other tissues and cell types; these 
fluctuations occur in response to physiological demands, as well as normal aging 
processes [36;70]. The Na+/K+-ATPase subunit isoforms of the myelin membrane also 
showed differences in expression between healthy and diseased myelin. The divergence 
in the expression levels of the Na+/K+-ATPase subunit isoforms, in ND4 mouse myelin, 
113 
 
may be a contributing factor to the demyelinating processes which occur in these 
transgenic mice; alternatively, it could be consequence of other biochemical changes 
which take place during demyelination. Regardless of cause or effect, ND4 myelin 
exhibited severe impairment in Na+/K+-ATPase β1 subunit maturation. Expression of its 
mature, fully glycosylated form was drastically reduced over the post-natal 
development of ND4 mice; at maximum expression, the diseased myelin only contained 
approxmately 50% as much of the mature Na+/K+-ATPase β1, as measured in the healthy 
CD1 mouse myelin. 
 Ultimately, the experimental evidence suggests that Na+/K+-ATPase provides 
significant structural and functional roles within the myelin membrane. The co-
expression of all six CNS isoforms, in addition to several different heterodimeric forms, 
implies that this enzyme is essential to the normal physiology of the myelin sheath. It is 
likely that each isoform and isozyme confers distinctive properties required to meet the 
unique physiological demands of the myelin membrane. Likewise, the observed 
disruption of Na+/K+-ATPase expression in ND4 mice may indicate Na+/K+-ATPase 
involvement in demyelinating processes. 
 In the future, differences in Na+/K+-ATPase expression between various control 
and demyelinating animal models should be further evaluated. By examining myelin 
from a greater range of developmental timepoints, in addition to performing more 
replicates and using different models of demyelination, the significance of the changes 
in Na+/K+-ATPase subunit isoform expression will be established. Similarly, an 
investigation pursuing the effects of beta subunit N-glycosylation on demyelination 
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would be worthwhile. As changes in the N-glycans of Na+/K+-ATPase β1 have been noted 
between healthy and diseased myelin, it would be beneficial to test whether or not 
manipulation of these carbohydrate constituents can trigger a diseased state 
reminiscent of demyelination, or specifically multiple sclerosis. Alternatively, 
manipulation of the N-glycans or N-glycosylation sequences of the Na+/K+-ATPase beta 
subunits could offer therapeutic benefit in the treatment of demyelination. 
Glycosylation has been previously proposed in the literature as a medicinal target for 
the treatment of a variety of human disorders [111;112]. 
 Lastly, the characterization of Na+/K+-ATPase in the myelin membrane needs to 
continue with the development of an effective method for evaluating its enzymatic 
activity. To date, typical enzymatic assays for Na+/K+-ATPase, such as the p-nitrophenyl 
phosphatase activity assay, have not been validated for measuring Na+/K+-ATPase 
activity in preparations of myelin vesicles. A preliminary investigation into the enzymatic 
activity of Na+/K+-ATPase, in the myelin membrane, is described in Appendix E. Na+/K+-
ATPase inhibitors, aside from ouabain, need to be identified such that enzymatic activity 
can be accurately measured. Recall that although Na+/K+-ATPase is generally inhibited 
by cardiac glycosides, Na+/K+-ATPase α2 and α3 are ouabain-sensitive, whereas the α1 
isoform is ouabain-resistant [75]. Therefore, the measurement of the total Na+/K+-
ATPase activity, as well as the activity of each individual catalytic alpha subunit isoform, 
will require the use of several different inhibitors. 
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Appendix A – Structure, Physical and Chemical Properties 
of Detergents 
Table A.1 Structure, physical and chemical properties of detergents used in this study 
Detergent Type Structure 
Molecular 
mass 
(g/mol) 
Critical 
Micelle 
Concentration 
(mM) 
CHAPS Zwitterionic 
 
614.9 6-10 
SDS Anionic 
 
288.4 7-10 
Tween-20 Non-ionic 
 
1228 0.059 
TX-100 Non-ionic 
 
650 0.2-0.9 
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Appendix B – Protein Sequence Analysis of Na+/K+-ATPase 
B.1 The Alpha Subunit 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
Alpha1 MGKGVGRDKYEPAAVSEHGDKKGKKAKKERDMDELKKEVSMDDHKLSLDELHRKYGTDLS 60 
Alpha2 MGRGAGRE-YSPAAT-TAENGGGKKKQKEKELDELKKEVAMDDHKLSLDELGRKYQVDLS 58 
Alpha3 MGDKKDDK-SSP---------KKSKAKERRDLDDLKKEVAMTEHKMSVEEVCRKYNTDCV 50 
       **     .  .*           .* ::.:::*:*****:* :**:*::*: *** .*   
 
Alpha1 RGLTPARAAEILARDGPNALTPPPTTPEWVKFCRQLFGGFSMLLWIGAILCFLAYGIRSA 120 
Alpha2 KGLTNQRAQDILARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGALLCFLAYGILAA 118 
Alpha3 QGLTHSKAQEILARDGPNALTPPPTTPEWVKFCRQLFGGFSILLWIGAILCFLAYGIQAG 110 
       :***  :* :*******************************:******:******** :. 
 
Alpha1 TEEEPPNDDLYLGVVLSAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIRNGEKMSI 180 
Alpha2 MEDEPSNDNLYLGIVLAAVVIVTGCFSYYQEAKSSKIMDSFKNMVPQQALVIREGEKMQI 178 
Alpha3 TEDDPSGDNLYLGIVLAAVVIITGCFSYYQEAKSSKIMESFKNMVPQQALVIREGEKMQV 170 
        *::*  *:****:**:****:****************:**************:****.: 
 
Alpha1 NAEDVVVGDLVEVKGGDRIPADLRIISANGCKVDNSSLTGESEPQTRSPDFTNENPLETR 240 
Alpha2 NAEEVVVGDLVEVKGGDRVPADLRIISSHGCKVDNSSLTGESEPQTRSPEFTHENPLETR 238 
Alpha3 NAEEVVVGDLVEIKGGDRVPADLRIISAHGCKVDNSSLTGESEPQTRSPDCTHDNPLETR 230 
       ***:********:*****:********:.********************: *.:****** 
 
Alpha1 NIAFFSTNCVEGTARGIVVYTGDRTVMGRIATLASGLEGGQTPIAEEIEHFIHLITGVAV 300 
Alpha2 NICFFSTNCVEGTARGIVIATGDRTVMGRIATLASGLEVGQTPIAMEIEHFIQLITGVAV 298 
Alpha3 NITFFSTNCVEGTARGVVVATGDRTVMGRIATLASGLEVGKTPIAIEIEHFIQLITGVAV 290 
       ** *************:*: ****************** *:**** ******:******* 
 
Alpha1 FLGVSFFILSLILEYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN 360 
Alpha2 FLGVSFFVLSLILGYSWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN 358 
Alpha3 FLGVSFFILSLILGYTWLEAVIFLIGIIVANVPEGLLATVTVCLTLTAKRMARKNCLVKN 350 
       *******:***** *:******************************************** 
 
Alpha1 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTENQSGVSFDKTSATWFA 420 
Alpha2 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGATFDKRSPTWTA 418 
Alpha3 LEAVETLGSTSTICSDKTGTLTQNRMTVAHMWFDNQIHEADTTEDQSGTSFDKSSHTWVA 410 
       ********************************************:***.:*** * ** * 
 
Alpha1 LSRIAGLCNRAVFQANQENLPILKRAVAGDASESALLKCIEVCCGSVMEMREKYSKIVEI 480 
Alpha2 LSRIAGLCNRAVFKAGQENISVSKRDTAGDASESALLKCIELSCGSVRKMRDRNPKVAEI 478 
Alpha3 LSHIAGLCNRAVFKGGQDNIPVLKRDVAGDASESALLKCIELSSGSVKLMRERNKKVAEI 470 
       **:**********:. *:*: : ** .**************:..***  **::  *:.** 
 
Alpha1 PFNSTNKYQLSIHKNPNASEPKHLLVMKGAPERILDRCSSILLHGKEQPLDEELKDAFQN 540 
Alpha2 PFNSTNKYQLSIHEREDSPQS-HVLVMKGAPERILDRCSTILVQGKEIPLDKEMQDAFQN 537 
Alpha3 PFNSTNKYQLSIHETEDPNDNRYLLVMKGAPERILDRCATILLQGKEQPLDEEMKEAFQN 530 
       *************:  :  :  ::**************::**::*** ***:*:::**** 
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Alpha1 AYLELGGLGERVLGFCHLLLPDEQFPEGFQFDTDDVNFPVDNLCFVGLISMIDPPRAAVP 600 
Alpha2 AYMELGGLGERVLGFCQLNLPSGKFPRGFKFDTDELNFPTEKLCFVGLMSMIDPPRAAVP 597 
Alpha3 AYLELGGLGERVLGFCHYYLPEEQFPKGFAFDCDDVNFTTDNLCFVGLMSMIDPPRAAVP 590 
       **:*************:  **. :**.** ** *::** .::******:*********** 
 
Alpha1 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVNQVNPRDA 660 
Alpha2 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPREA 657 
Alpha3 DAVGKCRSAGIKVIMVTGDHPITAKAIAKGVGIISEGNETVEDIAARLNIPVSQVNPRDA 650 
       ****************************************************.*****:* 
 
Alpha1 KACVVHGSDLKDMTSEELDDILRYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN 720 
Alpha2 KACVVHGSDLKDMTSEQLDEILRDHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN 717 
Alpha3 KACVIHGTDLKDFTSEQIDEILQNHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVN 710 
       ****:**:****:***::*:**: ************************************ 
 
Alpha1 DSPALKKADIGVAMGIVGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL 780 
Alpha2 DSPALKKADIGIAMGISGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL 777 
Alpha3 DSPALKKADIGVAMGIAGSDVSKQAADMILLDDNFASIVTGVEEGRLIFDNLKKSIAYTL 770 
       ***********:**** ******************************************* 
 
Alpha1 TSNIPEITPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPK 840 
Alpha2 TSNIPEITPFLLFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEAAESDIMKRQPRNSQ 837 
Alpha3 TSNIPEITPFLLFIMANIPLPLGTITILCIDLGTDMVPAISLAYEAAESDIMKRQPRNPR 830 
       ***********:**:*********:******************** ************ : 
 
Alpha1 TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPFHLLGIRETWDDRWVNDVED 900 
Alpha2 TDKLVNERLISMAYGQIGMIQALGGFFTYFVILAENGFLPSRLLGIRLDWDDRTTNDLED 897 
Alpha3 TDKLVNERLISMAYGQIGMIQALGGFFSYFVILAENGFLPGNLVGIRLNWDDRTVNDLED 890 
       ***************************:************ .*:***  **** .**:** 
 
Alpha1 SYGQQWTYEQRKIVEFTCHTAFFVSIVVVQWADLVICKTRRNSVFQQGMKNKILIFGLFE 960 
Alpha2 SYGQEWTYEQRKVVEFTCHTAFFASIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLLE 957 
Alpha3 SYGQQWTYEQRKVVEFTCHTAFFVSIVVVQWADLIICKTRRNSVFQQGMKNKILIFGLFE 950 
       ****:*******:**********.**********:***********************:* 
 
Alpha1 ETALAAFLSYCPGMGAALRMYPLKPTWWFCAFPYSLLIFVYDEVRKLIIRRRPGGWVEKE 1020 
Alpha2 ETALAAFLSYCPGMGVALRMYPLKVTWWFCAFPYSLLIFIYDEVRKLILRRYPGGWVEKE 1017 
Alpha3 ETALAAFLSYCPGMDVALRMYPLKPSWWFCAFPYSFLIFVYDEIRKLILRRNPGGWVEKE 1010 
       ************** .******** :*********:***:***:****:** ******** 
 
Alpha1 TYY 1023 
Alpha2 TYY 1020 
Alpha3 TYY 1013 
       *** 
Figure B.1 Multiple sequence alignment of mouse Na+/K+-ATPase α subunits 
 
Alignments were generated with Clustal Omega (1.2.1) on the EMBL-EBI website using UniProtKB 
accession numbers, Q8VDN2, Q6PIE5, and Q6PIC6 for alpha 1, 2, 3, respectively. The amino acids are 
coloured as follows: red (small and/or hydrophobic, i.e., A, V, F, P,M, I, L, W, and G), blue (acidic, i.e., D 
and E), magenta (basic, i.e., R and K, and including H), and green (polar, i.e., S, T, N, Q, and C). In the 
alignment, the consensus symbol asterisk (*) indicates positions which have a single, fully conserved 
residue; symbol colon (:) indicates conservation between groups of strongly similar properties; and 
symbol period (.) indicates conservation between groups of weakly similar properties. 
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3 (96.3%) 7 (100%) 9 (100%) 21 (78%) 22 (83.7%) 24 (92.9%) 25 (87.5%) 27 (90.5%) 28 (8
4.6%) 30 (89.7%) 36 (82.6%) 37 (84.6%) 45 (100%) 53 (100%) 54 (84.3%) 61 (100%) 67 (1
00%) 74 (100%) 91 (100%) 94 (100%) 118 (100%) 153 (100%)156 (100%) 162 (100%) 173 
(100%) 177 (100%) 194 (94.4%) 198 (94.1%) 204 (100%) 212 (100%) 227 (100%) 240 (10
0%) 255 (100%) 264 (100%) 269 (100%) 349 (87.3%) 350 (100%) 353 (95.3%) 354 (100%) 
359 (85.7%) 377 (100%) 385(100%) 413 (100%) 423 (100%) 430 (100%) 444 (91.8%) 445 
(100%) 458 (100%) 471 (100%) 473 (92.8%) 476 (100%) 487 (100%) 494 (100%) 502 (100
%) 508 (90.7%) 513 (75.6%) 517 (90.8%) 526 (100%) 535 (86.4%) 551 (94.1%) 596 (100%)
605 (100%) 607 (90.7%) 612 (100%) 625 (95.4%) 629 (100%) 647 (100%) 658 (100%) 661 
(95.4%) 671 (86.4%) 683 (100%) 692 (100%) 698 (100%) 707 (100%) 726 (82.6%) 727 (87
.5%) 743 (100%) 766 (100%) 773 (82.6%) 774 (90.9%) 833(100%) 834 (100%) 837 (100%) 
840 (100%) 843 (76.8%) 848 (100%) 887 (98.5%) 893 (100%) 911 (100%) 912 (100%) 938 
(100%) 940 (90.9%) 941 (100%) 950 (100%) 952 (100%) 979 (100%) 984 (49.7%) 1005 (1
00%) 1006 (83.7%) 1010(82.6%) 1011 (30.6%) 1012 (30.4%) 1019 (79.9%) 
Figure B.2 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α1 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number Q8VDN2 for Na
+
/K
+
-ATPase α1. Cleavage is predicted to occur on the right 
side (C-terminal direction) of the indicated amino acids. 
 
3 (100%) 7 (100%) 22 (92.9%) 23 (78%) 24 (75.5%) 26 (84.3%) 28 (79.9%) 34 (82.6%) 35 (
84.6%) 43 (100%) 51 (90.9%) 52 (84.3%) 59 (93.9%) 65 (100%) 72 (100%) 89 (100%) 92 (1
00%) 151 (100%) 154 (100%) 160 (100%) 171 (98.5%) 175(100%) 192 (94.4%) 196 (100%
) 202 (100%) 210 (100%) 225 (100%) 238 (100%) 253 (100%) 262 (100%) 267 (100%) 347 
(87.3%) 348 (100%) 351 (95.3%) 352 (100%) 357 (85.7%) 375 (100%) 383 (100%) 411 (73
.9%) 412 (100%) 421 (100%)428 (100%) 432 (86.4%) 442 (65%) 443 (100%) 456 (100%) 4
66 (100%) 467 (75%) 469 (100%) 471 (100%) 474 (100%) 485 (100%) 493 (78.4%) 505 (9
0.7%) 510 (75.6%) 514 (90.8%) 523 (100%) 529 (83.8%) 548 (94.1%) 561 (100%) 564(100
%) 567 (100%) 579 (94.7%) 593 (100%) 602 (100%) 604 (90.7%) 609 (100%) 622 (95.4%) 
626 (100%) 644 (100%) 655 (100%) 658 (95.4%) 668 (86.4%) 680 (91.8%) 689 (100%) 695
 (100%) 704 (100%) 723 (82.6%) 724 (87.5%) 740(100%) 763 (100%) 770 (82.6%) 771 (90
.9%) 830 (100%) 831 (100%) 834 (100%) 840 (76.8%) 845 (100%) 879 (100%) 884 (100%) 
890 (100%) 908 (100%) 909 (84.5%) 935 (100%) 937 (90.9%) 938 (100%) 947 (100%) 949 
(100%) 976 (100%)981 (92.4%) 1002 (100%) 1003 (83.7%) 1007 (100%) 1008 (87.3%) 10
16 (79.9%) 
Figure B.3 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α2 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number Q6PIE5 for Na
+
/K
+
-ATPase α2. Cleavage is predicted to occur on the right side 
(C-terminal direction) of the indicated amino acids. 
129 
 
 
4 (78%) 5 (84.6%) 8 (100%) 12 (86.6%) 13 (90.9%) 15 (100%) 17 (82%) 19 (100%) 20 (100
%) 26 (82.6%) 27 (84.6%) 35 (100%) 43 (45.3%) 44 (84.3%) 57 (100%) 64 (100%) 81 (100
%) 84 (100%) 143 (100%) 146 (100%) 152 (100%) 163 (98.5%)167 (100%) 184 (100%) 188
 (100%) 194 (100%) 202 (100%) 217 (100%) 230 (100%) 245 (100%) 254 (100%) 259 (100
%) 271 (100%) 339 (87.3%) 340 (100%) 343 (95.3%) 344 (100%) 349 (85.7%) 367 (100%) 
375 (100%) 403 (100%) 420(100%) 424 (100%) 434 (91.8%) 435 (100%) 448 (100%) 458 (
100%) 461 (100%) 463 (100%) 465 (84.1%) 466 (79.6%) 477 (100%) 492 (100%) 498 (90.7
%) 503 (75.6%) 507 (90.8%) 516 (100%) 525 (100%) 541 (94.1%) 557 (94%) 586 (100%)59
5 (100%) 597 (90.7%) 602 (100%) 615 (95.4%) 619 (100%) 637 (100%) 648 (100%) 651 (9
5.4%) 661 (86.4%) 682 (100%) 688 (100%) 697 (100%) 716 (82.6%) 717 (87.5%) 733 (100
%) 756 (100%) 763 (82.6%) 764 (90.9%) 823 (100%) 824(100%) 827 (100%) 830 (100%) 8
33 (76.8%) 838 (100%) 877 (100%) 883 (100%) 901 (100%) 902 (84.5%) 928 (100%) 930 (
90.9%) 931 (100%) 940 (100%) 942 (100%) 969 (100%) 974 (49.7%) 995 (84.6%) 996 (83.
7%) 1000 (100%) 1001(100%) 1009 (79.9%) 
Figure B.4 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase α3 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number Q6PIC6 for Na
+
/K
+
-ATPase α3. Cleavage is predicted to occur on the right side 
(C-terminal direction) of the indicated amino acids. 
B.2 The Beta Subunit 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
Beta1 -----MARGKAKEEGSWKKFIWNSEKKEFLGRTGGSWFKILLFYVIFYGCLAGIFIGTIQ 55  
Beta2 MVIQKEKKSCGQVVEEWKEFVWNPRTHQFMGRTGTSWAFILLFYLVFYGFLTAMFSLTMW 60  
Beta3 -MTKTEKKSFHQSLAEWKLFIYNPSSGEFLGRTSKSWGLILLFYLVFYGFLAALFTFTMW 59  
             :.  :   .** *::*  . :*:***. **  *****::*** *:.:*  *:  
 
Beta1 VMLLTISELKPTYQDRVAPPGLTQIPQIQK-TEISFRPNDPKSYEAYVLNIIRFLEKYKD 114  
Beta2 VMLQTVSDHTPKYQDRLATPGLMIRPKTEN-LDVIVNISDTESWGQHVQKLNKFLEPYND 119  
Beta3 AMLQTLNDEVPKYRDQIPSPGLMVFPKPQTALEYTFSMSEPQTYKKLVEDLESFLKPYSV 119  
      .** *:.:  *.*:*::  ***   *: :.  :  .  .: :::   * .:  **: *.  
 
Beta1 SAQKDDMIFEDCGNVPSEPKERGDINHERGERKVCRFKLDWLGNCSGLND-DSYGYREGK 173  
Beta2 SIQAQKNDV--CR--PGRYYEQPDNGVLNYPKRACQFNRTQLGDCSGIGDPTHYGYSTGQ 175  
Beta3 EEQKNL-TS--CP--DGAPFIQH-----GPDYRACQFPVSLLEECSGVTD-ANFGYSKGQ 168  
      . * :      *    .    :          :.*:*    * :***: *   :**  *:  
 
Beta1 PCIIIKLNRVLGFKPKPPKNESLETYPLMMKYNPNVLPVQCTGKRDEDKDKVGNIEYFGM 233  
Beta2 PCVFIKMNRVINFYAGANQ----------------SMNVTCVGKRDEDAENLGHFVMFPA 219  
Beta3 PCILVKMNRIIDLIPDGYP------------------QISCLPKEE-----NATIATYPE 205 
      **:::*:**:: :                         : *  *.:      . :  :  
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Beta1 GGYYGFPLQYYPYYGKLLQPKYLQPLLAVQ--FTNLTVDTEIRVECKAYGE-N-IGYSEK 289  
Beta2 NG--SIDLMYFPYYGKKFHVNYTQPLVAVK--FLNVTPNVEVNVECRINA-ANIATDDER 274  
Beta3 FG--VLDLKYFPYYGKKRHVGYRQPLVAVQVKFDSGLNKKEVTVECHIAGTRNLKNKNER 263  
       *   : * *:*****  :  * ***:**:  * .   . *: ***:  .  *    .*:  
 
Beta1 DRFQGRFDVKIEIKS- 304  
Beta2 DKFAGRVAFKLRINKT 290  
Beta3 DKFLGRVSFKVTARA- 278  
      *:* **. .*:  .  
 
Figure B.5 Multiple sequence alignment of mouse Na+/K+-ATPase β subunits 
 
Alignments were generated with Clustal Omega (1.2.1) on the EMBL-EBI website using UniProtKB 
accession numbers, P14094, P14231, and P97370 for beta 1, 2, 3, respectively. The amino acids are 
coloured as follows: red (small and/or hydrophobic, i.e., A, V, F, P,M, I, L, W, and G), blue (acidic, i.e., D 
and E), magenta (basic, i.e., R and K, and including H), and green (polar, i.e., S, T, N, Q, and C). In the 
alignment, the consensus symbol asterisk (*) indicates positions which have a single, fully conserved 
residue; symbol colon (:) indicates conservation between groups of strongly similar properties; and 
symbol period (.) indicates conservation between groups of weakly similar properties. 
 
3 (100%) 5 (100%) 7 (82%) 13 (100%) 14 (100%) 21 (87.3%) 22 (84.6%) 27 (100%) 34 (10
0%) 65 (49.7%) 71 (100%) 85 (100%) 91 (51%) 96 (100%) 107 (100%) 111 (92.8%) 113 (87
%) 118 (100%) 134 (90.7%) 136 (100%) 143 (100%) 146(88.4%) 147 (84.5%) 150 (100%) 1
52 (100%) 170 (85.3%) 173 (51.9%) 179 (100%) 182 (100%) 187 (40.6%) 189 (8.1%) 192 (
100%) 204 (100%) 217 (84.7%) 218 (100%) 222 (37.7%) 224 (89.7%) 249 (100%) 254 (100
%) 274 (100%) 278 (100%)289 (83.2%) 291 (100%) 295 (100%) 299 (100%) 303 (100%) 
 
Figure B.6 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β1 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number P14094 for Na
+
/K
+
-ATPase β1. Cleavage is predicted to occur on the right 
side (C-terminal direction) of the indicated amino acids. 
 
5 (84.3%) 7 (87.3%) 8 (90.9%) 18 (100%) 25 (100%) 32 (100%) 72 (100%) 76 (79.4%) 85 (3
4.9%) 87 (100%) 109 (100%) 112 (91.4%) 125 (88.7%) 130 (32.6%) 133 (100%) 147 (90.7
%) 148 (100%) 154 (100%) 181 (100%) 184 (100%) 203(84.7%) 204 (100%) 233 (92.9%) 2
34 (100%) 247 (100%) 262 (100%) 274 (89.7%) 276 (64.2%) 280 (100%) 284 (100%) 286 (
100%) 289 (100%) 
 
Figure B.7 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β2 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number P14231 for Na
+
/K
+
-ATPase β2. Cleavage is predicted to occur on the right 
side (C-terminal direction) of the indicated amino acids. 
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3 (93.1%) 6 (87.3%) 7 (90.9%) 17 (100%) 31 (100%) 34 (100%) 71 (100%) 73 (90.6%) 86 (8
.1%) 104 (100%) 105 (82%) 115 (49.7%) 123 (88.7%) 142 (100%) 166 (93.9%) 174 (100%) 
177 (100%) 194 (90.7%) 212 (100%) 219 (92.9%) 220(54.5%) 221 (70%) 226 (100%) 235 (
100%) 242 (84.1%) 243 (84.6%) 255 (100%) 258 (100%) 260 (80.3%) 263 (89.7%) 265 (64.
2%) 269 (100%) 273 (89.5%) 277 (100%) 
Figure B.8 The predicted trypsin cleavage sites for mouse Na+/K+-ATPase β3 
 
Trypsin cleavage sites were predicted by PeptideCutter (http://web.expasy.org/peptide_cutter/) using the 
UniProtKB accession number P97370 for Na
+
/K
+
-ATPase β3. Cleavage is predicted to occur on the right 
side (C-terminal direction) of the indicated amino acids. 
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Appendix C – Predicted Functional Partners 
C.1 Predicted Functional Partners of Na+/K+-ATPase Subunits 
Table C.1 Predicted functional partners of Na+/K+-ATPase α and β subunits 
Functional partners predicted for Na
+
/K
+
-ATPase α and β subunits in mice, using STRING 9.1 (http://string-
db.org/). Each suggested protein partner is listed in order of greatest evidence to least evidence. 
Na+/K+-
ATPase 
Subunit 
Predicted  Functional Partner 
Protein Gene Evidence 
Alpha 1 
Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 
Co-expression 
Experiments 
Databases 
Textmining 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-2 
Atp1b2 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-3 
Atp1b3 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-2 
Atp1a2 
Co-occurrence 
Co-expression 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-3 
Atp1a3 
Co-occurrence 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Co-occurrence 
Databases 
Homology 
Solute carrier family 8 
(sodium/calcium exchanger), 
member 1 
Scl8a1 
Experiments 
Textmining 
Klotho KI 
Experiments 
Textmining 
Inositol 1,4,5-triphosphate receptor 
1 
Itpr1 
Experiments 
Textmining 
Alpha 2 Sodium/potassium-transporting Atp1b2 Co-expression 
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ATPase subunit beta-2 Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 
Co-expression 
Databases 
Textmining 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-3 
Atp1b3 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-3 
Atp1a3 
Co-occurrence 
Co-expression 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Co-occurrence 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 
Co-occurrence 
Co-expression 
Databases 
Textmining 
Homology 
Solute carrier family 8 
(sodium/calcium exchanger), 
member 1 
Slc8a1 
Experiments 
Textmining 
Inositol 1,4,5-triphosphate receptor 
1 
Itpr1 
Experiments 
Textmining 
Potassium inwardly-rectifying 
channel, subfamily J, member 9 
Kcnj9 Textmining 
Alpha 3 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-2 
Atp1b2 
Co-expression 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-3 
Atp1b3 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 
Co-expression 
Databases 
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Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-2 
Atp1a2 
Co-occurrence 
Co-expression 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 
Co-occurrence 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Co-occurrence 
Databases 
Textmining 
Homology 
Agrin Agrn Textmining 
BR serine/threonine kinase 2 Brsk2 
Co-expression 
Textmining 
Dynein, axonemal, heavy chain 8 Dnahc8 Textmining 
Beta 1 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 
Co-expression 
Experiments 
Databases 
Textmining 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Sodium/potassium-transporting 
ATPase subunit alpha-2 
Atp1a2 
Co-expression 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-3 
Atp1a3 
Co-expression 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit beta-2 
Atp1b2 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit beta-3 
Atp1b3 
Databases 
Textmining 
Homology 
Sodium/potassium transporting 
ATPase interacting 1 
Nkain1 Textmining 
FXYD domain-containing ion 
transport regulator 7 
Fxyd7 
Experiments 
Textmining 
Sodium/potassium transporting Nkain4 Textmining 
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ATPase interacting 4 
Beta 2 
Sodium/potassium-transporting 
ATPase subunit alpha-2 
Atp1a2 
Co-expression 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-3 
Atp1a3 
Co-expression 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Databases 
Textmining 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Sodium/potassium-transporting 
ATPase subunit beta-3 
Atp1b3 
Co-expression 
Databases 
Textmining 
Homology 
Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 
Databases 
Textmining 
Homology 
WD repeat containing, antisense to 
TP53 
Wrap53 Textmining 
Lymphocyte antigen 6 complex, locus 
G6C 
Ly6g6c Textmining 
Rabaptin, RAB GTPase binding 
effector protein 2 
Rabep2 Textmining 
Beta 3 
Sodium/potassium-transporting 
ATPase subunit alpha-3 
Atp1a3 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-2 
Atp1a2 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-1 
Atp1a1 
Experiments 
Databases 
Textmining 
Sodium/potassium-transporting 
ATPase subunit alpha-4 
Atp1a4 
Experiments 
Databases 
FXYD domain-containing ion 
transport regulator 2 
Fxyd2 
Experiments 
Databases 
Sodium/potassium-transporting 
ATPase subunit beta-2 
Atp1b2 
Co-expression 
Databases 
Textmining 
Homology 
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Sodium/potassium-transporting 
ATPase subunit beta-1 
Atp1b1 
Databases 
Textmining 
Homology 
Cartilage associated protein Crtap Co-expression 
RAS related protein 1b Rap1b Co-expression 
 
C.2 Predicted Protein-Protein Interactions of Na+/K+-ATPase 
Subunits 
 
 
Figure C.1 The predicted functional partners of Na+/K+-ATPase α1 
 
Image generated using STRING 9.1. 
 
 
Figure C.2 The predicted functional partners of Na+/K+-ATPase α2 
 
Image generated using STRING 9.1. 
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Figure C.3 The predicted functional partners of Na+/K+-ATPase α3 
 
Image generated using STRING 9.1. 
 
 
Figure C.4 The predicted functional partners of Na+/K+-ATPase β1 
 
Image generated using STRING 9.1. 
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Figure C.5 The predicted functional partners of Na+/K+-ATPase β2 
 
Image generated using STRING 9.1. 
 
 
Figure C.6 The predicted functional partners of Na+/K+-ATPase β3 
 
Image generated using STRING 9.1. 
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Appendix D – Raw Data for Densitometric Analyses 
Table D.1 Western blot intensity data for CD1 and ND4 myelin comparison 
Raw data from densitometric analysis of CD1 and ND4 Western blot analysis. Intensities are provided for each Na
+
/K
+
-ATPase subunit isoform, as well as each 
glycosylation state of the β1 subunit; Band 1 to Band 4 represent the highest molecular mass protein band to the lowest molecular mass (unglycosylated core) 
protein band, respectively. Intensities were normalized to β-actin protein loading controls, and standard deviation of the pixel intensities in each sample was 
calculated by Image Lab Version 5.0 (Bio-Rad). 
 
Age 
Type of 
Data 
Measurement 
Subunit Isoform 
Alpha 1 Alpha 2 Alpha 3 Beta 1 Beta 2 Beta 3 
Beta 1 
Band 1 
Beta 1 
Band 2 
Beta 1 
Band 3 
Beta 1 
Band 4 
CD1 
Control 
Myelin 
3.10 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
1964105 2708061 1851844 1851844 1964105 2708061 1851844 1851844 1851844 1851844 
Standard Deviation 
of Fluorescent 
Signal 
799.0206 979.5301 801.8033 801.8033 799.0206 979.5301 801.8033 801.8033 801.8033 801.8033 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
483129.5 36782.64 1083381 1856270 2225996 3205753 250723 162529 176851 47232 
Standard Deviation 
of 
Chemiluminescent 
Signal 
3024.82 824.3722 4967.65 763.5356 7210.989 8782.518 979.4812 637.9062 625.3855 421.3716 
Normalized 
Data 
Relative Intensity 
Factor 
0.25 0.34 0.23 0.23 0.25 0.34 0.23 0.23 0.23 0.23 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
1961504 108311.6 4665167 7993317 9037536 9439782 1079643 699869.2 761541.4 203386.6 
Standard Deviation 
of Relative Intensity 
12306.66 2427.794 21486.45 4773.681 29506.54 26085.77 4243.588 2763.564 2713.095 1816.612 
7.65 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
7974260 6808667 1760731 1760731 7974260 6808667 1760731 1760731 1760731 1760731 
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(β-Actin control) 
Standard Deviation 
of Fluorescent 
Signal 
2567.282 2207.072 734.084 734.084 2567.282 2207.072 734.084 734.084 734.084 734.084 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
1175295 925577.6 2333128 1352819 6709981 6613303 94498.76 285076.6 367779.1 70889.52 
Standard Deviation 
of 
Chemiluminescent 
Signal 
9068.39 8504.181 10404.16 2258.68 18604.01 12467.35 1004.61 1836.48 3503.16 811.3904 
Normalized 
Data 
Relative Intensity 
Factor 
1.00 0.85 0.22 0.22 1.00 0.85 0.22 0.22 0.22 0.22 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
1175295 1084030 10566615 6126846 6709981 7745452 427980 1291097 1665653 321054.9 
Standard Deviation 
of Relative Intensity 
9076.281 9966.23 47325.39 10543.55 18729.01 14815.96 4553.324 8334.723 15880.82 3677.182 
9.00 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
4012486 4145130 4702827 4702827 4012486 4145130 4702827 4702827 4702827 4702827 
Standard Deviation 
of Fluorescent 
Signal 
1796.694 1850.12 2090.94 2090.94 1796.694 1850.12 2090.94 2090.94 2090.94 2090.94 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
1248363 694249.2 3619293 455475.7 5135876 3998997 45878.65 145469.6 87800.8 5208.42 
Standard Deviation 
of 
Chemiluminescent 
Signal 
8557.57 5894.32 12913.14 570.544 12736.53 8775.83 263.1928 649.2042 607.0426 116.3775 
Normalized 
Data 
Relative Intensity 
Factor 
0.50 0.52 0.59 0.59 0.50 0.52 0.59 0.59 0.59 0.59 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
2480948 1335573 6136986 772318.8 10206841 7693134 77793.27 246662.7 148877.8 8831.559 
Standard Deviation 
of Relative Intensity 
17043.23 11354.95 22065.28 1026.566 25721.39 17228.29 447.6162 1106.26 1031.447 197.3724 
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13.02 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
2266047 1818010 1281897 1281897 2266047 1818010 1281897 1281897 1281897 1281897 
Standard Deviation 
of Fluorescent 
Signal 
1123.899 789.0717 929.5972 929.5972 1123.899 789.0717 929.5972 929.5972 929.5972 929.5972 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
2697860 676230.2 3598350 650954.6 4566681 1653301 47033.25 198043 82480.5 49149.06 
Standard Deviation 
of 
Chemiluminescent 
Signal 
17006.02 5156.71 14758.39 1029.21 10633.07 4943.56 586.7155 1153.26 1489.24 421.3461 
Normalized 
Data 
Relative Intensity 
Factor 
0.28 0.23 0.16 0.16 0.28 0.23 0.16 0.16 0.16 0.16 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
9493819 2966119 22384155 4049375 16070232 7251803 292578.4 1231960 513084.1 305740.2 
Standard Deviation 
of Relative Intensity 
60029.45 22655.26 93231.07 7043.682 38257.44 21910.97 3655.926 7229.464 9271.542 2630.416 
ND4 
Transgenic 
Myelin 
3.10 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
2317390 3653502 1234209 1234209 2317390 3653502 1234209 1234209 1234209 1234209 
Standard Deviation 
of Fluorescent 
Signal 
958.5079 1127.46 736.5056 736.5056 958.5079 1127.46 736.5056 736.5056 736.5056 736.5056 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
873924.1 161674.6 1630287 842295.5 1510235 4864355 570 55844 258577 76477 
Standard Deviation 
of 
Chemiluminescent 
Signal 
4653.235 1382.791 7264.35 595.6856 4815.513 12951.38 381.5696 404.2201 938.8458 383.2174 
Normalized 
Data 
Relative Intensity 
Factor 
0.29 0.46 0.15 0.15 0.29 0.46 0.15 0.15 0.15 0.15 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
3007218 352876.6 10533328 5442093 5196798 10617108 3682.785 360809.6 1670673 494119.9 
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Standard Deviation 
of Relative Intensity 
16060.26 3020.092 47354.18 5035.797 16709.26 28457.38 2465.332 2620.537 6147.289 2493.474 
7.65 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
6932256 5945920 969985.3 969985.3 6932256 5945920 969985.3 969985.3 969985.3 969985.3 
Standard Deviation 
of Fluorescent 
Signal 
2417.751 1938.347 504.4575 504.4575 2417.751 1938.347 504.4575 504.4575 504.4575 504.4575 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
813033.6 455770 1621032 609532.3 6395463 6002612 2926.9 166333.5 168380.8 21381.14 
Standard Deviation 
of 
Chemiluminescent 
Signal 
6539.262 3467.39 7943.9 902.6996 18032.15 11167.67 205.0394 911.4549 1151.38 227.9837 
Normalized 
Data 
Relative Intensity 
Factor 
0.87 0.75 0.12 0.12 0.87 0.75 0.12 0.12 0.12 0.12 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
935242.6 611247.5 13326520 5010972 7356780 8050291 24062.08 1367430 1384260 175774.6 
Standard Deviation 
of Relative Intensity 
7529.263 4654.493 65673.62 7865.382 20900.7 15205.5 1685.677 7526.752 9492.845 1876.484 
9.00 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
5854361 5618304 6088181 6088181 5854361 5618304 6088181 6088181 6088181 6088181 
Standard Deviation 
of Fluorescent 
Signal 
2544.906 2239.23 2174.6 2174.6 2544.906 2239.23 2174.6 2174.6 2174.6 2174.6 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
2500319 1152316 5814317 1562077 8893667 5939907 31243.42 466539.3 461119.8 15398.23 
Standard Deviation 
of 
Chemiluminescent 
Signal 
15829.75 9213.09 16031.52 2536.84 20138.52 13223.55 305.6617 2257.18 3513.76 332.7187 
Normalized 
Data 
Relative Intensity 
Factor 
0.73 0.70 0.76 0.76 0.73 0.70 0.76 0.76 0.76 0.76 
Relative Intensity of 
Enhanced 
Chemiluminescent 
3405699 1635523 7615554 2045998 12114115 8430721 40922.43 611070.1 603971.7 20168.5 
143 
 
Signal 
Standard Deviation 
of Relative Intensity 
21612.56 13092.7 21173.44 3402.153 27931.7 19067.07 400.6204 2964.485 4607.353 435.8523 
13.02 
months 
Raw Data 
Intensity of 
Fluorescent Signal 
(β-Actin control) 
2821045 2185337 2443929 2443929 2821045 2185337 2443929 2443929 2443929 2443929 
Standard Deviation 
of Fluorescent 
Signal 
1343.626 970.8208 1115.91 1115.91 1343.626 970.8208 1115.91 1115.91 1115.91 1115.91 
Intensity of 
Enhanced 
Chemiluminescent 
Signal (Sample) 
2998635 1148146 4201894 993252.2 6297561 3457138 25295 425775.8 178040.8 50861.83 
Standard Deviation 
of 
Chemiluminescent 
Signal 
17870.8 7724.68 14417.33 1622.31 14580.09 10064.49 344.8458 1964.29 1961.05 357.1174 
Normalized 
Data 
Relative Intensity 
Factor 
0.35 0.27 0.31 0.31 0.35 0.27 0.31 0.31 0.31 0.31 
Relative Intensity of 
Enhanced 
Chemiluminescent 
Signal 
8476252 4189565 13710298 3240868 17801338 12615038 82534.68 1389258 580926.5 165956.3 
Standard Deviation 
of Relative Intensity 
50676.52 28248.61 47456.8 5496.362 42076.66 37150.28 1125.823 6440.567 6404.176 1167.694 
Normal-
ized ND4 
to CD1 
Myelin 
Ratios 
3.10 
months 
Normalized 
Data 
Ratio of Diseased to 
Healthy Relative 
Intensities 
1.53 3.26 2.26 0.68 0.58 1.12 0.00 0.52 2.19 2.43 
Standard Deviation 
of Normalized Ratio 
0.01 0.08 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.02 
7.65 
months 
Normalized 
Data 
Ratio of Diseased to 
Healthy Relative 
Intensities 
0.80 0.56 1.26 0.82 1.10 1.04 0.06 1.06 0.83 0.55 
Standard Deviation 
of Normalized Ratio 
0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 
9.00 
months 
Normalized 
Data 
Ratio of Diseased to 
Healthy Relative 
Intensities 
1.37 1.22 1.24 2.65 1.19 1.10 0.53 2.48 4.06 2.28 
Standard Deviation 
of Normalized Ratio 
0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.04 0.07 
13.02 
months 
Normalized 
Data 
Ratio of Diseased to 
Healthy Relative 
0.89 1.41 0.61 0.80 1.11 1.74 0.28 1.13 1.13 0.54 
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Intensities 
Standard Deviation 
of Normalized Ratio 
0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.01 
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Appendix E – Na+/K+-ATPase Endpoint and Kinetic Enzyme 
Assays 
E.1 Introduction 
Evaluation of the enzymatic activity of Na+/K+-ATPase is a necessary step in the 
characterization of this protein within the myelin membrane. The specific enzymatic 
activity of Na+/K+-ATPase has been determined in other tissue and cell types by using 
the K+-dependent p-nitrophenyl phosphatase (pNPPase) activity assay; it measures the 
enzymatic activity of phosphatases [2]. This assay takes advantage of the chemical 
reaction depicted in Figure E.1. The presence of phosphatases, such as Na+/K+-ATPase, 
catalyzes the conversion of 4-nitrophenyl to 4-nitrophenol [4]. This chromogenic 
product absorbs strongly at 410 nm, when deprotonated to produce p-nitrophenolate 
[4]. Without deprotonation, 4-nitrophenol only weakly absorbs light at 405 nm. Thus, 
this reaction can be manipulated by the addition of a strong base, such as sodium 
hydroxide (NaOH), to ensure full deprotonation and allow an endpoint measurement of 
absorption, such that Na+/K+-ATPase activity can be determined. 
 
Figure E.1 The reaction utilized in the K+-dependent p-nitrophenyl phosphatase 
activity assay 
 
Alternatively, the evaluation of enzyme kinetics using the pNPPase assay 
requires that the pH conditions of the reaction maximize both enzymatic activity and 
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spectrophotometric detection. Although the pKa of 4-nitrophenol is approximately 7.2, 
it is expected that physiological pH will provide the greatest Na+/K+-ATPase activity [6]. 
Studies of Na+/K+-ATPase activity in other tissue and cell types also generally use 
inhibitors to distinguish between the total ATPase activity and Na+/K+-ATPase activity. 
More specifically, the difference in enzyme activity between a reaction containing Na+, 
K+, and Mg2+, and one without K+ but with 10-4 M ouabain, is often considered the 
enzymatic activity attributed to Na+/K+-ATPase [7]. 
E.2 Materials and Methods 
E.2.1 Materials 
Ouabain octahydrate, sodium azide (NaN3) and p-nitrophenyl phosphate di(tris) 
(pNPP) were purchased from Sigma-Aldrich (St. Louis, MO, USA). NaOH was obtained 
from VWR Scientific Products (West Chester, PA, USA). All other materials were sourced 
as previously described in section 2.1. 
E.2.2 Methodology 
Myelin was isolated from CD1 mouse brains using a modified version of the 
sucrose gradient method developed by Norton [5]; this protocol was described 
previously in section 2.3.1. The K+-dependent p-nitrophenyl phosphatase activity assay 
was conducted using 96-well microplates, with 50 mM pNPP always prepared fresh 
using ultrapure water. Blanks consisted of 75 µL of 2X reaction buffer (100 mM Tris/HCl, 
0.1 mM EGTA, 5 mM MgCl2, and 15 mM KCl) and 65 µL of water; the pH of the reaction 
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buffer was adjusted as needed for each experiment; ranging from 7.4 to 8.2. Samples 
included 75 µL of 2X reaction buffer, 1-65 µL myelin protein (30 µg total), and were 
brought to a total volume of 140 µL with water. In samples with inhibitor, 10 µL of water 
was omitted and replaced with 10 µL of varying concentrations of either Na3VO4, NaN3, 
or ouabain; the sample or sample and inhibitor mixtures were incubated at 37oC for 10 
minutes prior to initiating the reaction. The reaction was initiated by the addition of 10 
µL of 50 mM pNPP; it was also added to blanks. For endpoint measurements, the 
reactions were incubated at 37oC for 20 minutes, stopped with the addition of 50 µL of 
2N NaOH, and immediately measuring the absorbance at 410 nm. Alternatively, kinetic 
measurements were taken every 30 seconds at 410 nm, over a 30 minute period, while 
the reaction mixtures were maintained at 37oC. After 30 minutes, the reactions were 
stopped by the addition of 50 µL of 2N NaOH, and the absorbance was measured again 
at 410 nm. Controls which contained myelin protein but omitted the addition of 10 µL of 
50 mM pNPP, by substituting it with water, were also prepared. The extinction 
coefficient of p-nitrophenolate at 410 nm (18300 M-1cm-1) was used to calculate enzyme 
activity. 
E.3 Results 
The enzyme activity of Na+/K+-ATPase in myelin, was evaluated kinetically at pH 
7.6, 7.8, 8.0 and 8.2, over a 30 minute period. The results of this kinetic pNPPase activity 
assay are shown in Figure E.2. The activity of Na+/K+-ATPase at each pH was determined 
using the slope of the line of best fit of the linear portion of each reaction curve. These 
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values, along with the activities determined using the absorbances at 410 nm after 
samples were stopped with NaOH, are shown in Table E.1. There was no significant 
change in absorbance over time in the blanks. 
 
Figure E.2 Determination of the rate of change in absorbance over time, in myelin 
samples of varying pH, at 410 nm 
 
 As expected, the blanks showed little or no enzymatic activity. Likewise, the 
control samples without pNPP did not demonstrate an increase in absorbance over 
time. The determined enzyme, and specific, activities from the pNPPase activity assays 
suggests that pH 7.8 is optimal for the continued kinetic analysis of Na+/K+-ATPase; this 
pH provides not only the highest measured absorbances, but also the greatest slope. 
The final measured absorbances at 410 nm established that alterations in the pH of the 
reaction buffer have little influence on the final measurement, post-addition of NaOH. 
Table E.1 Calculated enzymatic activity of Na+/K+-ATPase, over a range of pH values 
 
Endpoint Assay Kinetic Assay 
Enzyme Activity 
(µmol min-1) 
Specific Activity 
(µmol min-1 mg-1) 
Enzyme Activity 
(µmol min-1) 
Specific Activity 
(µmol min-1 mg-1) 
pH 7.6 3.64E-04 1.21E-02 3.03E-03 1.01-01 
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pH 7.8 3.71E-04 1.24E-02 5.94E-03 1.98E-01 
pH 8.0 3.56E-04 1.19E-02 4.24E-03 1.41E-01 
pH 8.2 3.55E-04 1.18E-02 2.82E-03 9.41E-02 
 
Endpoint pNPPase activity assays demonstrated that not only was phosphatase 
activity greater in brain homogenate samples when compared to purified myelin 
samples of equal protein content, but that enzyme activity exhibited a positive dose-
response; increased total myelin protein generated a linear increase in enzyme activity 
(results not shown). The addition of 100 mM Na3VO4, 15 mM NaN3, or 10 mM ouabain 
to the purified myelin samples also generated little or no change in enzyme activity, 
although it did demonstrate significant decreases in the phosphatase activity of brain 
homogenate samples of equal protein content (results not shown). 
E.4 Discussion and Conclusions 
Steady-state kinetics offers a very good approximation of the rates of enzymatic 
reactions [3]. Although pH 7.8 appears to be ideal for kinetic evaluation of Na+/K+-
ATPase using the pNPPase activity assay, the kinetic lag observed in Figure E.2 dictates 
that further method development is required. The kinetic lag may be a consequence of 
investigating Na+/K+-ATPase activity within vesicles; recall that the isolated myelin exists 
as vesicles and for the reaction substrate (pNPP) to interact with Na+/K+-ATPase, a 
membrane protein, it may need to be incorporated into these vesicles [8]. The substrate 
must be able to reach the active site of the enzyme, in order for this assay to be 
successfully applied. A delay in pNPPase activity may therefore be the result of the time 
requirement of this integration. The myelin vesicles themselves may also cause light 
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scattering during spectrophotometric analysis, which would in turn cause fluctuations in 
the measured absorbances at 410 nm. As a result, it may be necessary to further purify 
Na+/K+-ATPase from the myelin membrane, such that its activity can be more accurately 
assessed. 
Ouabain-sensitivity has historically been used to identify the phosphatase 
activity of a sample which is attributable to Na+/K+-ATPase [7]. Unfortunately, this does 
not account for any enzymatic activity associated with the α1 isoform, as it is ouabain-
resistant. Only Na+/K+-ATPase α2 and α3 are ouabain-sensitive and will be successfully 
inhibited [1]. Other inhibitors need to be examined for the accurate determination of 
Na+/K+-ATPase activity within the myelin membrane. These may include sodium 
vanadate, sodium azide, and potassium nitrate; they are inhibitors of P-type ATPase 
activity, F0F1-type ATPase activity, and V-type ATPase activity, respectively. By using a 
variety of phosphatase or ATPase inhibitors, it may also be possible to determine the 
enzymatic activity attributable to each of the three Na+/K+-ATPase alpha isoforms in 
myelin.  
Once a kinetic activity assay for Na+/K+-ATPase of myelin origin has been 
successfully developed, the reactions can be manipulated, and a variety of analyses can 
be performed using the acquired data. Specific enzymatic activity, as well as initial rates, 
Vmax, and the apparent Michaelis constant (KM) will be calculated. Dose-response 
experiments may be performed using a range of substrate concentrations. Similarly, the 
half maximal inhibitory concentration (IC50) of ouabain and other ATPase inhibitors can 
be determined. 
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Appendix F – Peptide Fragmentation in Mass Spectrometry 
 
Figure F.1 Peptide fragmentation in mass spectrometry 
 
The major y and b ions generated during protein identification by mass spectrometry are produced by 
fragmentation at amide bonds. The assignment of y and b ion values to amino acid residues or peptide 
fragments is indicated in red. 
 
Table F.1 Residue masses of amino acids for protein identification in mass 
spectrometry 
The monoisotopic masses of amino acid residues are used for the sequencing of peptides in mass 
spectrometry. The 20 common amino acids often fragment at amide bonds generating the major y and b 
fragment ions which have mass-to-charge ratios that correspond to these monoisotopic masses. 
Amino Acid Symbol Type Structure 
Monoisotopic Mass 
of Residue 
Alanine A 
Non-polar, 
aliphatic 
 
71.03711 
Arginine R 
Positively 
charged 
 
156.10111 
Asparagine N 
Polar, 
uncharged 
 
114.04293 
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Aspartate D 
Negatively 
charged 
 
115.02694 
Cysteine C 
Polar, 
uncharged 
 
103.00919 
Glutamine Q 
Polar, 
uncharged 
 
128.05858 
Glutamate E 
Negatively 
charged 
 
129.04259 
Glycine G 
Non-polar, 
aliphatic 
 
57.02146 
Histidine H 
Positively 
charged 
 
137.05891 
Isoleucine I 
Non-polar, 
aliphatic 
 
113.08406 
Leucine L 
Non-polar, 
aliphatic 
 
113.08406 
Lysine K 
Positively 
charged 
 
128.09496 
Methionine M 
Non-polar, 
aliphatic 
 
131.04049 
Phenylalanine F Aromatic 
 
147.06841 
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Proline P 
Non-polar, 
aliphatic 
 
97.05276 
Serine S 
Polar, 
uncharged 
 
87.03203 
Threonine T 
Polar, 
uncharged 
 
101.04768 
Tryptophan W Aromatic 
 
186.07931 
Tyrosine Y Aromatic 
 
163.06333 
Valine V 
Non-polar, 
aliphatic 
 
99.06841 
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Appendix G – Additional Western Blots 
 
Figure G.1 Protein expression in myelin isolated using sucrose and Percoll gradient 
methods 
 
Enhanced chemiluminescent Western blot detection of MCT1, VDAC, NQO1, and MBP in partially 
delipidated myelin samples, of equivalent protein content, from sucrose-gradient and Percoll-gradient 
isolation methods. Equal volumes (12.5 µL), and therefore equal protein (approximately 50 µg of total 
myelin protein), of each sample were separated on 14% SDS-PAGE and transferred to nitrocellulose 
membrane. The corresponding primary and secondary antibodies used are described in Table 2.3. Each 
Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an exposure time of 30-400 seconds, 
ensuring non-saturation. 
 
 
Figure G.2 Comparison of isolated myelin with brain homogenate 
 
Enhanced chemiluminescent Western blot detection of: A) Na+/K+-ATPase and VDAC; B) MCT1; in 
partially delipidated brain homogenate and myelin samples, of equivalent protein content, from sucrose-
gradient and Percoll-gradient isolation methods. Equal volumes (18.75 µL), and therefore equal protein 
(approximately 75 µg of total myelin protein), of each sample were separated on 14% SDS-PAGE and 
transferred to nitrocellulose membrane. The corresponding primary and secondary antibodies used are 
described in Table 2.3. Each Western blot was imaged using the VersaDoc 4000 (Bio-Rad) with an 
exposure time of 30-400 seconds, ensuring non-saturation.  
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Figure G.3 Detection of Na+/K+-
ATPase subunit isoforms in 
myelin DRMs 
 
Enhanced chemiluminescent Western 
blot detection of: A) Na
+
/K
+
-ATPase α2 
and β3; B) Na
+
/K
+
-ATPase α2 and β3; C) 
Na
+
/K
+
-ATPase β1. Equal volumes (20 
µL) of each acetone-precipitated lipid 
raft fraction (B1-10, C1-10, and D1-
10), isolated as CHAPS DRMs, were 
separated on 12% SDS-PAGE and 
transferred to nitrocellulose 
membrane. Fractions B3, B4, C3, C4, 
D3 and D4 represent the low density, 
raft fractions; alternatively, fractions 
B9, B10, C9, C10, D9 and D10 
represented the non-raft, high density 
fractions. The corresponding primary 
and secondary antibodies used are 
described in Table 2.3. Each Western 
blot was imaged using the VersaDoc 
4000 (Bio-Rad) with an exposure time 
of 30-200 seconds, ensuring non-
saturation.
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Appendix H – Comparison of Densitometric Data Without β-Actin Control 
Table H.1 Western blot intensity data for alternate sample sets without a β-actin control 
Raw data from densitometric analysis of CD1 and ND4 Western blot analysis, without normalization to β-actin. Intensities are provided for each Na
+
/K
+
-ATPase 
subunit isoform, as well as each glycosylation state of the β1 subunit; Band 1 to Band 4 represent the highest molecular mass protein band to the lowest 
molecular mass (unglycosylated core) protein band, respectively. Standard deviation of the pixel intensities in each sample was calculated by Image Lab 
Version 5.0 (Bio-Rad). 
 
Age 
Data 
Set 
Measurement 
Subunit Isoform 
Alpha 1 Alpha 2 Alpha 3 Beta 1 Beta 2 Beta 3 
Beta 1 
Band 1 
Beta 1 
Band 2 
Beta 1 
Band 3 
Beta 1 
Band 4 
CD1 Control 
Myelin 
3.10 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
949982 177210.5 3338678 369958.2 3736108 2786185 54978.14 68599 55692.29 29271 
Standard Deviation of 
Chemiluminescent Signal 
6188.159 2576.144 13824.59 588.9315 10654.79 7338.029 496.1169 572.695 762.3669 312.121 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
483129.5 36782.64 1083381 1856270 2225996 3205753 250723 162529 176851 47232 
Standard Deviation of 
Chemiluminescent Signal 
3024.82 824.3722 4967.65 763.5356 7210.989 8782.518 979.4812 637.9062 625.3855 421.3716 
7.65 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2385123 17775.33 3762310 1212395 6004631 3298992 43489.79 290223.8 473463.4 143777.6 
Standard Deviation of 
Chemiluminescent Signal 
15042.21 2149.99 16047.69 2054.5 14520.01 8695.68 363.794 1350.82 3290.72 806.4366 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
1175295 925577.6 2333128 1352819 6709981 6613303 94498.76 285076.6 367779.1 70889.52 
Standard Deviation of 
Chemiluminescent Signal 
9068.39 8504.181 10404.16 2258.68 18604.01 12467.35 1004.61 1836.48 3503.16 811.3904 
9.00 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
455076.3 366972 2568857 317021.5 5010588 4812661 28243.8 113739.1 81498.15 11115.8 
Standard Deviation of 
Chemiluminescent Signal 
2195.755 2800.039 13599.17 623.7382 11997.7 9867.872 335.1071 750.8703 938.0963 155.6221 
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2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
1248363 694249.2 3619293 455475.7 5135876 3998997 45878.65 145469.6 87800.8 5208.42 
Standard Deviation of 
Chemiluminescent Signal 
8557.57 5894.32 12913.14 570.544 12736.53 8775.83 263.1928 649.2042 607.0426 116.3775 
13.02 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2545489 34753.5 2764283 312825.4 3780305 3199185 44710.23 123206.2 35265.69 391.9821 
Standard Deviation of 
Chemiluminescent Signal 
17300.53 1325.992 11451.41 536.1424 10378.71 9319.39 472.5498 560.7273 521.9172 49.98207 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2697860 676230.2 3598350 650954.6 4566681 1653301 47033.25 198043 82480.5 49149.06 
Standard Deviation of 
Chemiluminescent Signal 
17006.02 5156.71 14758.39 1029.21 10633.07 4943.56 586.7155 1153.26 1489.24 421.3461 
ND4 
Transgenic 
Myelin 
3.10 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2791077 166966.3 4204345 413235.6 2247258 4700973 6645.86 79621.71 176561 30409.86 
Standard Deviation of 
Chemiluminescent Signal 
18301.66 4499.504 16928.69 1009.66 6156.039 11436.92 204.3782 580.6925 1912.33 317.0696 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
873924.1 161674.6 1630287 842295.5 1510235 4864355 570 55844 258577 76477 
Standard Deviation of 
Chemiluminescent Signal 
4653.235 1382.791 7264.35 595.6856 4815.513 12951.38 381.5696 404.2201 938.8458 383.2174 
7.65 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
1426324 87658.67 2845655 414859.3 5230054 4985924 -6062.7 205027.6 133935 11218.42 
Standard Deviation of 
Chemiluminescent Signal 
9267.994 1842.78 13517.72 908.0418 13567.35 10727.75 153.5906 1039.3 1163.36 173.7648 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
813033.6 455770 1621032 609532.3 6395463 6002612 2926.9 166333.5 168380.8 21381.14 
Standard Deviation of 
Chemiluminescent Signal 
6539.262 3467.39 7943.9 902.6996 18032.15 11167.67 205.0394 911.4549 1151.38 227.9837 
9.00 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
1804484 483497.7 3350180 855650.9 10624075 6537429 28272.75 260014.3 346565.8 19455 
Standard Deviation of 
Chemiluminescent Signal 
7956.94 2906.148 16027.87 1930.13 19336.02 13971.82 370.173 1394.09 3616.76 265.9338 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2500319 1152316 5814317 1562077 8893667 5939907 31243.42 466539.3 461119.8 15398.23 
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Standard Deviation of 
Chemiluminescent Signal 
15829.75 9213.09 16031.52 2536.84 20138.52 13223.55 305.6617 2257.18 3513.76 332.7187 
13.02 
months 
1 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
1550445 338870.9 2635873 669467.8 7384027 4600099 55969.46 319809 90608.92 9454.8 
Standard Deviation of 
Chemiluminescent Signal 
9899.051 3626.769 12132.26 1128.22 16507.52 12479.78 602.2975 1287.1 923.8873 101.5365 
2 
Intensity of Enhanced 
Chemiluminescent Signal 
(Sample) 
2998635 1148146 4201894 993252.2 6297561 3457138 25295 425775.8 178040.8 50861.83 
Standard Deviation of 
Chemiluminescent Signal 
17870.8 7724.68 14417.33 1622.31 14580.09 10064.49 344.8458 1964.29 1961.05 357.1174 
Ratio (CD1 
Control 
Myelin to 
ND4 
Transgenic 
Myelin) 
3.10 
months 
1 
Ratio of Diseased to Healthy 
Intensities 
2.938031 0.942192 1.259284 1.116979 0.601497 1.687244 0.120882 1.160683 3.170295 1.038907 
2 
Ratio of Diseased to Healthy 
Intensities 
1.808882 4.395406 1.504814 0.453757 0.678454 1.517383 0.002273 0.343594 1.462118 1.619178 
7.65 
months 
1 
Ratio of Diseased to Healthy 
Intensities 
0.598009 4.931479 0.756358 0.342182 0.871003 1.511348 -0.13941 0.706446 0.282883 0.078026 
2 
Ratio of Diseased to Healthy 
Intensities 
0.69177 0.492417 0.694789 0.450565 0.953127 0.907657 0.030973 0.583469 0.457831 0.301612 
9.00 
months 
1 
Ratio of Diseased to Healthy 
Intensities 
3.965235 1.317533 1.304152 2.699031 2.120325 1.358381 1.001025 2.28606 4.252437 1.750211 
2 
Ratio of Diseased to Healthy 
Intensities 
2.002878 1.659801 1.606479 3.429549 1.731675 1.485349 0.681001 3.207126 5.251886 2.956411 
13.02 
months 
1 
Ratio of Diseased to Healthy 
Intensities 
0.609095 9.750699 0.953547 2.140069 1.953288 1.437897 1.251827 2.595722 2.569322 24.12049 
2 
Ratio of Diseased to Healthy 
Intensities 
1.111486 1.697862 1.167728 1.525839 1.379024 2.091051 0.537811 2.149917 2.15858 1.034848 
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Figure H.1 Compared intensities of each Na+/K+-ATPase subunit isoform, between two 
sets of CD1 and ND4 myelin samples, in each age group 
 
Intensity of each Na
+
/K
+
-ATPase subunit isoform, ensuring non-saturation and subtracting background. 
Comparisons were for CD1 and ND4 myelin at: A) 3.00 months of age; B) 7.65 months of age; C) 9.00 
months of age; D) 13.02 months of age. 
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Figure H.2 Compared intensities of each Na+/K+-ATPase β1 glycosylation state, 
between two sets of CD1 and ND4 myelin samples, in each age group 
 
Intensity of each Na
+
/K
+
-ATPase β1 glycosylation state, ensuring non-saturation and subtracting 
background. Bands 1 to 4 represent the highest molecular weight form of Na
+
/K
+
-ATPase β1 (3 N-glycans) 
to the lowest molecular weight form (core, non-glycosylated), respectively. Comparisons were for CD1 
and ND4 myelin at: A) 3.00 months of age; B) 7.65 months of age; C) 9.00 months of age; D) 13.02 months 
of age. 
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Figure H.3 Ratio of intensities for each Na+/K+-ATPase subunit isoform in ND4 myelin, 
relative to CD1 myelin, with aging 
 
Intensity of each Na
+
/K
+
-ATPase subunit isoform in ND4 myelin relative to CD1 myelin, ensuring non-
saturation and subtracting background. Results from two separate Western blot data sets are shown 
(Sample 1 and Sample 2). Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. 
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Figure H.4 Ratio of intensities for each Na+/K+-ATPase β1 glycosylation state in ND4 
myelin, relative to CD1 myelin, with aging 
 
Intensity of each Na
+
/K
+
-ATPase β1 glycosylation state in ND4 myelin relative to CD1 myelin, ensuring non-
saturation and subtracting background. Bands 1 to 4 represent the highest molecular weight form of 
Na
+
/K
+
-ATPase β1 (3 N-glycans) to the lowest molecular weight form (core, non-glycosylated), 
respectively. Results from two separate Western blot data sets are shown (Sample 1 and Sample 2). 
Intensity was measured at 3.10, 7.65, 9.00 and 13.02 months of age. 
